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2Abstract
ǃ-Arrestins are essential adaptors for G protein-coupled receptor
(GPCR) trafficking. Evolutionary ancestors of the ǃ-arrestins 
dubbed Į-arrestins  are present in yeast/fungi and, similar to ǃ-
arrestins, recognise cargo proteins and mediate their intracellular
trafficking. Mammalian Į-arrestins include five largely
uncharacterised arrestin domain-containing (ARRDC1-5) proteins
that display a predicted arrestin structure; the current study focuses
on human ARRDC2.
Confocal microscopy of exogenous, fluorescent protein-tagged
ARRDC2 in U2OS cells in combination with compartment-specific
markers indicated that ARRDC2 is dynamically distributed
throughout the plasma membrane and endocytic system,
predominantly to late endosomes/lysosomes. Anti-ARRDC2
immunostaining in several primary cell lines broadly supported this
conclusion. ARRDC2 contains two proline-rich (PPxY) motifs that in
other Į-arrestins have been reported to mediate interactions with
WW domain-containing NEDD4 family E3 ubiquitin ligases.
Coimmunoprecipitation indicated that ARRDC2 is able to interact
with several NEDD4 E3s via its PPxY motifs, and confocal microscopy
suggested that this interaction may influence the subcellular
targeting of the ligases. Ubiquitination of ARRDC2 was detected by
coimmunoprecipitation, although this modification was independent
of ARRDC2 interaction with NEDD4 E3s.
ARRDC2 colocalised with agonist-stimulated, internalised GPCRs
(ǃ2-adrenergic receptor (ǃ2AR) and į-opioid receptor (įOR)) and
colocalisation analysis indicated that this involved compartmental
redistribution of ARRDC2 to receptor-containing early/recycling
endosomes, suggesting a specific effect. Interaction of ARRDC2 with
įOR was detected using coimmunoprecipitation, and confocal
analysis suggested that ARRDC2 may influence įOR and ǃ2AR
intracellular trafficking. ARRDC2 was also found to oligomerise with
itself and the ǃ-arrestins. Confocal microscopy showed that ARRDC2
overexpression can induce the redistribution of ǃ-arrestin1 to
3ARRDC2-positive vesicles, and a punctate bimolecular fluorescence
complementation (BiFC) signal was detected between ARRDC2 and
ǃ-arrestin2. From this, it is speculated that Į-/ǃ-arrestins may
function cooperatively or competitively to mediate discrete GPCR
sorting events in the endocytic pathway.
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8List of abbreviations
Abbreviations used throughout the text are listed. Those
abbreviations that appear only once are given in the text and are
not listed here. Standard three-letter abbreviations for the amino
acids are used (further abbreviated to single letters where indicated).
ADP adenosine 5-diphosphate
AF Alexa Fluor
AP2 adaptor protein 2
ARRDC arrestin-related domain containing protein
ART arrestin-related trafficking adaptor
ATP adenosine 5-triphosphate
ǃ2AR beta2-adrenoceptor
BRET bioluminescence resonance energy transfer
BSA bovine serum albumin
cAMP cyclic adenosine monophosphate
CCP clathrin-coated pit
CCV clathrin-coated vesicle
cDNA complementary DNA
CXCR CXC chemokine receptor
DMEM Dulbecco's modified Eagle's medium
įOR delta-opioid receptor
DUB deubiquitinating enzyme
E3 ubiquitin-protein ligase enzyme
ECL extracellular loop
EEA1 early endosomal antigen 1
eGFP enhanced GFP
EGFR epidermal growth factor receptor
9Eps15 EGFR pathway substrate 15
ERK extracellular regulated kinase
ESCRT endosomal sorting complex required for transport
EST expressed sequence tag
FRET fluorescence resonance energy transfer
G protein guanine nucleotide binding protein
GABA Ǆ-aminobutyric acid
GDP guanosine 5'-diphosphate
GFP green fluorescent protein
GPCR G protein-coupled receptor
GRK GPCR kinase
GST glutathione S-transferase
GTP guanosine 5'-triphosphate
HA haemagglutinin
HECT homologous to E6-associated protein C-terminus
HEK human embryonic kidney cell line
HRS hepatocyte growth factor-regulated tyrosine kinase
substrate
ICL intracellular loop
ILV intralumenal vesicle
JNK c-Jun N-terminal kinase
kD kilodalton
LAMP1 lysosome-associated membrane protein 1
MAPK mitogen-activated protein kinase
Mdm2 murine double minute 2
MEF mouse embryonic fibroblast
mGluR metabotropic glutamate receptor
MVB multivesicular body
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NEDD4 neural precursor cell expressed, developmentally-
downregulated 4
NMR nuclear magnetic resonance
PAR protease-activated receptor
PBS phosphate-buffered saline
PCR polymerase chain reaction
PI3K phosphoinositide 3-kinase
PKA protein kinase A
PKC protein kinase C
PPxY proline-proline-x-tyrosine
R inactive receptor state
R* active receptor state
RING really interesting new gene
RT-PCR reverse transcriptase PCR
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
SH src homology domain
SNX sorting nexin
src non-receptor src (sarcoma) family tyrosine kinase
ss signal SNAP
TFN transferrin
TGN trans-Golgi network
TM transmembrane domain
TR tetracycline repressor
Tsg101 tumour susceptibility gene 101 protein
TXNIP thioredoxin-interacting protein
U2OS human osteosarcoma cell line
UV ultraviolet
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Vps Vacuolar protein sorting
YFP yellow fluorescent protein
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1 Introduction
1.1 Cell signalling and GPCRs
Cells sense their external environment via the ligand-induced
modulation of cell surface signalling receptor activity, which initiates
multiple overlapping intracellular signalling cascades to produce a
wide range of responses. Multicellular organisms depend on this
mechanism for cell-cell communication; mediators released into the
extracellular milieu give rise to cell responses whose coordinated
integration underlies the regulation of many important physiological
processes. Adaptation to changes in extracellular signals is essential
for organism homeostasis, emphasised by various disease states
that arise when cell signalling is in some way deregulated.
Fundamental to this regulation in many biological systems are G
protein-coupled receptors (GPCRs), which comprise the largest
superfamily of cell surface receptors in animals, with around 800
members representing ~2% of the human genome (Vassilatis et al.,
2003). GPCRs are sufficiently diverse to enable the selective
association with a broad range of endogenous ligands, including
photons, ions, small organic compounds, amines, lipids, proteins
and nucleotides (Lagerstrom et al., 2008). As such, GPCRs are of
huge physiological importance, and it is perhaps not surprising that
the pharmaceutical industry is dominated by drugs that modulate
GPCR function, accounting for around 30% of the market according
to the latest estimate (Overington et al., 2006). However, these
drugs act at only a small number (>40) of well-characterised GPCRs.
There are ~400 non-olfactory GPCRs that represent potential drug
targets, including ~150 whose endogenous ligand is unknown
(orphan receptors); therefore, there remains a large proportion of
GCPRs whose therapeutic potential is unexplored (Lagerstrom et al.,
2008).
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1.1.1 Classification of GPCRs
GPCRs are integral plasma membrane proteins with a conserved
structure consisting of seven transmembrane (TM) D-helices
separated by intracellular (ICL) and extracellular loops (ECL), with
an extracellular amino(N)-terminal domain and an intracellular
carboxy(C)-terminal domain. Based on phylogenetics, GPCRs have
been classified into five main families: Rhodopsin, Secretin,
Glutamate, Adhesion and Frizzled/Taste2 (Fredriksson et al., 2003).
Rhodopsin-like receptors (also known as class A) form the largest
family, with ~670 human members, of which ~390 represent
olfactory receptors. Class A receptors bind the widest variety of
ligands, from small molecules (e.g. lipids, nucleotides) to larger
peptides and proteins. The diversity in ligand preference is a
function of the sequence heterogeneity of individual class A GPCRs,
with the most variation found within the TM and ECL domains.
However, there are several highly conserved amino acid residues
within the TM domains that are essential for the structural integrity
of the helical bundle and for receptor inactivation-activation. These
include the aspartate-arginine-tyrosine (DRY) motif at the cytosolic
end of TM3, the asparagine-proline-x-x-tyrosine (NPXXY; X denotes
a hydrophobic residue) motif in TM7, and single proline residues
within TM5 and TM6 (see section 1.1.2 for more detail).
The Secretin receptor family (class B) comprises 15 human
members, all of which bind moderately large peptide hormones. In
contrast to class A receptors, class B receptors have an extended N-
terminal tail (>120 residues) that contains six conserved cysteine
residues; these form a network of three disulfide bridges,
contributing to an extracellular domain of high structural integrity
(Lisenbee et al., 2005). Based on a 3D nuclear magnetic resonance
(NMR) structure of the N-terminal domain of the corticotrophin
releasing factor receptor 2beta (CRF-R2ǃ; a class B GPCR), it
appears that this domain provides a molecular architecture that is
critical for class B receptor-peptide ligand interactions (Grace et al.,
2004).
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The Glutamate or class C family includes receptors for
metabotropic neurotransmitters (glutamate, gamma-aminobutyric
acid [GABA]), taste compounds, amino acids and Ca2+, and has 22
members in humans. Most class C receptors have a very large N-
terminal tail that forms a two-lobe structure separated by a cleft,
within which the endogenous ligands bind (Kniazeff et al., 2011).
Agonist binding leads to rearrangement of the lobes to enclose the
agonist, hence the two-lobe structure being known as the Venus
flytrap (VFT) domain. Another feature of class C receptors is their
constitutive homo- or hetero-dimerisation, which is required for
their function (see section 1.1.4).
The Adhesion receptor family is the second largest in humans,
with 33 members (Yona et al., 2008). Although ancestrally related
to Secretin/class B receptors (Fredriksson et al., 2003), the
Adhesion family is distinct, not only in the TM domains, but notably
in the presence of a large multidomain N-terminus. Multiple common
structural domains within this region are implicated in cell-cell and
cell-matrix contacts, hence the nomenclature adopted for these
receptors. Unlike other GPCRs, it was thought that Adhesion
receptors may not couple to intracellular signalling pathways,
although there are now several reports suggesting they may retain
this ability (Bohnekamp et al., 2011; Iguchi et al., 2008), possibly
following cleavage of the extended N-domain (Volynski et al., 2004).
The final GPCR family is a phylogenetic amalgamation of the so-
called Frizzled and Taste2 subgroups (Fredriksson et al., 2003). The
Frizzled subgroup comprises 10 frizzled receptors (FZD1-10) and the
smoothened receptor (SMO) in humans. Ligands for the FZDs are
secreted lipoglycoproteins of the Wingless/Integration-1 (Wnt)
family, whereas SMO mediates sonic hedgehog (SHH) signalling in
complex with patched (Klaus et al., 2008; Murone et al., 1999).
Both pathways are crucial to development, and are frequently
deregulated in cancer. A conserved feature of Frizzled receptors is
the N-terminal cysteine-rich domain (CRD), which in the FZDs is
assumed to be the site for Wnt binding (Dann et al., 2001),
although additional receptor regions may be involved (Chen et al.,
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2004b). The Taste2 receptors (T2Rs) respond to a diverse array of
bitter taste compounds (Chandrashekar et al., 2000). T2Rs lack
many conserved motifs (e.g. in class A GPCRs), and consequently
are probably divergent in terms of structure and activation
mechanisms (Singh et al., 2011).
The proceeding sections will focus largely on class A GPCRs, since
these are the most widely studied and have provided the classical
models for GPCR structure and function, and are the receptor type
that it utilised in the current study.
1.1.2 Molecular mechanisms of ligand binding and
receptor activation
The orthosteric binding site (that recognised by the endogenous
agonist) for classical small-molecule ligands (e.g. neurotransmitters)
is a pocket formed within the upper third of the receptor TM helical
bundle (Gether, 2000). For example, adrenaline binding to the
prototypic GPCR, the beta2-adrenoceptor (ǃ2AR), involves residues
in the upper sections of TM3 and TM5. In particular, the adrenaline
charged amine group forms an ionic bond with Asp113 in TM3
(Strader et al., 1988), and hydroxyls of the adrenaline phenol ring
form hydrogen bonds with Ser204 and Ser207 in TM5 (Strader et al.,
1989). These contacts are conserved for many GPCRs that bind
chemically similar amines (e.g. acetylcholine, dopamine, histamine),
and the general mode of ligand binding within a helical bundle
pocket is shared by other class A GPCRs that bind small ligands.
However, many ligands, especially larger peptides, bind to epitopes
formed by the N-domain and ECLs. This is true for ligands binding to
class B and C GPCRs as mentioned in section 1.1.1 above, but is
also seen for class A receptors, such as in the interaction of
substance P with its cognate GPCR, the neurokinin 1 receptor (NK1)
(Gether, 2000). Thus, there is great diversity in the modes of ligand
binding, even within class A GPCRs. Despite these different modes,
multiple class A GPCRs couple to the same preferred intracellular
effector, namely, a particular class of guanine nucleotide binding (G)
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protein; therefore, mechanistically distinct agonist binding must
induce functionally homogeneous active receptor conformations.
This is enabled by intramolecular interactions between conserved
motifs within class A GPCRs that constrain the receptor in a closed
inactive state, and are disrupted or altered in the active
conformation. These include the NPXXY motif at the base of TM7,
which participates in a hydrogen bond network with residues in
TM1/TM2, and the TM3 DRY motif that was originally thought to
form an ionic lock with an aspartate in TM6 (Gether, 2000).
Mutation of these motifs was found to induce constitutively active
receptor conformations, and these and other biophysical studies led
to a global toggle switch model for receptor activation (Schwartz et
al., 2006). Activation was proposed to involve breakage of the TM
links mentioned above, causing a see-saw movement of TM domains
(especially TM6) involving closure on the extracellular side around
the agonist, and opening on the intracellular side, thereby providing
a cleft for effector binding.
Recent X-ray crystallographic structures have further illuminated
the model of receptor activation (Choe et al., 2011; Granier et al.,
2012; Lebon et al., 2011b; Park et al., 2008; Rasmussen et al.,
2011; Warne et al., 2011; Xu et al., 2011). Except for rhodopsin
(Choe et al., 2011), the presence of the DRY ionic lock  and its
disruption upon agonist binding  has not been conclusively
demonstrated in these studies. The solution of crystal structures for
GPCRs except rhodopsin has proved challenging, necessitating the
adoption of strategies such as the mutagenic thermostabilisation of
specific receptor conformations (Lebon et al., 2011a). Such
modifications may be the source of disagreement between the
resulting structures and earlier biophysical models. Overall, however,
crystal structures support the predicted view of a helical bundle and
the toggle switch model for activation. In particular, they
demonstrate the likely widespread mechanism of subtle
rearrangements in the ligand binding pocket upon agonist
interaction (i.e. enclosing the agonist) that are accompanied by
large-scale outward movements at the TM cytoplasmic ends (Lebon
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et al., 2011b; Rasmussen et al., 2011; Warne et al., 2011; Xu et al.,
2011).
1.1.3 Coupling receptor activation to intracellular
signalling
The paradigm for transduction of GPCR signalling involves an active
conformation  with an open cytoplasmic cleft as described above 
that enables interaction with a heterotrimeric G protein. This
promotes release of guanosine 5-diphosphate (GDP) from the GĮ
subunit; GĮ then binds guanosine 5-triphosphate (GTP), whose
intracellular concentration exceeds GDP, resulting in the dissociation
of GĮ-GTP and GǃǄ which couple to their respective downstream
effector proteins (Milligan et al., 2006). The concept of a three-way
stabilised complex (agonist-GPCR-G protein) has long been central
to the simplest model for GPCR activation/signalling, the ternary
complex model (De Lean et al., 1980). In this model, the receptor is
in equilibrium between inactive (R) and active (R*) states. Agonists
bind with higher affinity to R*, thus favouring the active, G protein-
coupled conformation. The model was subsequently extended to
allow for the spontaneous formation of R* in the absence of agonist
(i.e. constitutive activity), and has since been expanded with the
identification of multiple possible distinct R* states with or without
ligand present (Kenakin, 2004; Samama et al., 1993).
The GPCR-G protein binding interface was probed in detail some
years ago (Bourne, 1997). The GĮ subunit was found to directly
interact with GPCRs, and approaches such as alanine-scanning
mutagenesis defined the GĮ C-terminal Į-helix as the main region
responsible (Onrust et al., 1997). Several GPCR regions contribute
to a G protein binding surface, with the most important being ICL2,
ICL3 and portions of the C-terminal tail. The first crystal structure of
a GPCR (the ǃ2AR) in complex with its entire cognate G protein has
recently been published (Rasmussen et al., 2011). The principal
interactions discussed above are supported by this report, in
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particular the insertion of the GĮ C-terminal helix into a cleft formed
by outward movement of ǃ2AR TM6 (section 1.1.2 above).
It is not yet fully clear how G protein subtype selectivity of GPCRs
is determined. There are sixteen GĮ isoforms, which are divided into
distinct subtypes (Gs, Gq, Gi and G12/13) based on structural and
functional similarities (Hurowitz et al., 2000); individual GPCRs are
generally considered to preferentially interact with a particular GĮ
subtype. The different subtypes couple to discrete signalling
pathways via their interaction with different effector proteins (Table
1.1). GǃJ subunits, of which there are five Gǃ and eleven GJ isoforms
(Hurowitz et al., 2000), were originally considered merely as
inhibitors that prevented GĮ activation in the absence of receptor
stimulation. However, it is now clear that GǃJ subunits also mediate
signalling, for example in the regulation of some adenylyl cyclase
isoforms (Diel et al., 2006; Steiner et al., 2006) and phospholipase
Cǃ (Bonacci et al., 2005; Poon et al., 2009), and the activation of
mitogen-activated protein kinase (MAPK) (Shi et al., 2003) and c-
Jun N-terminal kinase (JNK) (Coso et al., 1996).
Table 1.1 Summary of the signalling profiles of GĮ subtypes
GĮ subtype Effector coupling Outcome
Gs Stimulates adenylyl cyclase Increased cAMP
Gi Inhibits adenylyl cyclase Decreased cAMP
Gq Activation of PLCǃ Cleavage of PIP2 to generate IP3 and DAG
G12/13 Activation of RhoGEFs Activation of small monomeric GTPase RhoA
RhoGEFs activated by G12/13 include p115-RhoGEF, PDZ-RhoGEF, leukaemia-
associated RhoGEF and lymphoid blast crisis-RhoGEF. PLCǃ, phospholipase Cǃ; PIP2,
phosphatidylinositol bisphosphate; IP3, inositol trisphosphate; DAG, diacylglycerol;
RhoGEF, RhoGTPase guanine nucleotide exchange factor.
1.1.4 Evolving concepts: allosterism, biased agonism
and oligomerisation
Traditionally, GPCR-targeted drug discovery strategies have
focussed on the binding site for endogenous agonists, denoted the
orthosteric site. However, there is great diversity in the nature of
potential ligand binding sites (section 1.1.2), and it has recently
19
become evident that molecules may bind to distinct regions
(designated as allosteric sites) from the orthosteric site (Keov et al.,
2010). Such molecules are known as allosteric modulators, since
their binding induces receptor conformational changes that may
enhance or reduce the affinity or efficacy of an agonist at the
orthosteric site. Thus, the allosteric site may represent a tractable
pharmacological opportunity for the development of drugs with
greater subtype selectivity.
Another recent phenomenon in GPCR research is that of biased
agonism, also known as ligand-directed signalling or functional
selectivity (Gesty-Palmer et al., 2011; Reiter et al., 2012). As noted
in section 1.1.3, GPCRs are now accepted to be capable of adopting
multiple distinct R* states. Biased ligands are those that selectively
stabilise only a subset of R* states, and thus preferentially activate
only certain signalling pathways. This may involve selective receptor
interaction with and signalling through specific GĮ subtypes, as has
been observed for the prostaglandin EP4 receptor, which may signal
through GĮs or GĮi, depending on the ligand used (Leduc et al.,
2009). Alternatively, in several cases ligands have been found to
bias signalling through another group of intracellular GPCR effectors,
the arrestins (for detailed description of arrestins, see section 1.2).
The molecular mechanisms involved in such bias are just beginning
to be elucidated. For example, using site-specific NMR labelling
within the ǃ2AR, Liu and colleagues have identified two distinct
active receptor conformations involving movements of TM6 or TM7;
ligands functionally biased toward G protein-specific signalling
caused a shift in TM6, whereas arrestin-biased ligands primarily
impacted the TM7 equilibrium state (Liu et al., 2012). Thus, the
mechanism and functional relevance of biased signalling are
beginning to be established, investigations that may well pave the
way for the development of improved pathway-specific therapeutics
with fewer side-effects (Gesty-Palmer et al., 2011).
The final relatively new concept that will be touched upon here is
that of GPCR oligomerisation. As mentioned in section 1.1.1,
Glutamate/class C receptors form constitutive dimers (Kniazeff et al.,
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2011). For example, the functional GABA receptor unit is a
heterodimer composed of GABAB1 and GABAB2 subunits. GABAB1
contains a binding site for GABA, but when expressed alone the
nascent protein is unable to escape the endoplasmic reticulum due
to a C-terminal retention motif; interaction between coexpressed
GABAB1 and GABAB2 is required to mask this motif, enabling delivery
to the cell surface (Margeta-Mitrovic et al., 2000). A similar role for
heterodimerisation in the anterograde delivery of a nascent class A
GPCR, protease-activated receptor 4 (PAR4), to the plasma
membrane has also been reported (Cunningham et al., 2012).
Recently, fluorescence resonance energy transfer (FRET) has
demonstrated that subunits within mGluR dimers undergo
conformational changes relative to each other (Yanagawa et al.,
2011), and it is suggested that dimer activation may be transduced
in a synergistic manner. Whether class A/B GPCRs dimerise, and
whether this is required for signal transduction, has been a more
contentious issue. Classically, a single GPCR was thought to couple
to a single G protein. This model was challenged by the structural
observation of multiple GPCR contacts with both GĮ and GǃǄ and the
fact that, based on crystallographic structures, the cytoplasmic
surface of a single GPCR alone is not large enough to support these
contacts (Terrillon et al., 2004b). However, a section of the GPCR
research community still holds to the notion of GPCRs as monomers
(Chabre et al., 2005). This has historically been based on classical
studies of detergent-solubilised GPCR monomers. More recently,
experiments using GPCRs (rhodopsin, ǃ2AR) in reconstituted lipid
particles have indicated that a monomeric GPCR unit is sufficient for
G protein coupling (Whorton et al., 2007; Whorton et al., 2008).
Nevertheless, there is mounting evidence that GPCRs, including
class A, are capable of forming dimers and/or higher order
oligomers when coexpressed, and that these species are functionally
relevant (Milligan, 2007). Such interactions (for example, allosteric
interaction between receptor heterodimers) have the potential for
introducing another layer of complexity to GPCR signalling; effects
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on receptor function, including pharmacology and trafficking, are
just beginning to be established.
1.2 Arrestins and GPCR regulation
In addition to promoting G protein-coupled signalling responses,
agonist-dependent GPCR activation initiates the subsequent
regulatory processes of receptor desensitisation, endocytosis and
trafficking/sorting. The two non-visual arrestin isoforms, ǃ-arrestin1
and ǃ-arrestin2, display ubiquitous cell and tissue expression and
are involved in all of these events (Gurevich et al., 2008c; Luttrell et
al., 2002).
1.2.1 Desensitisation
Desensitisation refers to the weakening of a receptor-induced
response to a given concentration of agonist, upon prolonged
exposure to that agonist. The decrease in response may be rapid,
and may function to prevent hyperactivation. The paradigm for
desensitisation of GPCRs involves their phosphorylation by specific
kinase enzymes, within seconds of exposure to agonist. The same
R* conformation that interacts with G proteins provides a substrate
for phosphorylation at serine/threonine residues in the receptor C-
tail and/or IL3 by GPCR kinases (GRKs); receptors are also targets
for second messenger-dependent kinases (protein kinase A and C;
PKA, PKC) (Ferguson, 2001; Lohse et al., 1992). As described in
section 1.1.2, transition to the active receptor state is characterised
by exposure of various cytoplasmic residues. These include the ten
amino acid segment in the proximal IL2 containing the conserved
DRY motif (Marion et al., 2006). The agonist-activated presentation
of phosphorylated GPCR C-tail residues and the exposure of
cytoplasmic GPCR residues synergistically stabilise the high affinity
binding of arrestin, whose activation and phosphate sensors
interact with each respective GPCR module (Gurevich et al., 2006b).
Notably, G proteins and arrestins may share a common interaction
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interface on the receptor; for example, they both interact with IL2
as mentioned above. The structure of arrestins (detailed description
in section 1.4) includes a central polar core that is responsible for
interaction with GRK-phosphorylated GPCR C-tail residues. GPCR-
bound arrestin sterically interdicts G protein binding, resulting in
cessation of G protein-dependent signalling.
Several exceptions and additions to this paradigm for
desensitisation exist. Arrestin binding does not always require
receptor phosphorylation (Chen et al., 2004a; Zhang et al., 2005).
Also, desensitisation by GRKs may occur in a phosphorylation-
independent manner (Ferguson, 2007), perhaps involving direct
GRK binding to GPCRs  and blocking of G protein coupling  in a
fashion analogous to arrestins. Additionally, a non receptor-
mediated mechanism for desensitisation involves the regulators of
GPCR signalling (RGS) proteins, comprising a family of 20 proteins
in mammals (Xie et al., 2007). RGS proteins specifically and
selectively interact with GĮ subunits of Gq and Gi/o proteins,
enhancing the intrinsic GTPase activity of GĮ, thereby leading to GTP
hydrolysis and termination of GĮ-mediated signalling. RGS proteins
can also interact specifically with GPCRs themselves, and
accumulating data (for example, from knockout studies (Zachariou
et al., 2003)) suggests that RGS regulation of GPCR signalling has
important physiological consequences. Thus, although the GRK-
arrestin pathway remains the dogma for GPCR desensitisation, a
multiplicity of mechanisms exist, the extent of which is far from fully
understood.
1.2.2 Internalisation
In addition to uncoupling GPCRs from their cognate G protein, ǃ-
arrestins also act as adaptors, coupling the receptor to members of
the endocytic machinery that leads to internalisation of the receptor
from the plasma membrane to intracellular compartments.
Internalisation can occur within minutes of agonist stimulation, and
contributes further to GPCR desensitisation since the acidic
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endosomal environment promotes ligand dissociation (Ferguson,
2001; Ferguson et al., 1998; Krupnick et al., 1998). The best
defined route for GPCR internalisation is the clathrin-mediated
endocytic pathway. Clathrin, along with associated proteins such as
the adaptor protein 2 (AP2) complex, forms clathrin-coated pits at
the plasma membrane. The triskelion structure of clathrin enables
the formation of a lattice, along with accessory proteins. This
induces membrane curvature, leading to invagination, budding and
eventual dynamin-dependent scission to produce an intracellular
endocytic vesicle (Ungewickell et al., 2007). ǃ-Arrestins directly
interact with the ǃ2-adaptin subunit of AP2 and with clathrin,
thereby targeting the associated GPCR cargo to clathrin-coated pits
(Goodman et al., 1996b; Laporte et al., 2000).
However, again this is a rule to which there are exceptions. For
instance, although protease-activated receptor 1 (PAR1) is
desensitised by ǃ-arrestin, its internalisation is ǃ-arrestin-
independent (Paing et al., 2002), and is instead mediated by
interactions with AP2 and another endocytic adaptor, called epsin-1
(Chen et al., 2011). Moreover, internalisation of cargo receptors is
not always via clathrin-dependent endocytosis; clathrin-independent
pathways are increasingly recognised (Sandvig et al., 2011).
Clathrin-independent routes have been proposed for several GPCRs,
including the constitutively internalising mGluR5 and mGluR7
(Fourgeaud et al., 2003; Lavezzari et al., 2007). The M3 muscarinic
receptor and ǃ2AR also undergo a degree of constitutive
internalisation; this is clathrin-independent, and may be
mechanistically separate from the clathrin-dependent pathway that
these receptors enter upon agonist stimulation (Scarselli et al.,
2009). The molecular mechanisms behind these alternative
pathways are not known; additional unidentified factors/adaptors
may well be involved.
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1.2.3 Overview of cargo sorting: a conserved role for
ubiquitin
Following their biosynthesis, proteins are subject to quality control
and complex intracellular sorting at multiple different stages. These
processes are essential in determining the subcellular localisation
and abundance of proteins, including integral membrane protein
cargoes. Ubiquitination is a widely used post-translational
modification that influences these decisions, from the quality control
and release of nascent proteins in the secretory pathway, to the
context-dependent endocytosis of plasma membrane cargo, to the
intracellular trafficking of endocytosed cargoes (MacGurn et al.,
2012).
Ubiquitin is a highly conserved short polypeptide of 76 amino
acids that exists either in a free form within cells, or covalently
conjugated to another protein. Attachment of ubiquitin to target
proteins, or ubiquitination, involves the formation of a reversible
isopeptide bond between the ubiquitin C-terminal glycine residue
and an H-amino group of a lysine residue within the substrate.
Proteins may be ubiquitinated by the addition of a single moiety at a
single lysine residue (monoubiquitination), or single moieties at
multiple residues (multiubiquitination). Additionally, since ubiquitin
itself contains seven lysine residues (K6, K11, K27, K29, K33, K48, K63),
ubiquitin chains can be formed, linked through any of these residues
(polyubiquitination). The type of ubiquitination has different
functional consequences for the substrate protein. K48-linked
polyubiquitination is well known to target soluble, cytosolic proteins
for degradation by the 26S proteasome (Pickart, 1997). In contrast,
monoubiquitination or K63-linked chains are the major forms
employed in the regulation of endocytosis and membrane protein
trafficking (Acconcia et al., 2009).
The process of protein ubiquitination involves the sequential
transfer of ubiquitin between an ubiquitin-activating enzyme (E1),
an ubiquitin-conjugating enzyme (E2) and an ubiquitin-protein
ligase (E3). E3 ligases mediate the final transfer of ubiquitin to the
substrate protein, and it is primarily the E3s that determine
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substrate specificity and the type of ubiquitination employed (Rotin
et al., 2009). The E3s are divided into two main families: really
interesting new gene (RING) finger (616 members in humans) and
homologous to E6-associated protein C-terminus (HECT) domain (28
members in humans) E3s. HECT E3s contain a catalytic HECT
domain of ~350 amino acids in their C-terminus, plus various N-
terminal functional domains that prompt their division into three
subfamilies: HECT and RCC1 domain (HERC; 6 members), neural
precursor cell expressed, developmentally-downregulated 4 (NEDD4;
9 members) and other HECTs (13 members) (Rotin et al., 2009).
The current study will focus on the NEDD4 family, since these have
been linked to arrestin protein binding and GPCR trafficking (see
section 4.1). Here, it is sufficient to note that, in several cases,
NEDD4 E3s have been found to ubiquitinate activated plasma
membrane cargo proteins (e.g. receptors), thereby signposting
them for endocytosis and/or incorporation into the ESCRT sorting
pathway (see below). Similar to protein phosphorylation,
ubiquitination is a dynamic, reversible process; E3-mediated
ubiquitination can be antagonised by the activity of deubiquitinating
enzymes (DUBs), comprising over 100 members in humans.
The non-proteasomal functions of ubiquitination in endocytosis
and membrane trafficking regularly involve the ubiquitin conjugate
providing a platform for interaction between the target protein and
another protein, often called an adaptor. These interactions are
enabled by the presence of various ubiquitin-binding domains (UBDs)
within adaptor proteins, including ubiquitin-interacting motifs (UIMs),
Src homology 3 (SH3) and Vps27, Hrs and STAM (VHS) domains.
For example, in clathrin-mediated endocytosis, ubiquitinated
cargoes (exemplified by the epidermal growth factor receptor, EGFR)
interact with accessory proteins such as epsin and EGFR pathway
substrate 15 (Eps15) (Bertelsen et al., 2011). Epsin and Eps15 are
recruited early in the initiation of clathrin-coated pit formation, and
both proteins contain multiple ubiquitin-interacting motifs (UIMs),
allowing them to congregate ubiquitinated cargo into the newly
forming pits. Additionally, epsin/Eps15 contribute to the initial
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deformation of the plasma membrane (Horvath et al., 2007),
leading to invagination that is further stabilised by the clathrin
lattice.
In the context of cargo sorting (after internalisation into
endosomes), ubiquitination is commonly recognised by the
endosomal sorting complexes required for transport (ESCRT)
machinery, leading to commitment to the lysosomal pathway of
degradation. The ESCRT machinery is comprised of four multimeric
complexes, ESCRT-0, -I, -II and -III, as well as several accessory
proteins (Raiborg et al., 2009). These highly conserved complexes
interact with each other, and are localised to early endosomal
membranes. Here they facilitate the sorting of cargo through three
main activities: first, ubiquitinated cargoes are captured through
direct interaction with UIMs present in ESCRT-0, -I and -II
complexes; second, assembly of ESCRT components, notably
ESCRT-III, causes involution of the endosomal membrane,
producing invaginations that contain ubiquitinated cargo (Saksena
et al., 2009); third, enzymatic activity of ESCRT-III components
(Vps4 AAA-ATPase) catalyses the final membrane scission step
(Wollert et al., 2009), forming cargo-containing intralumenal
vesicles (ILVs) within a multivesicular body (MVB). MVBs are then
committed to maturation into late endosomes and fusion with
lysosomes, where the sorted cargo is eventually degraded by acid
hydrolases. Deubiquitination also plays an important role in the fine-
tuning of these processes. Two DUBs, ubiquitin-specific protease 8
(Usp8) and associated molecule with the SH3 domain of STAM
(AMSH) interact with various ESCRT components. In so doing, Usp8
and AMSH are able to deubiquitinate cargo proteins and ESCRTs
(Wright et al., 2011), which can negatively regulate lysosomal
trafficking and degradation, but may also positively drive cargo MVB
incorporation and degradation (Berlin et al., 2010; Sierra et al.,
2010).
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1.2.4 GPCR sorting
Once internalised, GPCR-containing coated vesicles are uncoated,
and subsequently fuse with early endosomes. From these
compartments, GPCRs are either recycled back to the plasma
membrane (resensitisation) or trafficked to the lysosome for
degradation (downregulation) (Hanyaloglu et al., 2008). These
decisions  along with the rate of synthesis/delivery of nascent
receptors to the plasma membrane  are essential in determining
the strength and duration of signalling. Moreover, based on in vivo
studies performed so far, tight regulation of GPCR endocytosis and
sorting is likely to be of high physiological importance (Kim et al.,
2008; Odley et al., 2004; Thompson et al., 2010). Factors
influencing these decisions include GPCR phosphorylation and
ubiquitination profiles. Most GPCRs can be classified into one of two
groups. Group A GPCRs, exemplified by the ǃ2AR, are transiently
phosphorylated and ubiquitinated. This produces a transient
interaction with ǃ-arrestins, preferentially the ǃ-arrestin2 isoform.
ǃ-Arrestin is thus transiently ubiquitinated, and dissociates from the
GPCR soon after internalisation; the receptor is rapidly recycled back
to the cell surface (Shenoy et al., 2003). Other GPCRs such as the
angiotensin II type IA and delta-opioid receptors (ATIAR, įOR;
group B receptors) display more prolonged phosphorylation and
ubiquitination profiles. In particular, a cluster of serine residues in
the receptor C-tail are phosphorylated. This leads to more stable
association and co-internalisation with ǃ-arrestin and prolonged ǃ-
arrestin ubiquitination (Oakley et al., 2001; Shenoy et al., 2003).
Thus, group B GPCRs typically exhibit slower resensitisation profiles
due to sequestration in endosomes and may be more readily
trafficked to the lysosome for degradation (Oakley et al., 1999).
In addition to ǃ-arrestins, there are many other GPCR-interacting
proteins that act as adaptors for GPCR endocytic and intracellular
sorting (Magalhaes et al., 2012). These include PDZ proteins (post
synaptic density protein 95 [PSD95], Drosophila disc large tumour
suppressor [Dlg1], zonula occludens-1 protein [zo-1]), which
contain multiple globular PDZ domains that bind to specific
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sequences called PDZ binding motifs in the C-termini of interacting
proteins. Many GPCRs contain C-tail PDZ motifs, promoting
interactions with various PDZ proteins that differentially impact
receptor endocytosis and trafficking. For example, the ǃ2AR contains
a C-tail aspartate-serine-leucine-leucine (DSLL) motif that drives
interaction with the PDZ protein NHERF/EBP50 (Na+/H+ exchanger
regulatory factor /ezrinradixinmoesin (ERM)-binding
phosphoprotein-50). This interaction is required for efficient ǃ2AR
plasma membrane recycling (Cao et al., 1999); indeed, mutagenic
incorporation of the DSLL motif into the įOR  a receptor
characterised by slow recycling/lysosomal targeting  is sufficient to
redirect įOR into a rapid recycling pathway (Gage et al., 2001).
Alternatively, association with the PDZ protein PSD-95, whilst not
affecting desensitisation, was found to inhibit agonist-induced
internalisation of the ǃ1AR and serotonin 2A receptor (5-HT2A) (Hu et
al., 2000; Xia et al., 2003). It is now clear that individual GPCRs
may interact with multiple different PDZs, possibly dependent on the
cell type and physiological context, and that these interactions have
the capacity to modulate many, often opposing, GPCR trafficking
events.
GPCR-associated sorting proteins (GASPs) are another family of
trafficking adaptors that influence GPCR sorting, in particular
following endocytosis. First identified for GASP-1 regulation of the
įOR (Whistler et al., 2002), GASPs have been shown to specifically
bind to the C-tail of many GPCRs, an interaction that may be
required for efficient receptor lysosomal targeting and
downregulation (Kargl et al., 2011; Thompson et al., 2011;
Tschische et al., 2010). The mechanisms involved are unclear,
although it may be that GASPs provide a link between GPCRs and
the ESCRT machinery and/or accessory proteins (Marley et al.,
2010).
Another recent development is the observed role for sorting
nexin-1 (SNX1), a component of the retromer complex involved in
endosome-to-trans-Golgi retrograde transport, in GPCR trafficking.
SNX1 interacts directly with PAR1 (Wang et al., 2002), and small
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interfering RNA (siRNA) depletion of SNX1 inhibited PAR1
degradation, implicating SNX1 in the lysosomal sorting of PAR1
(Gullapalli et al., 2006). Interestingly, depletion of other
components of the retromer and of the ESCRT-0 complex did not
affect PAR1 degradation, suggesting that SNX1 may function
independently of these scaffolds. SNX1 regulation of GPCRs is
clearly receptor- and/or context-specific, however; in the case of the
purinergic P2Y1 receptor, SNX1 is not involved in receptor
degradation but instead is required for P2Y1 sorting into a slow
recycling pathway (Nisar et al., 2010). Moreover, in these studies
several GPCRs were found not to interact with or be regulated by
SNX1; hence, the involvement of SNX1 is not likely to be universal
to all GPCRs, leaving the door open for additional, as yet
unidentified, factors that may be required to link GPCRs to the
various appropriate sorting apparatus.
1.3 ǃ-Arrestins: emerging role as
multifunctional adaptors
In recent years the role of ǃ-arrestins has been extended beyond
their canonical regulation of GPCR desensitisation and endocytosis.
It is now known that ǃ-arrestins interact with several catalytically
active non-receptor proteins, prompting the recognition of ǃ-
arrestins as scaffolds for effector signalling in their own right.
Among the ǃ-arrestin interacting partners are protein
kinases/phosphatases, ubiquitin ligases, small G proteins and their
regulators (Gurevich et al., 2006a; Leftowitz et al., 2005). In many
cases interaction with ǃ-arrestin is thought to recruit the signalling
effectors to agonist-activated GPCRs, thus opening up a new avenue
of previously unrecognised GPCR signalling that is independent of G
protein activation. It has also become clear that ǃ-arrestin
regulation of cell surface receptors is not limited to GPCRs. ǃ-
arrestins have been reported to bind and downregulate several
structurally diverse non-GPCR receptors, including the insulin-like
growth factor-1 receptor (IGF-1R), transforming growth factor-ǃ
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type III receptor (TGFǃRIII), peroxisome proliferator-activated
receptor-JDPPD33$5ǄDQG1D+H[FKDQJHUV1+(DQG1+(
(Chen et al., 2003; Girnita et al., 2005; Lin et al., 1998; Simonin et
al., 2010; Szabo et al., 2005). Of these, direct interaction with ǃ-
arrestin was only demonstrated for NHE5; it remains possible that
the effects seen may be explained by transactivation between, for
example, receptor tyrosine kinases (RTKs) and GPCRs, rather than
direct regulation. Regardless, these reports expand the scope of ǃ-
arrestin influence on cell signalling pathways.
1.3.1 ǃ-Arrestin-dependent signalling
The first indication that ǃ-arrestins might mediate GPCR signalling
came from the observed formation of a ǃ-arrestin-dependent ǃ2AR-
src tyrosine kinase signalling complex (Luttrell et al., 1999). Since
then, ǃ-arrestins have been shown to scaffold multiple signalling
complexes. These include other c-Src family kinases (Imamura et al.,
2001) and MAPKs (Gong et al., 2008; McDonald et al., 2000),
members of the Akt/phosphoinositide 3-kinase (PI3K) pathway
(Beaulieu et al., 2005; Povsic et al., 2003), phosphodiesterase 4
(PDE4) (Baillie et al., 2003), diacylglycerol (DAG) kinases (Nelson et
al., 2007) and signal transducer and activator of transcription 1
(STAT1) (Mo et al., 2008).
One pathway in which ǃ-arrestin-dependent transduction has been
demonstrated for several different GPCRs is the extracellular
regulated kinase/MAPK (ERK/MAPK) cascade. Since ǃ-arrestin
binding to GPCRs uncouples the receptor and G protein, and
promotes internalisation of the GCPR-ǃ-arrestin complex, it would
be expected that ǃ-arrestin-dependent signalling be temporally, if
not also spatially, segregated from G protein-dependent signalling.
Indeed, two discrete phases of ERK1/2 activation have been
detected arising from the stimulation of GPCRs such as the
angiotensin II type IA receptor (ATIAR), lysophosphatidic acid (LPA)
receptor and ǃ2AR (Ahn et al., 2004; Gesty-Palmer et al., 2005;
Shenoy et al., 2006). The first rapid, transient phase is dependent
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upon G protein activation, not ǃ-arrestins, producing phosphorylated
ERK that translocates to the nucleus and initiates the transcription
of target genes (Gesty-Palmer et al., 2005). The second, ǃ-arrestin-
dependent, phase is slower in onset yet sustained over a longer
period, and is insensitive to inhibitors of G proteins (Ahn et al., 2004;
Shenoy et al., 2006). Since the internalised GPCR-ǃ-arrestin
complex and associated ERK are segregated within endosomes
(signalosome), this phase produces an endosomal pool of
phosphorylated ERK that does not translocate to the nucleus and
may therefore have different functional consequences (Ahn et al.,
2004; DeFea et al., 2000). The physiological implications of these
observations are beginning to be understood. For example,
glucagon-like peptide-1 (GLP-1) is a polypeptide hormone that
simulates glucose-stimulated insulin secretion in pancreatic ǃ-cells
by activating its cognate GPCR, GLP-1R. ǃ-arrestin1 has been
shown to be required for this signalling by mediating the activation
of ERK stimulated by GLP-1R (Sonoda et al., 2008)
ǃ-Arrestins interact with nearly all GPCRs, and the conclusion from
the above studies is that ǃ-arrestins act as a scaffold for multiple
factors. However, a given GPCR-ǃ-arrestin pair only couples to a
selection of downstream effectors. Thus, specificity must somehow
be introduced in order to scaffold some partners and not others.
There are a number of theoretical possibilities for how this could be
achieved, discussed below, many of which are supported
experimentally. Additionally, it is possible that there are other
receptor-binding proteins (Į-arrestins, perhaps; see section 1.4), in
addition to ǃ-arrestins, which are required to achieve the observed
level of signalling complexity.
First, despite the near ubiquitous presence of ǃ-arrestins, GPCRs
and signalling effectors are often expressed in a tissue-specific
manner, allowing for the possibility of a particular GPCR recruiting a
subset of effectors owing to their cell type-specific availability.
Furthermore, GPCRs may be segregated into specific microdomains
within the plasma membrane, such as lipid rafts and caveolae,
thereby restricting their coupling to only those effectors localised
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within the same microenvironment (Patel et al., 2008), a concept
known as compartmentalised signalling.
Second, the rapidity and longevity of ǃ-arrestin recruitment varies
for different GPCRs and different ligands acting at individual GPCRs,
depending on factors including receptor phosphorylation and
ubiquitination profiles. This produces spatiotemporal variations in
the ability of ǃ-arrestins to scaffold downstream partners.
Third, the affinity of the two ǃ-arrestin isoforms for different
GPCRs varies; some receptors preferentially bind one isoform over
the other (related to GPCR classification into group A or B), other
receptors have no preference (Oakley et al., 2000). Similarly, the
affinity of downstream effectors for either ǃ-arrestin isoform may be
different, as may be the nature of the complexes formed. For
example, both ǃ-arrestin1/2 bind JNK3, but only ǃ-arrestin2 holds
JNK3 in an orientation that results in enhanced JNK3 activity (Song
et al., 2009). Thus, differential affinities and conformations between
GPCR-ǃ-arrestin and ǃ-arrestin-effector may produce specificity the
signalling pathways elicited. Further to this, the propensity of GPCRs
to oligomerise has been discussed (section 1.1.4). The capacity of ǃ-
arrestins to self-associate has also been reported (see Chapter 5 for
more detail), although the precise role of such interactions is
unclear (Defea, 2008; Xu et al., 2008). Nonetheless, conceptually at
least, given the specificities in ǃ-arrestin receptor and effector
binding affinity, it is conceivable that the ability to form higher order
structures could add yet another level of complexity to the system.
Fourth, interaction with different GPCRs, and stimulation of a
single GPCR with different agonists, may result in ǃ-arrestin
coupling to specific effectors (biased signalling, as noted in section
1.1.4). ǃ-Arrestin binding to GPCRs induces the exposure of ǃ-
arrestin C-tail residues responsible for clathrin/AP2 interaction,
known as the active conformation (Krupnick et al., 1997a; Laporte
et al., 1999), and it is likely that ǃ-arrestin affinity for various other
scaffolding partners will also be higher in the active state (Gurevich
et al., 2006b). However, the implication is that the ǃ-arrestin active
state is not rigid; there may be multiple receptor-bound ǃ-arrestin
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conformations (dependent upon the individual GPCR bound and/or
which agonist is responsible for stimulation) that can be considered
as active, with variable affinities for different effector proteins.
Evidence for distinct ǃ-arrestin active conformations has come from
a study in which bioluminescence resonance energy transfer (BRET)
was used to detect structural rearrangements within the ǃ-arrestin
molecule (Shukla et al., 2008). BRET donor (Renilla luciferase) and
acceptor (yellow fluorescent protein) were fused to ǃ-arrestin2 N-
and C-termini, respectively, such that movement of the globular
domains with respect to each other was detected as a change in
BRET efficiency. Several different GPCRs were assayed and, as
expected, agonist stimulation resulted in an altered BRET signal.
However, the change in BRET signal was dependent on the agonist
used; ǃ-arrestin-pathway specific biased agonists reduced the BRET
signal, whereas standard agonists that also mobilise G protein
signalling increased BRET signal. Hence, specific agonists can
promote the adoption of distinct GPCR conformations that are
transmitted to ǃ-arrestin, which in turn adopts distinct
conformations with potentially functionally divergent consequences.
1.3.2 ǃ-arrestins determine intracellular receptor
trafficking
As mentioned in section 1.2.4, ǃ-arrestins have been found to
influence GPCR sorting decisions following receptor internalisation
into endosomes. In addition to the differences between ǃ-arrestin
binding kinetics (group A versus B GPCRs), ǃ-arrestins can exert
these effects by acting as adaptors for E3 ubiquitin ligases and/or
DUBs. For example, ǃ2AR ubiquitination status is modulated by the
HECT E3 ligase neural precursor cell expressed developmentally-
downregulated 4 (NEDD4) and DUB ubiquitin-specific 33 (USP33),
thereby determining the balance between ǃ2AR lysosomal trafficking
versus recycling (Shenoy et al., 2001; Shenoy et al., 2009; Shenoy
et al., 2008). ǃ-Arrestin2 coimmunoprecipitates with NEDD4 in an
agonist-dependent manner, and siRNA knockdown of ǃ-arrestin2
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inhibits NEDD4 binding to activated ǃ2AR (Shenoy et al., 2008).
USP33 binds to non-stimulated ǃ2AR, and ǃ-Arrestin2 also
coimmunoprecipitates with USP33 in an agonist-dependent manner,
although with slower kinetics than the NEDD4 interaction (Berthouze
et al., 2009). Thus, it is proposed that ǃ-arrestin2 acts as an
adaptor for the recruitment of NEDD4 to the activated ǃ2AR, and
may also compete with the receptor for USP33 binding, thereby
having an net positive effect on ǃ2AR ubiquitination and lysosomal
degradation (Berthouze et al., 2009).
ǃ-Arrestin is also involved in the trafficking of the chemokine
receptor CXCR4. CXCR4 ubiquitination and sorting to the
degradative pathway are mediated by the E3 ligase atrophin-
interacting protein 4 (AIP4, also known as Itch) (Marchese et al.,
2003). In this case AIP4 interacts directly with CXCR4, removing the
need for ǃ-arrestin to act as an adaptor for E3 ligase recruitment
and receptor ubiquitination (Bhandari et al., 2009). Nonetheless, ǃ-
arrestin1 is required for CXCR4 targeting to lysosomes following
internalisation, and ǃ-arrestin1 does interact with AIP4, albeit at a
later stage on early endosomes (Bhandari et al., 2007).
Interestingly, ǃ-arrestin1 interacts directly with a component of the
ESCRT machinery, signal-transducing adaptor molecule-1 (STAM-1),
thereby recruiting AIP4 to the complex. This enables AIP4 to
ubiquitinate another ESCRT component, hepatocyte growth factor-
regulated tyrosine kinase substrate (HRS) (Malik et al., 2010), a
function that is reciprocally regulated in conjunction with the DUB
USP8 (Berlin et al., 2010). Although ǃ-arrestin1 is clearly required
for CXCR4 lysosomal targeting, disruption of the ǃ-arrestin1/STAM-1
interaction actually enhances CXCR4 degradation (Malik et al.,
2010). Thus, the authors propose that ǃ-arrestin1 has a dual role in
the sorting of CXCR4, initially linking CXCR4 to the ESCRT
machinery but then also attenuating CXCR4 degradation via an
interaction with STAM-1, thereby determining the fine balance of
CXCR4 degradation versus recycling.
The role of ǃ-arrestins in recruiting E3 ubiquitin ligases to promote
receptor downregulation has also been extended to non-GPCR
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receptor cargoes. For example, ǃ-arrestin1 or 2 recruit the E3 ligase
murine double minute 2 (Mdm2) for the ubiquitination and
downregulation of IGF-1R or the androgen receptor, respectively;
similarly, ǃ-arrestin1 modulates NHE1 ubiquitination and
degradation via the recruitment of NEDD4 (Girnita et al., 2005;
Lakshmikanthan et al., 2009; Simonin et al., 2010).
Overall, studies on ǃ-arrestin roles in receptor signalling and
trafficking have established the arrestin fold as an adaptable scaffold
for the mediation of a remarkable array of cell biological functions.
1.4 Expansion of the arrestin family
Arrestins are defined by the presence of two conserved protein
sequences known as the arrestin N- and C-domains. The crystal
structures of ǃ-arrestin1/2 have been solved (Han et al., 2001;
Zhan et al., 2011), revealing that the N- and C-domains form
globular ǃ-sheets that give rise to a characteristic ǃ-sandwich fold,
separated by a flexible polar core hinge region (Gurevich et al.,
2006a). Until recently, humans were assumed to have four proteins
that display the arrestin fold: two photoreceptor-specific visual
arrestins and two ǃ-arrestins. However, phylogenetic analysis has
expanded the evolutionary tree of arrestins to include many
previously unrecognised eukaryotic homologues of these four (see
Figure 1.1). It is now apparent that the known animal visual/ǃ-
arrestins (herein collectively referred to as ǃ-arrestins) are part of a
subset of the arrestin family that emerged more recently in
evolutionary history, and that many ancient arrestin-related proteins
exist that form a second proposed subset (Alvarez, 2008). These
novel proteins comprise five mammalian arrestin domain-
containing proteins (ARRDC1-5), vacuolar protein sorting 26
(Vps26) and thioredoxin-interacting protein (TXNIP), and have been
collectively termed Į-arrestins as distinct from ǃ-arrestins (Alvarez,
2008). Over the past five or six years a broad mode of action has
begun to emerge for the Į-arrestins, primarily through studies in
lower eukaryotes but more recently in humans.
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Figure 1.1 Phylogram demonstrating the evolutionary relationship
between human arrestin family proteins
A neighbour-joining phylogenetic tree was generated using ClustalW2
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). The scale bar shows the
number of substitutions per site (nucleotide position). Note the branching
of the ǃ-arrestin subfamily (visual and non-visual ǃ-arrestins) as distinct
from the Į-arrestins. A more comprehensive phylogenetic tree including
orthologous arrestins from other species can be found elsewhere (Alvarez,
2008).
1.4.1 Structural comparison of Į- and ǃ-arrestins
Structurally, at least, there is reason to postulate that Į-arrestins
may perform related roles to ǃ-arrestins. Į-Arrestins share a
moderate degree of sequence homology with ǃ-arrestins and have
the same predicted arrestin N- and C-domain topology (for
sequence alignment see Figure 1.2). Furthermore, three-
dimensional modelling of the structure of the human arrestin clan
proteins indicated that the human Į-arrestins likely adopt an overall
structure that is very similar to the ǃ-arrestin sandwich fold (Aubry
et al., 2009). In addition to the ARRDC proteins, phylogenetic
analysis also identified human Vps26, a subunit of the retromer
complex, as a more distant arrestin relative (Alvarez, 2008).
Interestingly, X-ray crystallography had previously revealed that
Vps26 has two arrestin domains that give an overall structure that is
remarkably similar to ǃ-arrestin (Collins et al., 2008; Shi et al.,
2006). Although it was concluded that there is no protein sequence
homology between Vps26 and arrestins (Shi et al., 2006), this was
on the basis of comparison with the ǃ-arrestins, not the more
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closely related Į-arrestins. It has since been proposed that Vps26 is
indeed a true homologue of the arrestin clan, and that the Į-
arrestins map structurally onto known ǃ-arrestin structures with
high confidence (Alvarez, 2008), undermining the suggestion that Į-
/ǃ-arrestin structural similarities are mainly superficial (Collins et al.,
2008). The identification of Vps26 as a bona fide Į-arrestin supports
the proposed role of the arrestin fold as a conserved molecular
architecture for intracellular protein trafficking, a role which may
extend to other Į-arrestin members (Aubry et al., 2009).
Despite these similarities, protein sequence alignment indicates
that the Į-arrestins are clearly distinct from the ǃ-arrestins (for
comparison see Table 1.2). Comparison reveals that Į-arrestins lack
the known C-tail clathrin- and AP2-interacting motifs present in ǃ-
arrestins, although interactions between yeast Į-arrestins and
clathrin/clathrin adaptor proteins have been reported (O'Donnell et
al., 2010); hence, it is possible that other as yet unrecognised
motifs are capable of performing the same function. Į-Arrestins do,
however, contain additional PPxY motifs (proline-proline-[any
amino acid]-tyrosine sequences, not present in ǃ-arrestins) in their
C-terminus that may mediate interaction with WW domain-
containing proteins  WW domains are ~40 amino acid modules
present in diverse signalling and structural proteins that enable
interaction with proline-rich ligands (Macias et al., 2002). ǃ-
Arrestins contain a conserved amphipathic Į-helix in their N-domain
(helix I) that is sequestered in the inactive state (Han et al., 2001;
Hirsch et al., 1999). It was initially proposed that helix I may be
released upon receptor engagement to interact with downstream
partners or facilitate membrane docking (Han et al., 2001). However,
subsequent mutational analysis in this region suggested that helix I
is dispensable for receptor internalisation (Dinh et al., 2005) and
that, although it may facilitate receptor binding, movement of the
helix is not triggered upon binding (Vishnivetskiy et al., 2010).
Multiple sequence alignments performed by Alvarez (2008)
suggested that the region containing the hydrophobic and basic
residues of helix I in ǃ-arrestins is not present in Į-arrestins. This
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implied that helix I may have evolved later in ǃ-arrestins as a
module involved in receptor regulation. However, in contrast, three-
dimensional modelling of the human arrestin clan proteins against
ǃ-arrestin crystal structures yielded structures of the Į-arrestins
ARRDC2, ARRDC3 and ARRDC4 that do each contain a characteristic
N-domain Į-helix (Aubry et al., 2009). Thus, it is unclear whether
this motif is present in Į-arrestins, a question that may only be
conclusively answered through the solution of Į-arrestin crystal
structures.
ARRDC2 -----------MLFDKVKAFSVQLDGATAGVEPVFSGGQAVAGRVLLELSSAARVGALRL 49
ARRDC3 -----------MVLGKVKSLTISFDCLNDSNVPVYSSGDTVSGRVNLEVTGEIRVKSLKI 49
ARRDC4 MGGEAGCAAAVGAEGRVKSLGLVFEDERKG---CYSSGETVAGHVLLEASEPVALRALRL 57
TXNIP ----------MVMFKKIKSFEVVFN----DPEKVYGSGEKVAGRVIVEVCEVTRVKAVRI 46
beta-arr1 ------------MGDK-GTRVFKKASPNGKLTVYLGKRDFVDHIDLVDPVDGVVLVDPEY 47
beta-arr2 ------------MGEKPGTRVFKKSSPNCKLTVYLGKRDFVDHLDKVDPVDGVVLVDPDY 48
ARRDC1 -------------MGRVQLFEISLSHG----RVVYSPGEPLAGTVRVRLGAPLPFRAIRV 43
ARRDC5 ----MGDREECLSTPQPPMSVVKSIELVLPEDRIYLAGSSIKGQVILTLNSTLVDPIVKV 56
Vps26A ------MSFLGGFFGPICEIDIVLNDGETRKMAEMKTEDGKVEKHYLFYDGESVSGKVNL 54
Consensus . . :
Arr domain NNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
ARRDC2 ARGRAHVHWTESRS--AGSSTAYTQSYSERVEVVSHRATLLAPDTGETT------TLPP 101
ARRDC3 HARGHAKVRWTESRN--AGSNTAYTQNYTEEVEYFNHKDILIGHERDDDNSEEGFHTIHS 107
ARRDC4 EAQGRATAAWGPSTCPRASASTAALAVFSE-VEYLNVRLSLREPPAGEGII-----LLQP 111
TXNIP LACGVAKVLWMQGSQ-----------QCKQTSEYLRYEDTLLLEDQPTGENE--MVIMRP 93
beta-arr1 LKERRVYVTLTCAFRYGREDLDVLGLTFRKDLFVANVQSFPPAPEDKKPLTRLQERLIKK 107
beta-arr2 LKDRKVFVTLTCAFRYGREDLDVLGLSFRKDLFIATYQAFPPVPNPPRPPTRLQDRLLRK 108
ARRDC1 TCIGSCGVSNKANDT-----------AWVVEEGYFNSSLSLADKG------------SLP 80
ARRDC5 ELVGRGYVEWSEEAG--ASCDYSRNVICNNKADYVHKTKTFPVEDN-----------WLS 103
Vps26A AFKQPGKRLEHQGIRIEFVGQIELFNDKSNTHEFVNLVKELALPG-------------EL 101
Consensus
Arr domain NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
ARRDC2 GR-HEFLFSFQLPPT--------LVTSFEGKHGSVRYCIKATLHRP-WVPARRARKVFTV 151
ARRDC3 GR-HEYAFSFELPQTP-------LATSFEGRHGSVRYWVKAELHRP-WLLPVKLKKEFTV 158
ARRDC4 GK-HEFPFRFQLPSEP-------LVTSFTGKYGSIQYCVRAVLERP-KVPDQSVKRELQV 162
TXNIP GNKYEYKFGFELPQGP-------LGTSFKGKYGCVDYWVKAFLDRP-SQPTQETKKNFEV 145
beta-arr1 LGEHAYPFTFEIPPNLPCSVTLQPGPEDTGKACGVDYEVKAFCAEN-LEEKIHKRNSVRL 166
beta-arr2 LGQHAHPFFFTIPQNLPCSVTLQPGPEDTGKACGVDFEIRAFCAKS-LEEKSHKRNSVRL 167
ARRDC1 AGEHSFPFQFLLPATAP--------TSFEGPFGKIVHQVRAAIHTPRFSKDHKCSLVFYI 132
39
ARRDC5 AGSHTFDFHFNLPPRLP--------STFTSKFGHVFYFVQASCMGR-EHILAKKRMYLLV 154
Vps26A TQSRSYDFEFMQVEKP--------YESYIGANVRLRYFLKVTIVRR---LTDLVKEYDLI 150
Consensus .* * . : . ::. :
Arr domain NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
ARRDC2 IEPVDIN-TPALLAPQAGAREKVARSWYCNRGLVSLSAKIDRKGYTPGEVIPVFAEIDNG 210
ARRDC3 FEHIDIN-TPSLLSPQAGTKEKTLCCWFCTSGPISLSAKIERKGYTPGESIQIFAEIENC 217
ARRDC4 VSHVDVN-TPALLTPVLKTQEKMVGCWFFTSGPVSLSAKIERKGYCNGEAIPIYAEIENC 221
TXNIP VDLVDVN-TPDLMAPVSAKKEKKVSCMFIPDGRVSVSARIDRKGFCEGDEISIHADFENT 204
beta-arr1 VIRKVQY-APERPGPQPT--AETTRQFLMSDKPLHLEASLDKEIYYHGEPISVNVHVTNN 223
beta-arr2 VIRKVQF-APEKPGPQPS--AETTRHFLMSDRSLHLEASLDKELYYHGEPLNVNVHVTNN 224
ARRDC1 LSPLNLNSIPDIEQPNVASATKKFSYKLVKTGSVVLTASTDLRGYVVGQALQLHADVENQ 192
ARRDC5 QGTSTFHKETPFQNPLFVEAEEKVSYNCCRQGTVCLQIQMERNTFTPGEKVVFTTEINNQ 214
Vps26A VHQLATY--PDVN--------NSIKMEVGIEDCLHIEFEYNKSKYHLKDVIVGKIYFLLV 200
Consensus . : : : : : : : .
Arr domain NNNNNNNN CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
ARRDC2 STRPVLPRAAVVQTQTFMA----RGARKQKRAVVASLAGEPVGPGQRALWQGRALR---- 262
ARRDC3 SSRMVVPKAAIYQTQAFYA----KGKMKEVKQLVANLRGESLSSGKTETWNGKLLK---- 269
ARRDC4 SSRLIVPKAAIFQTQTYLA----SGKTKTIRHMVANVRGNHIASGSTDTWNGKTLK---- 273
TXNIP CSRIVVPKAAIVARHTYLA----NGQTKVLTQKLSSVRGNHIISGTCASWRGKSLR---- 256
beta-arr1 TNKTVKKIKISVRQYADIC----LFNTAQYKCPVAMEEADDTVAPSSTFCKVYTLTPFLA 279
beta-arr2 STKTVKKIKVSVRQYADIC----LFSTAQYKCPVAQLEQDDQVSPSSTFCKVYTITPLLS 280
ARRDC1 SGKDTSPVVASLLQKVSYK----AKRWIHDVRTIAEVEGAGVKAWRRAQWHEQILVP--- 245
ARRDC5 TSKCIKTVVFALYAHIQYEGFTPSAERRSRLDSSELLRQEANTPVTRFNTTKVVSTFNLP 274
Vps26A RIKIQHMELQLIKKEITGIG----PSTTTETETIAKYEIMDGAPVKGESIPIRLFLAG-- 254
Consensus : .
Arr domain CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
ARRDC2 -IPPVGPSILHCRVLHVDYALKVCVDIPGTSK-LLLELPLVIGTIPLHPFGSRSSSVGSH 320
ARRDC3 -IPPVSPSILDCSIIRVEYSLMVYVDIPGAMD-LFLNLPLVIGTIPLHPFGSRTSSVSSQ 327
ARRDC4 -IPPVTPSILDCCIIRVDYSLAVYIHIPGAKK-LMLELPLVIGTIPYNGFGSRNSSIASQ 331
TXNIP -VQKIRPSILGCNILRVEYSLLIYVSVPGSKK-VILDLPLVIGSR--SGLSSRTSSMASR 312
beta-arr1 NNREKRGLALDGKLKHEDTNLASSTLLREGAN-REILGIIVSYKVKVKLVVSRGGLLGDL 338
beta-arr2 DNREKRGLALDGKLKHEDTNLASSTIVKEGAN-KEVLGILVSYRVKVKLVVSRGG----- 334
ARRDC1 --ALPQSALPGCSLIHIDYYLQVSLKAPEAT----VTLPVFIGNIAVNHAPVSPRPGLGL 299
ARRDC5 LLLSVSSSTQDGEIMHTRYELVTTVHLPWSLTSLKAKVPIIITSASVDSAICQLS----- 329
Vps26A --YDPTPTMRDVNKKFSVRYFLNLVLVDEEDRRYFKQQEIILWRKAPEKLRKQRTN---- 308
Consensus : :.
Arr domain CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
ARRDC2 ASFLLDWRLGALPERPEAPPEYSE---------VVADTEEAALGQSPFPLPQDPDMSLEG 371
ARRDC3 CSMNMNWLSLSLPERPEAPPSYAE---------VVTE-EQRRNNLAPVSACDDFERALQG 377
ARRDC4 FSMDMSWLTLTLPEQPEAPPNYAD---------VVSE-EEFSRHIPPYPQPPNCEGEVCC 381
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TXNIP TSSEMSWVDLNIPDTPEAPPCYMD---------VIPE--DHRLESPTTPLLDDMDGSQDS 361
beta-arr1 ASSDVAVELPFTLMHPKPKEEP-------------PHREVPENETPVDTNLIELDTN--- 382
beta-arr2 ---DVSVELPFVLMHPKPHDHIPL---------PRPQSAAPETDVPVDTNLIEFDTNYAT 382
ARRDC1 PPGAPPLVVPSAPPQEEAEAEAAAGGPHFLDPVFLSTKSHSQRQPLLATLSSVPGAPEPC 359
ARRDC5 -------EDGVLPVNPDHQN---------------------------------------- 342
Vps26A --FHQRFESPESQASAEQPEM--------------------------------------- 327
Consensus .
Arr domain CCCCCCCCCCCCCCCCCC
ARRDC2 PFFAYIQEFRYRPPPLYSEEDPNP-LLGDMRPRCMTC----------------------- 407
ARRDC3 PLFAYIQEFRFLPPPLYSEIDPNPDQSADDRPSCPSR----------------------- 414
ARRDC4 PVFACIQEFRFQPPPLYSEVDPHPSDVEESQPVSFIL----------------------- 418
TXNIP PIFMYAPEFKFMPPPTYTEVDPCILNNNVQ------------------------------ 391
beta-arr1 DDDIVFEDFARQRLKGMKDDKEEEEDGTGSPQLNNR------------------------ 418
beta-arr2 DDDIVFEDFARLRLKGMKDDDYDD-------QLC-------------------------- 409
ARRDC1 PQDGSPASHPLHPPLCISTGATVPYFAEGSGGPVPTTSTLILPPEYSSWGYPYEAPPSYE 419
ARRDC5 ------------------------------------------------------------
Vps26A ------------------------------------------------------------
Consensus
Arr domain
ARRDC2 --------------
ARRDC3 --------------
ARRDC4 --------------
TXNIP --------------
beta-arr1 --------------
beta-arr2 --------------
ARRDC1 QSCGGVEPSLTPES 433
ARRDC5 --------------
Vps26A --------------
Consensus
Arr domain
Figure 1.2 Multiple sequence alignment of human arrestin family
proteins
ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used to
generate alignments. PPxY motifs are highlighted in red. The five residues
constituting the ǃ-arrestin polar core phosphate sensor (Gurevich et al.,
2006b) are in orange (Asp29, Arg169, Asp290, Asp297, Arg293 in ǃ-arrestin1),
as are conserved residues (with the same charge) in Į-arrestins (note that
all five residues are not conserved in Į-arrestins). The two essential
residues for ǃ-arrestin binding to ǃ2-adaptin (Phe391, Arg395 in ǃ-arrestin1)
and the motif for clathrin binding (LIELD in ǃ-arrestin1; residues 376-380)
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are underlined. Of these, only the Phe residue is conserved in Į-arrestins;
it is also underlined. The ARRDC1 residues (Phe88, Gly180, Asn191) recently
reported to be required for its membrane targeting (Nabhan et al., 2012)
are in green, as are conserved residues. The TXNIP cysteine residue
(Cys247) required to form a disulfide bond with thioredoxin (Patwari et al.,
2006) is in light blue. Consensus is shown as: *, fully conserved residue; :,
stongly similar residues; ., partially conserved residues. The ǃ-arrestin2
PFAM predicted arrestin N- and C-domains are denoted below (Arr
domain).
Table 1.2 Comparison of Į- and ǃ-arrestins
Similarities Differences
Primary sequence homology Į-Arrestins lack the endocytic C-tail clathrin- and
AP2-interacting motifs present in ǃ-arrestins
Predicted 3D structure (curved ǃ-sandwich)  solved for
Vps26 and ǃ-arrestins
Į-Arrestins contain WW domain-interacting
C-terminal PY motifs not found in ǃ-arrestins
Mediate endocytosis of several cell surface
receptors/transporters  e.g. Į-arrestins: Hatakeyama et
al., (2010); Lin et al., (2008); Nikko and Pelham, (2009);
Nikko et al., (2008)
Sequence required for ǃ-arrestin recognition of
phosphorylated GPCR C-tail (i.e. phosphate sensor)
may not be present in Į-arrestins
Determinate intracellular cargo protein trafficking fate
Mediate ubiquitination of cargo proteins through
interaction with E3 ubiquitin ligases
1.4.2 Lessons from lower eukaryotes
As mentioned above, recent phylogenetic analysis has expanded the
tree of known arrestins in eukaryotes, revealing the presence of
arrestins in fungi and in all multicellular organisms except plants
(Alvarez, 2008). These include members of both the Į-arrestin and
ǃ-arrestin branches. For example, the fruit fly Drosophila
melanogaster has two visual arrestins, a non-visual ǃ-arrestin and
around fifteen presumed Į-arrestins; the nematode worm
Caenorhabditis elegans has a single ǃ-arrestin and over twenty Į-
arrestins. To date, it is in lower eukaryotes such as these that the
most work has been done to investigate Į-arrestin function.
The first Į-arrestin to be ascribed a function was PalF, a pH-
response regulator protein in the fungus Aspergillus nidulans
(Herranz et al., 2005; Maccheroni Jr et al., 1997). PalF contains
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conserved arrestin N- and C-domains, and was shown to bind
directly to the seven-transmembrane domain, putative pH sensor,
PalH (Herranz et al., 2005). Mammalian ǃ-arrestin binding to GPCRs
directly involves the ǃ-arrestin N-domain, although additional
residues in regions including the C-domain contribute to an
extensive binding interface and determine receptor binding
specificity (Gurevich et al., 1995; Vishnivetskiy et al., 2011;
Vishnivetskiy et al., 2004). Similarly, truncated PalF lacking the C-
terminal portion produced a moderate interaction with PalH in a
yeast two-hybrid assay, but full length PalF was required for full
interaction. Moreover, a loss-of-function mutation within the PalF N-
domain (Ser86Pro substitution) strongly impaired PalH binding.
Ser86 is located within the conserved arrestin ǃ-strand V, which in
mammalian arrestins is essential for GPCR binding (Gurevich et al.,
1995). Indeed, mutation of a closely related residue in ǃ-arrestin1
(Val53) similarly impairs the GPCR interaction (Krupnick et al.,
1997b). Thus, the structural basis of the arrestin-GPCR interaction
may be conserved in Į-arrestins.
Interestingly, the PalF-PalH interaction was acutely required for
PalH pH-dependent signalling in vivo. Furthermore, like the ǃ-
arrestins, phosphorylation and ubiquitination of PalF occurred in a
manner dependent on signal (pH) and seven-transmembrane
protein (PalH). However, there is no apparent role for a G protein in
fungal pH signalling, and a potential difference is that PalF had a
necessary positive role in the PalH pH-sensitive response, although
the ability of ǃ-arrestins to mediate signalling responses is
increasingly recognised (section 1.3.1). In a subsequent report,
expression of a PalF-ubiquitin fusion protein was found to promote
pH signalling activation even in the absence of PalH (Hervas-Aguilar
et al., 2010). It seems, then, that PalF does not desensitise PalH;
rather, PalF is directly involved in PalH signal transduction in a
manner that may depend on endocytosis and coupling to the ESCRT
machinery (Herranz et al., 2005; Xu et al., 2004).
Since this first report in fungus, the role of Į-arrestins has been
further elucidated in studies on various orthologous proteins in the
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yeast Saccharomyces cerevisiae (Herrador et al., 2009; Lin et al.,
2008; Nikko et al., 2009; Nikko et al., 2008). Yeast have eleven
candidate Į-arrestins, comprising nine so-called arrestin-related
trafficking adaptors (ARTs), the yeast orthologue of Vps26 (Pep8),
and Spo23 (a protein involved in sporulation) (Aubry et al., 2009).
The ARTs have been identified as adaptors for Rsp5, the sole HECT
E3 ubiquitin ligase present in yeast. Rsp5 is responsible for the
ubiquitination and endocytosis of several plasma membrane
transporters and permeases. For example, the manganese
transporter, Smf1, is ubiquitinated by Rsp5 in response to its toxic
substrate cadmium, leading to Smf1 endocytosis. Smf1
ubiquitination is dependent on ART2 or ART8 (also known as Ecm21
and Csr2, respectively), both of which bind Rsp5 WW domains via
their PPxY motifs (Nikko et al., 2008). ART2 was found to bind to
Smf1, providing the link between Smf1, Rsp5 and the facilitation of
ubiquitination/endocytosis. Indeed, wild-type ART2 was able to
rescue Smf1 endocytosis in an arrestin null background, whereas a
mutant ART2 lacking its three PPxY motifs was not. The question of
whether ART8 also binds Smf1 was not investigated (Nikko et al.,
2008). It is notable that the efficient binding of ART2 to Smf1 was
dependent upon the constitutive phosphorylation of Smf1. This
suggests that yeast ARTs and mammalian ǃ-arrestins may share a
dependence on interaction with phosphate modules for their
recruitment to cargo proteins. Whether there are also structural
parallels between ART-Smf1 binding and that of ǃ-arrestins-GPCRs
is unclear since the structure of Smf1 is unknown. Mammalian
orthologues of Smf1, the Natural resistance-associated membrane
protein (Nramp)/DMT family of divalent-metal transporters (Forbes
et al., 2001) are predicted to contain 10-12 transmembrane
domains that form a hydrophobic core (Cellier et al., 1995);
assuming this domain organisation to be conserved in Smf1, it
would appear that ART binding may be structurally distinct to the ǃ-
arrestin-GPCR association.
Following on from this study, glutathione S-transferase (GST)
pull-down experiments tested the interaction of all the ARTs except
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ART4 for interaction with Rsp5; of those tested all but ART9
demonstrated an interaction and, in the case of ART1 and ART2, this
was confirmed to require the C-terminus (i.e. likely involvement of
ART PPxY motifs) (Lin et al., 2008). Furthermore, similar roles were
observed for ART1 and ART2 in the regulation of several specific
amino acid transporter cargoes. ART1 (also called Cvs7) is recruited
to the plasma membrane in response to changes in nutrient
availability and is required for the endocytic downregulation of
amino acid transporters Can1 and Mup1 to the vacuole (the yeast
equivalent of the lysosome), in a manner dependent on ART1
interaction with Rsp5 (Lin et al., 2008). ART1 or ART2 also mediate
stimulus-dependent endocytosis of another amino acid transporter,
Lyp1. Since a degree of redundancy in ART roles appeared in these
studies, a subsequent report tested the ability of individual ARTs to
rescue various functions in an arrestin-null yeast background (Nikko
et al., 2009). This again revealed a role for ARTs in specific cargo
endocytosis/downregulation: ART5 was required for inositol-induced
Itr1 transporter endocytosis/degradation; internalisation of the
glucose transporter Hxt6 was mediated by ART4 or ART8 depending
on the conditions. A similar role was also elucidated for ART3 (also
called Aly2) in the regulation of the aspartate/glutamate transporter,
Dip5 (Hatakeyama et al., 2010). As previously observed (Nikko et
al., 2009), ART3 also binds the Rsp5 ligase via a PPxY motif-WW
domain interaction, and was found to be ubiquitinated by Rsp5
(Hatakeyama et al., 2010). ART3 was shown to interact with
phosphorylated Dip5 in an aspartate signal-dependent manner,
thereby acting as an adaptor for the recruitment of Rsp5. Rsp5 then
ubiquitinates Dip5, promoting its endocytosis and vacuolar
degradation.
Although the structures of the ART cargo proteins described above
(Can1, Mup1, Lyp1, Itr1, Hxt6 and Dip5) have not been
experimentally determined, they are thought to be multipass
membrane permeases, typically with 12 TM-spanning domains
(based on UniProtKB database predictions). Thus, they may bear
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little structural relation to GPCRs, suggesting that ART binding to
these transporters may be via an unrelated mechanism.
These studies have led to the development of a model for the
mode of action of Į-arrestins, in particular in yeast (Figure 1.4),
whereby Į-arrestins act as adaptors for the recruitment of NEDD4
ubiquitin ligases to plasma membrane cargo, thereby mediating
cargo ubiquitination, resulting in internalisation and downregulation.
Within this model, it is notable that several Į-arrestins have
themselves reported to be ubiquitinated by the NEDD4 ligase with
which they interact, and that this may represent a dynamic, signal-
dependent modulator of Į-arrestin function (Becuwe et al., 2012).
In addition to this emerging paradigm, a further mechanism by
which ARTs may regulate cargo protein signalling and/or trafficking
was identified for ART9 in yeast (also called Rim8; orthologue of the
fungal protein PalF, see above) (Herrador et al., 2009). As was
observed in fungi (Herranz et al., 2005), ART9 interacts with the
putative seven-transmembrane domain pH sensor, Rim21 (PalH in
fungi). Interestingly, ART9 was also found to interact directly with
Vps23, and coimmunoprecipitated with both Vps23 and Vps28,
components of the ESCRT-I complex (Herrador et al., 2009).
Furthermore, ART9 overexpression resulted in the redistribution of
Vps23 from endosomal structures to the plasma membrane where it
colocalised with ART9. From this, the authors proposed a model
whereby ART9 recruits the ESCRT machinery to Rim21 at the
plasma membrane, allowing Rim21 signalling through ESCRT
components, although direct evidence for a Rim21-ESCRT signalling
link remains to be uncovered.
Another apparent exception to the paradigm is the Į-arrestin-
mediated regulation of the intracellular trafficking of the general
amino acid permease 1 (Gap1) in yeast (O'Donnell et al., 2010).
Both ART3 and ART6 (also called Aly2, Aly1, respectively) were
found to interact with Gap1 and, in contrast to the reports described
above, increased the levels of Gap1. ART3 and ART6 localised to
endosomes, and were required for the efficient recycling of Gap1
from endosomes to the trans-Golgi but not Gap1 endocytosis. This
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led to the proposal that ART3/6 maintain intracellular and plasma
membrane levels of Gap1 via the diversion of the transporter away
from a trafficking itinerary that results in vacuolar degradation. As
described above, with respect to an alternative specific cargo (Dip5),
ART3 acts in agreement with the above paradigm, mediating cargo
endocytosis (Hatakeyama et al., 2010). Thus, individual Į-arrestins
may mediate spatially and mechanistically distinct trafficking events
in a cargo-specific manner.
transporter
Į-arrestin
PY
Rsp5WW
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Figure 1.4 Į-Arrestins are cargo-specific ubiquitin ligase adaptors
Į-Arrestins, in particular in yeast (also called arrestin-related trafficking
adaptors, ARTs) act as adaptors for HECT domain E3 ubiquitin ligases of
the NEDD4 family, whose sole member in yeast is Rsp5. The PPxY motifs of
Į-arrestins and WW domains of E3 ligases mediate the interaction, which
may result in the ubiquitination of the Į-arrestin (Becuwe et al., 2012;
Gupta et al., 2007; Hatakeyama et al., 2010; Kee et al., 2006; Lin et al.,
2008; Rauch et al., 2011). In response to environmental cues, for example
changes in pH or nutrient availability, Į-arrestins are recruited to cargoes
(e.g. amino acid transporters) at the plasma membrane, a process that
may require cargo phosphorylation (Hatakeyama et al., 2010; Lin et al.,
2008; Nikko et al., 2008). This results in cargo ubiquitination, which acts
as a trigger for endocytosis and subsequent degradation.
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1.4.3 Į-Arrestins in man
Knowledge pertaining to the human Į-arrestins is currently limited,
although a few recent reports suggest that the model presented by
yeast/fungal Į-arrestins may represent a reasonable functional
template for their actions in mammalian cells.
1.4.3.1 Primary structure
As mentioned in section 1.4.1, although they share a moderate
degree of homology with ǃ-arrestins, the human Į-arrestins are
clearly a distinct subset within the arrestin clan that appeared earlier
in evolutionary history. The Į-arrestins themselves share a similar
putative domain organisation (see Figure 1.3). They all possess
predicted arrestin N- and C-domains, as well as an additional C-
terminal tail region that contains two PPxY motifs, except for
ARRDC5 and Vps26 which are shorter and do not contain any PPxY
motifs. The highest protein sequence identities are between
ARRDC2/3/4 at around 50% (see Figures 1.1 and 1.2). At a local
level ARRDC2/3/4 display marked similarities too, such as a
consensus surrounding the second PPxY motif  PPPLYSEXDP(N/H)P
(PPxY motif in bold) present in all three  suggesting that the
structural integrity of this and possibly other motifs may underlie
important conserved functions (in the case of the PPxY motif,
presumably interaction with WW domains; see section 1.4.3.3
below). Differences exist, however, such as the lack of PPxY motifs
in ARRDC5 and Vps26, and lower overall sequence identity between
different members, suggesting that the Į-arrestins may have
distinct characteristics and roles.
1.4.3.2 Divergent human Į-arrestins: TXNIP and Vps26
TXNIP
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TXNIP (also called thioredoxin-binding protein-2 (TBP-2) or vitamin
D3 up-regulated protein 1 (VDUP1)) is a mammalian Į-arrestin that
is homologous to the ARRDC proteins; it has predicted arrestin N-
ARRDC2 407aa
ARRDC1 433aa
ARRDC3 414aa
ARRDC4 418aa
ARRDC5 342aa
Txnip 391aa
Vps26 327aa
100 amino acids
Arrestin N-domain
Arrestin C-domain
PY motif
Figure 1.3 Domain organisation of the human Į-arrestin proteins
PFAM predicted arrestin N- and C-domains are indicated with blue and red
boxes, respectively. For Vps26, X-ray crystal structures indicate that these
domains do indeed give an arrestin fold (Collins et al., 2008; Shi et al.,
2006). PY motifs (black boxes) are conserved PPxY sequences that have
been shown to mediate interaction with WW domains.
and C-domains and two PPxY motifs within its C-terminus.
Additionally, TXNIP interacts with thioredoxin and inhibits
thioredoxin disulphide reducing activity (Junn et al., 2000;
Nishiyama et al., 1999). TXNIP interacts with the reduced form of
thioredoxin via a disulphide bond involving TXNIP Cys247, a residue
that is not conserved in other arrestins (Figure 1.2), and it appears
that this interaction is unique to TXNIP; ARRDC2, ARRDC3 and
ARRDC4 do not interact with thioredoxin (Oka et al., 2006; Patwari
et al., 2006).
Thioredoxin is a small ubiquitous antioxidant protein, and through
its interaction with and inhibition of thioredoxin, TXNIP has critical
roles in metabolism and controlling the cell redox state (Patwari et
al., 2012). TXNIP expression is suppressed by insulin (Parikh et al.,
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2007), induced by high glucose levels (Schulze et al., 2004;
Stoltzman et al., 2008) and upregulated in diabetes (Parikh et al.,
2007). The induction of TXNIP expression by glucose forms part of a
negative feedback mechanism, whereby TXNIP inhibits insulin-
stimulated glucose uptake into fat and muscle (Parikh et al., 2007;
Zhou et al., 2010). Thus, TXNIP has been linked to insulin resistance,
supported by the finding that TXNIP-null mice are protected against
diabetes (Chen et al., 2008). Indeed, elsewhere TXNIP-null mice
were found to be hypoglycaemic, hypoinsulinaemic and exhibit
enhanced glucose uptake in insulin-responsive tissues (Chutkow et
al., 2008).
The mechanisms underlying TXNIP actions in glucose homeostasis
remain unclear. A mutant version of TXNIP lacking Cys247 retains the
ability to inhibit glucose uptake (Patwari et al., 2009). Inhibition of
glucose uptake is thus independent of TXNIP interaction with
thioredoxin; rather, it is dependent upon the presence of TXNIP
arrestin N- and C-domains (Patwari et al., 2009). Interestingly,
although ARRDC4 does not bind thioredoxin (Patwari et al., 2006), it
too was a potent inhibitor of glucose uptake (ARRDC2 or ARRDC3
had no effect), indicating the potential involvement of conserved
arrestin domains in glucose metabolism. The manner in which the
arrestin architecture may regulate glucose uptake is not known,
although it could be hypothesised that Į-arrestins interact with and
influence glucose transporter activity (for example,
endocytosis/trafficking of the two most abundant glucose
transporters, GLUT1/4). A precedent for this has already been
described in yeast (section 1.4.2): the Į-arrestins ART4 and ART8
are required for endocytosis of the glucose transporter Hxt6 (Nikko
et al., 2009). However, GLUT4 or GLUT1 levels were largely
unaffected by TXNIP deletion in mice (Andres et al., 2011; Yoshioka
et al., 2007); thus, whether the scaffolding of glucose transporters
by yeast ARTs is conserved in mammalian Į-arrestins is unknown.
Vps26
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The retromer is a conserved pentameric complex required for the
retrograde sorting of cargo proteins, exemplified by the cation-
independent mannose 6-phosphate receptor and Shiga toxin, from
late endosomes to the trans-Golgi network (TGN) (Attar et al.,
2011). The function of the retromer is crucial to several
developmental and disease-related events, including the generation
of Wnt gradients and sorting of enzymes involved in Alzheimers
disease. Mammalian retromer comprises two subcomplexes: a
cargo-recognition heterotrimer consisting of Vps26-Vps29-Vps35;
and a membrane-deforming module comprising sorting nexin-
bin/amphiphysin/rvs (SNX-BAR) proteins (typically SNX1 and SNX2).
As noted in section 1.4.1, the crystal structure of Vps26  a member
of the cargo recognition complex  revealed that it has an arrestin
fold (Collins et al., 2008; Shi et al., 2006), and it was later placed in
a phylogenetic grouping with the Į-arrestins (Alvarez, 2008).
The identification of an Į-arrestin as a component of the retromer
cargo-recognition complex supports the proposed role of the arrestin
fold, found in Į- and ǃ-arrestins, as a conserved architecture for
intracellular cargo protein trafficking. It could be hypothesised that
ǃ-arrestins arose later in evolution as a result of adaptations, such
as the polar core and clathrin/AP2-binding motifs (not present in
Vps26/Į-arrestins; Figure 1.2), that enable their interaction with
and regulation of GPCRs, and that Į-arrestins do not therefore share
these specific capabilities. However, a recent investigation has
provided a tentative refutation of this hypothesis (Feinstein et al.,
2011). As has been described for several GPCRs (section 1.3.1),
signalling by the parathyroid hormone (PTH) receptor (PTHR)  in
response to the clinically-used PTH analogue, PTH(1-34)  was
found to have a ǃ-arrestin-dependent component; ǃ-arrestin1
overexpression potentiated, rather than inhibited, cAMP
accumulation induced by PTH(1-34). This corresponded to the
persistence of a PTHR-ǃ-arrestin1 complex on endosomes following
PTH(1-34)-induced internalisation, and the authors concluded that
the prolonged signalling detected arose from PTHR-ǃ-arrestin1
complexes that remained on endosomes, although the localisation of
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the unit responsible for continued signalling was not directly
demonstrated. Interestingly, overexpression of various retromer
components attenuated PTH(1-34)-induced cAMP accumulation, and
conversely siRNA knockdown of the retromer prolonged the
response, leading to the proposal that the retromer terminates PTHR
signalling on endosomes. A ǃ-arrestin1 mutant that has increased
affinity for PTHR was able to rescue the observed attenuation of
PTHR cAMP response caused by retromer overexpression,
suggesting that ǃ-arrestin1 and retromer may compete for PTHR
binding. Agonist-dependent interaction of Vps29 with PTHR was
detected by coimmunoprecipitation over a similar time-scale to the
observed attenuation effect of the retromer, although whether this
represents a direct association was not tested. A candidate for the
direct mediator of the retromer-PTHR interaction is Vps26. Given its
structural similarity to ǃ-arrestins, Vps26 could conceivably compete
with ǃ-arrestin1 for PTHR binding. In future experiments it will be
intriguing to determine whether Vps26 does directly bind PTHR, and
to elaborate on the possible mechanism of this interaction.
Detection of a Vps26-PTHR interaction would support the idea that
GPCR binding ability extends to the Į-arrestins.
1.4.3.3 Initial identification of ARRDC proteins
As with many proteins, the initial identification of several human
ARRDCs was through the observation of physiological or
pathophysiological circumstances in which their gene expression is
altered. The first of these was ARRDC4, whose expression was
identified as being significantly lowered in hepatocellular carcinoma
(HCC), hence its original designation as down-regulated in advanced
hepatocellular carcinoma (DRH1) (Yamamoto et al., 2001). ARRDC4
was observed within the cytoplasm when expressed exogenously as
a green fluorescent protein (GFP) fusion in COS-7 cells, and was
frequently downregulated at a late stage of HCC development. Next,
rat ARRDC2 was discovered in a screen for genes responsive to the
hallucinogen, lysergic acid diethylamide (LSD) (Nichols et al., 2004).
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ARRDC2 (denoted therein as induced by lysergic acid diethylamide-1;
ILAD-1) expression increased significantly (around two-fold) in
different brain regions in response to LSD. These increases were
partially blocked by co-incubation with antagonists at 5-HT2A
receptors (GPCRs involved in neurotransmission), providing the first
tentative link between ARRDCs and GPCR function. The mechanism
by which 5-HT2A receptors may be involved in regulating ARRDC2
expression was not investigated.
Also identified was ARRDC3, originally as a homologue of TXNIP.
ARRDC3 localised to the plasma membrane, endosomes and
lysosomes when expressed exogenously in HeLa, HEK-293, COS-7
or CHO cells. In contrast to TXNIP, ARRDC3 did not bind to
thioredoxin, but ARRDC3 expression was upregulated in HL-60 cells
in response to vitamin D3 or activation of peroxisome proliferator-
activated receptor-Ǆ33$5Ǆ(Oka et al., 2006). Thus, ARRDC3 may
have a role in energy metabolism and cell growth inhibition. The
ARRDC3 gene was also reported as downregulated early on in breast
cancer (Draheim et al., 2010). Loss of ARRDC3 expression was
correlated with tumour grade, metastatic potential and recurrence;
furthermore, overexpression or knockdown of ARRDC3 expression
had potent antagonistic effects on in vivo markers of
tumourigenicity. In this study, ARRDC3 was coimmunoprecipitated
with the cell surface adhesion molecule, ǃ-4 integrin (ITGǃ4), a
protein strongly associated with the progression of cancer. ARRDC3
preferentially associated with phosphorylated ITGǃ4, leading to
ITGǃ4 internalisation, ubiquitination and proteasome-dependent
degradation, hence supporting the purported tumour suppressor
activity of ARRDC3.
Collectively, these early studies provided the first indication that
human ARRDCs may perform important roles whose dysregulation
could lead to various physiological impairments, thus warranting
their further investigation.
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1.4.3.4 Possible molecular functions of ARRDCs
ARRDC3 mediates ǃ2AR degradation
The first detailed investigation into the molecular function of a
human ARRDC investigated the role of ARRDC3 in the regulation of
the prototypic GPCR, ǃ2AR (Nabhan et al., 2010). ARRDC3 was
identified in a genome-wide screen for short hairpin RNAs (shRNAs)
that inhibited ǃ2AR degradation. In the screen, a truncated version
of the receptor (ǃ2ARt) was used that lacked the C-terminal
recycling sequence, the PDZ-binding motif (DSLL); hence, prolonged
agonist stimulation resulted in efficient degradation of ǃ2ARt.
However, in cells expressing Arrdc3-specific shRNA, immunostaining
and fluorescence-activated cell sorting (FACS) analysis indicated
that stimulated ǃ2ARt levels were higher (>20%) than in cells
expressing control shRNAs. Furthermore, siRNA knockdown of
ARRDC3 drastically inhibited the agonist-stimulated degradation of
ǃ2ARt, as detected by immunoblotting, and was also suggested to
inhibit the degradation of full-length ǃ2AR, although in this case the
effect was expectedly much less pronounced. Hence, ARRDC3 may
be required for the degradation of ǃ2AR.
ARRDC3 was also found to affect ǃ2AR ubiquitination; siRNA
knockdown of ARRDC3 inhibited the agonist-stimulated increase in
ǃ2AR ubiquitination, whereas efficient knockdown of another ARRDC,
ARRDC1, had no effect. This suggested that the effect on ǃ2AR may
be specific to ARRDC3, although given that the greater protein
sequence similarities exist between ARRDC2/3/4, it may have been
more informative to also test for an effect of ARRDC2 or ARRDC4
knockdown. Given the similarities between ARRDC2/3/4, it would
also have been informative to know whether the siRNAs used to
target ARRDC3 were indeed specific, or also affected ARRDC2
and/or ARRDC4 expression levels.
As for many of the Į-arrestins present in lower eukaryotes
mentioned in section 1.4.2, ARRDC3 was found to interact with an
E3 ubiquitin ligase  the HECT ligase NEDD4  via its PPxY motifs;
ARRDC3 coimmunoprecipitated with NEDD4 in basal conditions in a
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manner dependent on the presence of ARRDC3 PPxY motifs. As for
the yeast/fungal Į-arrestins, the authors proposed that in so doing,
ARRDC3 may act as an adaptor for the recruitment of NEDD4 to the
activated receptor (in this case, ǃ2AR), in order to promote receptor
ubiquitination and lysosomal degradation. To support this, they
showed that ARRDC3 coimmunoprecipitates with ǃ2AR in an agonist-
dependent manner. Importantly, this is the first report of an
interaction between any ARRDC and a GPCR; moreover, as for ǃ-
arrestins, the apparent interaction was strongly promoted by
receptor activation. In addition, a double mutant at the ARRDC3
PPxY motifs that did not coimmunoprecipitate NEDD4 was used to
test the role of the ARRDC3-NEDD4 interaction on ǃ2AR
ubiquitination and degradation. It was found that overexpression of
the PPxY mutant ARRDC3 drastically inhibited agonist-stimulated
ǃ2AR ubiquitination and degradation, whereas wild-type ARRDC3
had no observable effect. In support of these data, siRNA
knockdown of ARRDC3 expression rendered the apparent
coimmunoprecipitation between ǃ2AR and NEDD4 (which, albeit
weak, appeared to occur in an agonist-dependent manner)
undetectable. It is notable here that, as mentioned in section 1.3.1,
the same adaptor role in recruiting NEDD4 to the activated ǃ2AR had
been previously reported for ǃ-arrestin2 (Shenoy et al., 2008). The
same result had been reported in this study but for ǃ-arrestin2:
siRNA knockdown of ǃ-arrestin2 appeared to abolish the ǃ2AR-
NEDD4 interaction. To address this, Nabhan and co-workers
performed the same experiment: siRNA was used to knockdown ǃ-
arrestin2 and, in this case, no effect upon the ǃ2AR-NEDD4
coimmunoprecipitation was observed (Nabhan et al., 2010). Thus,
they concluded that ARRDC3, not ǃ-arrestin2, is crucial for NEDD4
recruitment to ǃ2AR and subsequent receptor ubiquitination and
degradation. The reason for the disparity in these results is unclear,
although it may stem from the use of different siRNAs and
immunoprecipitation conditions. In particular, the ǃ-arrestin2-
specific siRNA used by Shenoy and colleagues (2008) appeared to
produce a marked reduction in ǃ-arrestin2 expression, as evidenced
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by immunoblotting, thus giving an apparent effect on the ǃ2AR-
NEDD4 interaction. In contrast, Nabhan and colleagues (2010) used
a different siRNA that was much less efficient at reducing ǃ-
arrestin2 expression (indeed it appeared to have more effect on ǃ-
arrestin1 levels), making it difficult to detect even a genuine effect.
Therefore, it remains unresolved as to whether any one arrestin
family member is solely responsible for performing the adaptor role
between ǃ2AR and NEDD4, or whether functional overlap, or indeed
cooperativity (see note on arrestin oligomerisation, section 1.3.1),
between arrestin members may occur.
ARRDC3: a novel regulator of energy metabolism?
Following on from the study by Nabhan et al. (2010), a subsequent
article reported ARRDC3 as a regulator of obesity and energy
expenditure via its actions on ǃ-adrenoceptors (Patwari et al., 2011).
A precedent for human Į-arrestin involvement in metabolism
already existed prior to this report in the established ability of TXNIP
to modulate glucose metabolism in vivo (described in section
1.4.3.2), a role that may also be held by ARRDC4 (Chutkow et al.,
2008; Hui et al., 2008; Patwari et al., 2009). ARRDC3  or indeed
ARRDC2  does not appear to affect glucose transport (Patwari et al.,
2009), although a potential link between ARRDC3 and energy
metabolism had previously been noted (Oka et al., 2006; section
1.4.3.3). It is worth mentioning that roles in metabolism may be
conserved throughout the arrestin family (Patwari et al., 2012),
evidenced by the fact that ǃ-arrestin knockout mice are insulin-
resistant and that insulin receptor signalling is directly modulated by
ǃ-arrestin (Luan et al., 2009; Usui et al., 2004).
Patwari and colleagues (2011) identified a potential metabolic role
for ARRDC3 through a genome-wide linkage scan in which an
association between single polynucleotide polymorphisms (SNPs) at
the ARRDC3 locus and high body-mass index (BMI) in males was
discovered. The authors went on to assess the tissue distribution of
ARRDC3 in human tissues: Northern analysis indicated ARRDC3
expression in various tissues (including skeletal muscle, kidney, liver,
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placenta and lung) but notably not in brain. However, ARRDC3 was
expressed in adipose tissue and, interestingly, this expression
positively correlated with BMI in male omental (central) adipose
tissue. This implicated ARRDC3 as a potential metabolic regulator in
this and maybe other tissues. To test this, the expression of
ARRDC3 was assessed in mice subject to either a fed or fasting
regimen. Microarray, real-time PCR and Northern analysis all
indicated that ARRDC3 levels are elevated in the fasting state, most
prominently in visceral (epididymal) fat (5.6-fold), but also
significantly in brown fat and skeletal muscle. Following this, the
authors hypothesised that ARRDC3 deficiency may protect against
the development of obesity. Using a mouse strain prone to age-
induced obesity, they show that Arrdc3 null (-/-) males have a
significantly lower total body mass than their wild-type counterparts
throughout development (15% lower at five weeks of age; 29%
lower at twenty weeks). The effect was less pronounced in female
mice: no effect was observed at an early stage, but Arrdc3 null
females were resistant to the development of obesity over time, and
by twenty weeks total body mass was 29% lower than in wild-type
mice. These differences were reflected in the fact that percentage
body fat was lower in Arrdc3 null mice in both males and females.
The mechanism by which Arrdc3 deficiency may confer resistance
to obesity in mice was next investigated. Serum thyroid hormone
and catecholamine levels were largely unaffected by the lack of
Arrdc3, suggesting that ARRDC3 may primarily act downstream of
hormone activation at the site of effector tissues in which it is
expressed. In agreement with this, several catecholamine-induced
genes involved in thermogenesis were found to be upregulated in
the brown and white adipose of Arrdc3 null mice, and mice
heterozygous for Arrdc3 had higher oxygen uptake and heat
production. As previously shown (Nabhan et al., 2010), Patwari and
colleagues (2010) detected coimmunoprecipitation of ARRDC3 with
ǃ2AR in vitro. In this case, immunoprecipitation was performed
under unstimulated conditions; whether the interaction is enhanced
by ǃ2AR stimulation was not tested. ARRDC1 and ARRDC4 were also
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found to coimmunoprecipitate with ǃ2AR under these conditions
(TXNIP did not; ARRDC2 was not tested). Interestingly, ARRDC3
also coimmunoprecipitated with ǃ3AR, a GPCR that lacks the
phosphorylation sites present in ǃ1AR and ǃ2AR that are required for
interaction with ǃ-arrestins and desensitisation (Liggett et al., 1993;
Nantel et al., 1993). Consistent with the putative role for ARRDC3 in
downregulating receptor signalling (Draheim et al., 2010; Nabhan et
al., 2010), Arrdc3 deficiency potentiated the adrenoceptor
stimulation of lipolysis, as measured by the increase in glycerol
release in response to noradrenaline in ex vivo mouse adipose tissue.
Levels of cyclic adenosine monophosphate (cAMP), a common
second messenger produced in response to ǃ-adrenoceptor
signalling, were also elevated in Arrdc3 null mice adipose compared
to controls.
Collectively, these data point to ARRDC3 being a downregulator of
ǃ-adrenoceptor signalling whose absence results in increased
thermogenesis and therefore may protect against obesity.
ARRDCs as adaptors for PPxY-dependent viral budding
The final stage in the release of retroviruses from infected cells
involves fusion with the host cell plasma membrane, budding and
scission of a nascent virion particle. Topologically, the membrane
deformation and scission of a lipid encased nascent vesicle involved
in these events resemble those mediated by the ESCRT machinery
in the formation of ILVs of multivesicular bodies MVBs (section
1.2.3), and it has been shown that many viruses co-opt ESCRT
components in order to perform these functions (Martin-Serrano et
al., 2011). The factors involved are short amino acid sequences
called late-budding activity domains (L-domains), present in
retroviral group-specific antigen (Gag) proteins (Demirov et al.,
2004). At least three categories of L-domains exist in different
viruses that bind various components of the ESCRT machinery:
these include P(S/T)AP L-domains, which recruit the ESCRT-I
subunit tumour susceptibility gene 101 protein (Tsg101), and LYPXL
L-domains, which interact with AIP1/ALIX, an ESCRT accessory
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protein (reviewed in Demirov and Freed, 2004). The third type of L-
domains are PPxY motifs. These are thought to link Gag proteins to
the ESCRT machinery via interaction with several NEDD4 family
HECT E3 ubiquitin ligases (NEDD4, WWP1, WWP2 and AIP4/Itch).
However, direct binding between the E3 ligases and ESCRT
components has not been detected: thus, a recent report addressed
this by testing whether Į-arrestins may act as ligase-ESCRT
adaptors in the context of PPxY-dependent viral budding (Rauch et
al., 2011).
First, the authors used a yeast two-hybrid system to assay for Į-
arrestin interactions with the relevant HECT E3 ligases NEDD4,
WWP1, WWP2 and AIP4. All Į-arrestins tested (ARRDC1, ARRDC2,
ARRDC3, ARRDC4 and TXNIP) interacted with each ligase, except for
the pairings of ARRDC2-AIP4 and ARRDC4-WWP2. GST experiments
using the Į-arrestins to pull-down the WW domains of each
respective ligase confirmed that all these interactions were direct; in
this case even ARRDC2-AIP4 and ARRDC4-WWP2 were shown to
interact. The interactions detected were presumed to involve contact
between Į-arrestin PPxY motifs and ligase WW domains. This was at
least supported by the demonstration that an ARRDC1 mutant
lacking the C-terminus (containing the two PPxY motifs) was no
longer able to produce an interaction with any of the ligases in the
yeast two-hybrid assay.
Importantly, out of a panel of all known ESCRT components tested
in yeast two-hybrid experiments, ARRDC1, ARRDC2 and ARRDC3
appeared to interact with ALIX, and ARRDC1 also interacted with
Tsg101. ARRDC1 is the only human Į-arrestin that contains a PSAP
motif (in the C-terminus); truncated ARRDC1 lacking the C-terminus
failed to interact with Tsg101, implying that the PSAP motif may be
responsible for the interaction. All the Į-arrestins mentioned above
were also found to interact to some degree in yeast two-hybrid
experiments with ubiquitin. This suggested that they may be
ubiquitinated, or may contain ubiquitin-binding motifs, although this
has not been reported elsewhere and was not investigated further
by Rauch and Martin-Serrano (2011). In addition, GST pull-down
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experiments indicated that ARRDC1 is itself modified by ubiquitin,
and that this may be performed by WWP1. In general, this
reinforces the idea that the Į-arrestins may be involved in the
endocytic sorting machinery.
The authors next investigated the potential role of Į-arrestins,
notably ARRDC1, in viral budding. They presented evidence that
ARRDC1 may be recruited to the site of viral assembly: exogenously
expressed, fluorescent protein-tagged ARRDC1 in HEK-293 cells
redistributed from an intracellular pattern to the plasma membrane
upon coexpression with Ebola virus matrix protein VP40. This
redistribution required the presence of the PTAPPEY motif in VP40,
suggesting that PPxY-dependent viral budding may involve Į-
arrestin recruitment to the plasma membrane via interaction with a
HECT E3 ligase such as WWP1. In support of this, overexpression of
ARRDC1, ARRDC2 or ARRDC3 caused a dose-dependent inhibition of
the infectious particle production of another PPxY-dependent virus,
murine leukaemia virus (MLV). This suggested that multiple Į-
arrestins may act redundantly as adaptors for PPxY-dependent viral
budding; this was further indicated by the fact that targeted siRNA
knockdown of individual Į-arrestins had no effect on virus budding
efficiency.
In addition to establishing a potential role for human Į-arrestins in
viral budding, the study by Rauch and Martin-Serrano (2011) further
developed our knowledge of Į-arrestin interactions that point
strongly towards their involvement in the endo-lysosomal system.
These include their ability to bind to multiple different HECT E3
ligases and be modified by ubiquitin, possibly by those same ligases.
Also, interaction with members of the ESCRT machinery, as noted
previously for an Į-arrestin (ART9) in yeast (Herrador et al., 2009;
see section 1.4.2), further suggests that the human Į-arrestins may
function in the sorting of endocytic cargo proteins, thus adhering to
the emerging paradigm in lower eukaryotes.
ARRDC1 mediates microvesicle budding
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Cells release a number of membrane-bound particles into the
extracellular space, including endosome/MVB-derived vesicles
(exosomes), non-endosome/MVB-derived vesicles (microvesicles or
microparticles) and apoptic bodies (György et al., 2011). Although
far from fully understood, these particles may contain cellular
proteins, RNAs and mRNAs that mediate intercellular communication
for a variety of biological functions. Recent observations suggest
that they share characteristics with virus particles, such as
biophysical properties, biogenesis and the ability to transfer
biological information between cells (Meckes et al., 2011).
As a corollary to the role described for ARRDC1 in viral budding
(Rauch et al., 2011), it has been reported that ARRDC1 mediates
the formation and release of a distinct type of extracellular particle,
termed ARRDC1-mediated microvesicles (ARMMs) (Nabhan et al.,
2012). ARRDC1 was previously found to interact with the ESCRT-I
component, Tsg101, likely via its C-terminal PSAP motif (Rauch et
al., 2011). Nabhan et al. (2012) corroborate this claim, and report
that ARRDC1 targets to the plasma membrane and that the
overexpression of ARRDC1 stimulates redistribution of Tsg101 from
the cytosol to the plasma membrane in a manner requiring the
ARRDC1 PSAP motif. The authors show that ARRDC1 can be
packaged into microvesicles in a manner dependent upon the
ARRDC1-Tsg101 interaction, revealing a potential link with retroviral
budding, in which the retroviral Gag protein recruits Tsg101 via an
equivalent motif (PTAP). The apparent plasma membrane targeting
of ARRDC1-Tsg101 suggests that ARMMS may bud at this site rather
than from an intracellular location (for example, endosomes/MVBs),
hence their designation as microvesicles, not exosomes. This is
supported by the lack of late endosomal markers present in ARMMS.
Nonetheless, ARMMS release is dependent upon the ESCRT
machinery (demonstrated for Tsg101 and the Vps4 ATPase) and is
enhanced by the NEDD4 family E3 ligase, WWP2, which interacts
with and ubiquitinates ARRDC1.
There are notable similarities between ARMMs release and
retroviral budding: plasma membrane location, requirement for
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ESCRT components  including the P(S/T)AP motif-driven
recruitment of Tsg101  and involvement of NEDD4 family ligases.
This led the authors to hypothesise that Gag proteins may have
evolved to mimic ARRDC1 in order to hijack what appears to be an
intrinsic cellular mechanism for plasma membrane budding.
1.6 Objectives
The emergence of Į-arrestins as important novel regulators of
protein trafficking and signalling has been described above.
Although the majority of these data come from studies in lower
eukaryotes, the existence of Į-arrestins in man begs the question of
whether these proteins perform similar, important roles in the
regulation of human cellular functions. The few existing reports
detailed above ascribe to the importance of human ARRDCs and
their likely mechanistic similarity in function to lower eukaryotic Į-
arrestins. In particular, the probable structural conservation
between arrestin family proteins is noted, and it is hypothesised that
this may result in a similar repertoire of interaction partners
between Į-arrestin orthologues.
The following thesis outlines characterisation of the human Į-
arrestin, ARRDC2. Initial experiments investigated ARRDC
subcellular localisation, which has been poorly addressed thus far in
the literature, focussing on ARRDC2. Through the use of a panel of
compartment-specific markers in combination with fluorescent
protein-tagged ARRDC2 expression in the U2OS cell line, confocal
microscopy indicated that ARRDC2 is dynamically targeted to the
endocytic system, predominantly the lysosome (Chapter 3).
Assessment of endogenous ARRDC2 expression in several primary
cell lines was enabled through the development of an anti-ARRDC2
antibody. This supported a plasma membrane and endocytic
localisation for ARRDC2.
As mentioned above, ARRDC2 displays sequence similarity to
other Į-arrestins, retaining sequence motifs such as the C-terminal
PPxY motifs that are strongly linked to Į-arrestin roles in scaffolding
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NEDD4 family ubiquitin ligases. Thus, Chapter 4 describes the
detection of interactions between ARRDC2 and the nine human
members of the NEDD4 ligase family using coimmunoprecipitation.
ARRDC2 interactions with NEDD4 ligases were further delineated
through molecular (mutagenesis) and cell biological (coexpression
and confocal microscopy) approaches. The ubiquitination status of
ARRDC2 was also investigated via coimmunoprecipitation.
In addition to their close homology with Į-arrestins from other
species, human ARRDCs are ancestrally related to the ǃ-arrestins.
Whether the regulation of GPCRs is a newly evolved feature of ǃ-
arrestins, or is conserved in Į-arrestins, remains unclear, although a
few recent reports hint that the latter may be the case (see section
1.4.3). Chapter 5 investigated this by assessing the potential
involvement of ARRDC2 in the function of two model GPCRs: ǃ2AR, a
GPCR that rapidly recycles to the plasma membrane following
agonist-induced internalisation, and įOR, which in contrast is
efficiently delivered to the lysosome for degradation upon agonist
stimulation. These studies established to what extent ARRDC2
colocalises and associates with each GPCR, and the potential effect
of ARRDC2 upon the trafficking and signalling of the receptors was
investigated. Finally, the potential for cooperation or competition
between Į- and ǃ-arrestins was addressed through testing of the
ability of ARRDC2 to oligomerise with itself and ǃ-arrestins.
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2 Materials and methods
2.1 Materials and reagents
Tissue culture flasks were from Sarstedt (Numbrecht, Germany).
Tissue culture medium and other reagents were from Sigma
(Wokingham, UK). Antibiotics used in eukaryotic cell
selection/induction were zeocin, G418 and blasticidin (all Invitrogen,
Paisley, UK) and tetracycline (Sigma).
2.2 Molecular biology
The approach used here to transfer target complementary DNA
(cDNA) sequences of interest into the relevant mammalian
expression plasmids (i.e. subcloning), for example into a plasmid
containing a desired epitope tag, is summarised in Figure 2.1.
Where required, this process included the initial polymerase chain
reaction (PCR) amplification of the target cDNA from a pre-existing
plasmid, in order to engineer desired restriction endonuclease
recognition sequences outside of the coding sequence (Figure 2.1,
steps 1-6, left side). Alternatively, pre-existing plasmids containing
target cDNAs already flanked by convenient restriction sequences
were used for the donation of insert cDNAs without the need for
PCR amplification (i.e. entering Figure 2.1 at step 7). The methods
involved in each step of this process are detailed here (sections
2.2.1  2.2.9).
In addition to the canonical restriction digest-based method above,
in some cases the Gateway® method of homologous recombination-
based cloning (Invitrogen) was used; this is described in section
2.2.10.
In several instances, PCR was used for the site-directed
introduction of mutations into target cDNA sequences. The approach
used is described in section 2.2.11.
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Lastly, in addition to detailing the general gene cloning and
mutagenesis methods used here, the generation of each individual
plasmid construct is described in section 2.2.12, including primer
sequences/unique conditions, etc.
2.2.1 PCR amplification of target cDNA sequences
(step 1)
cDNA sequences of interest were amplified from the relevant host
vectors by PCR. PCR reactions included, in a final volume of 50 µl: 5
µl 10X Pwo reaction buffer containing 1.5 mM MgSO4 (Roche,
Burgess Hill, UK), dNTPs mix (200 µM of each of dATP, dCTP, dGTP
and dTTP; Promega, Madison, WI, USA), 25 ng cDNA template, 600
µM final concentration of each of the oligonucleotide primers and
double-distilled H2O (ddH2O). Where indicated, 2.5 µl (5%) dimethyl
sulphoxide (DMSO, Sigma) was included to reduce primer secondary
structure formation.
The reaction mixture was set up in a thin-walled 200 µl PCR tube
(Scientific Laboratory Supplies, UK). Hot-start PCR method was
used here to avoid nonspecific priming of unwanted templates
and/or primer dimer formation that may occur at lower (i.e. less
stringent) temperatures. To do this, prior to addition of the DNA
polymerase, reaction tubes were placed in a thermocycler block
(Mastercycler gradient, Eppendorf, UK) which was set to perform an
initial denaturation step at 95ºC for 30 seconds before lowering to
the annealing temperature (55-60ºC depending on primers), at
which point 0.5 µl (2.5 units) Pwo DNA polymerase (Roche) was
added to the reaction mixture. Pwo DNA polymerase was used for
its 3  5 exonuclease (proofreading) activity that gives it greater
accuracy than, for example, Taq DNA polymerase. The thermocycler
was then set to continue through 25 cycles of replication as follows:
denaturation at 95ºC for 30 seconds, annealing (~55ºC) for 45-60
seconds, and extension at 68-72ºC for ~1 min per kilobase pair (kbp)
of template length. This was followed by cooling (hold) at 4ºC.
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1. PCR amplification of target cDNA
2. Analysis and gel extraction of PCR products
3. Ligation of PCR amplicon into pJET1.2
4. Transformation into competent E.coli
5. Miniprep isolation of plasmid cDNA
6. Restriction digest and electrophoresis
analysis to check presence of insert
Transfer target cDNA insert
into appropriate host vector
7a. Restriction digest vector
containing insert
7b. Restriction digest host
vector and SAP digest
8a. Gel extraction of insert 8b. Column purification of
digested host vector
9. Ligation of insert cDNA
into host vector
10. Transformation into competent E.coli
11. Small-scale (miniprep) isolation
of plasmid cDNA
12. Restriction digest and electrophoresis
analysis to check presence of correct insert
13. Large-scale (maxiprep) isolation
of plasmid cDNA
14. Sequencing of new construct
Figure 2.1 Generalised scheme for the subcloning of target cDNA
sequences into the preferred mammlian expression plasmids
2.2.2 Analysis and gel extraction of PCR products
(step 2)
Following PCR amplification of target cDNA sequences, the entire
resulting reaction  25 µl into each of two lanes  was run on a 1 %
(w/v) agarose gel (section 2.2.2.1). Having confirmed the size of
the amplified PCR product, the relevant band was excised from the
agarose gel and the DNA extracted (section 2.2.2.2).
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2.2.2.1 Analysis of DNA samples by agarose gel
electrophoresis
DNA samples were analysed in gels consisting of 1 % (w/v) agarose
dissolved in tris-borate-ethylenediaminetetraacetic acid (EDTA)
buffer (TBE; 89 mM Tris-HCl [pH 7.6], 89 mM Boric acid, 2 mM
EDTA) by heating in a microwave oven. Ethidium bromide (Sigma),
an intercalating agent, was added to a final concentration of 0.1
µg/ml for the visualisation of DNA under ultraviolet (UV) illumination.
The gel was poured into a casting tray with a comb, allowed to set
at room temperature, and then inserted into an electrophoresis tank
and immersed in TBE buffer. DNA samples, mixed with loading
buffer (0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol,
50% v/v glycerol, 1X TBE), were loaded into the appropriate wells
alongside a molecular weight marker (BenchTop 1kb DNA ladder,
Promega). Gels were run at a constant voltage of 80 V until the dye
front had migrated towards the positive electrode an appropriate
distance. DNA was visualised by UV illumination on a Syngene GVS-
30 Transilluminator. The amount and size of DNA samples could be
estimated by reference to the molecular weight marker.
2.2.2.2 Gel extraction of DNA samples
Once DNA samples were confirmed on agarose gels, the desired
product bands were carefully excised from the gel, ensuring the
minimal possible UV exposure time to prevent damage to the DNA.
Excised fragments were transferred to sterile 1.5 ml tubes and the
DNA was extracted using the GenElute Gel Extraction Kit (Sigma),
using the solutions and columns provided. This kit employs a silica
gel-based method of DNA purification by column chromatography. A
slice of agarose gel containing the desired plasmid DNA was
dissolved in 3 volumes of gel solubilisation solution by heating to 60
ºC for ~10 min. 1 gel volume of isopropanolol was added to this
solution prior to column loading. The solubilisation solution contains
a chaotropic salt, which removes the water shell surrounding the
DNA phosphate backbone; this allows the phosphate residues of the
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disordered DNA to adsorb to the silica in the columns. The addition
of the alcohol isopropanol also aids dehydration of the DNA
phosphates, thereby enhancing binding to the silica. Once this
solution was loaded onto a column, the solution was removed by
centrifugation leaving the DNA adsorbed onto the silica. The column
was then washed with a solution containing solvent (e.g. 50%
ethanol), which removed contaminants such as RNA and
carbohydrate but did not displace the double-stranded DNA. The
plasmid DNA was then eluted in Tris buffer, which rehydrated the
DNA leading to disruption of the DNA-silica electrostatic contacts.
2.2.3 Blunt-ended ligation of PCR amplicon into
pJET1.2 vector (step 3)
In order to perform restriction digest of newly synthesised PCR
amplicons for their insertion into the relevant mammalian
expression vectors, the amplicons (blunt-ended, since the DNA
polymerase used, Pwo, is a proofreading polymerase) were first
subcloned into the pJET1.2/blunt cloning vector (Fermentas; Thermo
Fisher Scientific, Massachusetts, USA). This was to aid the DNA
digestion, since restriction enzymes inefficiently digest close to the
ends of DNA fragments, such as PCR amplicons. The pJET1.2 vector
contains the eco47IR gene whose product is a restriction
endonuclease that is lethal to E.coli host cells. Insertion of a PCR
amplicon into pJET1.2 disrupts the eco47IR gene, thus acting as a
mechanism for selection of positive bacterial colonies containing
ligated vector after transformation.
Blunt-ended ligation of gel extracted PCR amplicons (insert) into
pJET1.2 (vector) was performed such that a molar ratio of 1:3
(vector:insert) was achieved for optimal insert incorporation. 50 ng
of vector was used in the reaction, and, assuming that the ratio of
vector to insert size was 3:1 (e.g. 3 kbp vector; 1 kbp insert) 50 ng
of insert was used to achieve a 1:3 molar ratio. Assuming a yield of
~2.5 µg insert (in a total of 50 µl) was obtained from the PCR (this
was routinely estimated by reference to the molecular weight
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marker on agarose gels), 1 µl of this was required to provide 50 ng.
Thus, reactions were prepared in 0.5 ml tubes with a total volume of
20 µl containing: 50 ng pJET1.2/blunt cloning vector DNA, 1 µl
insert DNA (derived from 50 µl insert DNA resulting from gel
extraction of the PCR product), 10 µl 2X Reaction Buffer (Fermentas)
and ddH2O. The reaction buffer used contains polyethylene glycol
(PEG). PEG is a neutral polymer that, by sterically excluding volume,
induces a compact structure in DNA, increasing its effective
concentration (Louie et al., 1994). Thus, PEG enhances the
efficiency of blunt-ended ligations. 1 µl (5 units) T4 DNA ligase
(Fermentas) was added and the reaction was allowed to proceed at
22ºC for 30 min by incubation in a bench-top heat block. The
products of the ligation were then introduced into competent E.coli
by transformation (section 2.2.4.2).
2.2.4 Transformation of cDNA into chemically
competent E.coli (steps 4 and 10)
2.2.4.1 Preparation of chemically competent E.coli
Chemically competent XL-1 strain E.coli cells were prepared sterile
from a previous frozen stock of XL-1 cells streaked onto an agar
plate (LB agar, Sigma) containing 10 µg/ml tetracycline, incubated
overnight at 37ºC. A single colony from this plate was inoculated
into 5 ml LB broth (Sigma) and grown at 37ºC overnight with
agitation (250 rpm). Between 1  5 ml of the resulting culture was
inoculated into 100 ml 2YT medium (Sigma) containing 10 µg/ml
tetracycline in a 1 litre flask (the richer 2YT medium was used for
faster growth). The culture was incubated at 37ºC with agitation
(250 rpm), and growth was regularly monitored by the
measurement of optical density at 600 nm (OD600). Once OD600
reached between 0.5  0.9, the culture was further diluted to 250
ml with 2YT medium, and this culture was grown further until OD600
reached 0.6. The culture was rapidly cooled in ice-cold water with
gentle shaking, and was then centrifuged for 15 min at 4000 rpm in
a pre-cooled centrifuge at 4ºC. The resulting pellet was resuspended
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in 50 ml TfB I buffer (30 mM potassium acetate [KAc], 50 mM MnCl2,
64 mM KCl, 10 mM CaCl2, 15% glycerol, pH 5.8) on ice, and this
solution was re-centrifuged for 8 min at 4000 rpm, 4ºC. The pellet
was resuspended in 10 ml ice-cold TfB II buffer (10 mM 3-(N-
morpholino)propanesulphonic acid [MOPS], 1 mM KCl, 75 mM CaCl2,
15% glycerol, pH 7.0), from which 0.5 ml aliquots were transferred
into pre-chilled 1.5 ml tubes. The aliquots were snap-frozen in liquid
nitrogen and stored at -80ºC.
2.2.4.2 Transformation
An aliquot of competent XL-1 cells was removed from -80ºC storage
and thawed on ice. For each transformation reaction, 100 µl of cells
was transferred to a pre-chilled sterile 1.5 ml tube. 1.5 µl of 1.4 M
ǃ-mercaptoethanol was added, and the cells were incubated with
gentle mixing on ice for 10 min. An appropriate volume of DNA
(typically 10 ng of plasmid DNA, or 5 µl of a ligation reaction) was
added, and the mixture was gently mixed followed by incubation on
ice for 30 min. The mix was then subjected to a heat-pulse at 42ºC
for 45 seconds, followed by immediately returning the tube(s) to ice
for approximately 2 min. 400 µl LB broth was added, and the culture
was incubated at 37ºC for 1h with agitation (250 rpm). Between 10
 200 µl of the transformation culture was streaked onto LB agar
plate(s) containing the relevant selection antibiotic, and inverted
plates were incubated at 37ºC overnight.
2.2.5 Small-scale (miniprep) isolation of recombinant
plasmid cDNA from E.coli (steps 5 and 11)
Small yield plasmid preparations were obtained from previously
grown XL-1 plate cultures by the inoculation of a single colony into 5
ml LB broth (containing the appropriate antibiotic) followed by
incubation of the culture overnight at 37ºC with agitation (250 rpm).
cDNA was subsequently isolated from the cells using the GenElute
Plasmid Miniprep kit (Sigma), using the columns and reagents
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provided and following the manufacturers instructions, except the
final elution step was performed in 100 µl ddH2O. This kit enables
purification of plasmid DNA by a modified alkaline-SDS lysis method
(Birnboim et al., 1979) followed by DNA recovery by silica-based
spin format column chromatography. Briefly, an overnight culture
(typically 2-3 ml of a 5 ml culture) was harvested by centrifugation
and the bacterial pellet was resuspended. The bacteria were then
lysed in an alkaline solution containing SDS. The strong anionic
detergent SDS lyses the cell wall and denatures chromosomal DNA
and proteins, as well as releasing plasmid DNA into the supernatant.
The alkaline solution disrupts base pairing, but the closed,
intertwined structure of plasmid DNA means that the strands do not
separate. Cell debris (proteins, lipids, chromosomal DNA) are coated
with dodecyl sulphate; a neutralisation solution is next added, which
promotes precipitation of this debris by replacement of Na+ with K+
ions (Ish-Horowicz et al., 1981). The precipitate is removed by
centrifugation, leaving a supernatant lysate containing plasmid DNA
that is loaded onto a silica column and purified based on the method
described in section 2.2.2.2.
2.2.6 Restriction endonuclease digest analysis (steps
6 and 12)
Purified DNA was typically digested in a total reaction volume of 20
µl containing: ~2 µg DNA, 1 µl (1 unit) each relevant enzyme
(FastDigest restriction enzymes, Fermentas), 2 µl 10X FastDigest
buffer (supplied with enzyme) and ddH2O. Mixtures were prepared
in sterile 0.5 ml tubes, and the reaction was allowed to proceed for
1 h at 37ºC, followed by incubation at 60ºC for 20 min and then 80ºC
for 5 min to denature (inactivate) the enzymes. Typically, uncut,
singly digested and doubly digested DNA samples were all analysed
by electrophoresis in 1% agarose (w/v) gels (section 2.2.2.1).
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2.2.7 Subcloning insert cDNA into new host vectors:
preparation (steps 7 and 8)
2.2.7.1 Preparation of insert cDNA (steps 7a and 8a)
In order to prepare an insert for transfer into an alternative plasmid
background, it was excised from its plasmid using the relevant
restriction enzymes (section 2.2.6) to produce overhanging (sticky)
ends. The digest reaction was then run on an agarose gel (section
2.2.2.1), and the correct insert-sized band was excised and purified
(section 2.2.2.2), with a final elution of purified insert DNA in 50 µl
ddH2O.
2.2.7.2 Preparation of host vector (steps 7b and 8b)
In order to prepare a plasmid into which an insert (from above,
2.2.7.1) was to be transferred (i.e. the host vector), the plasmid
was digested with the corresponding restriction enzymes used in
section 2.2.7.1 (according to the standard digestion protocol, 2.2.6).
The digested (linearised) plasmid was then subjected to treatment
with shrimp alkaline phosphatase (SAP), which catalyses 5-
dephosphorylation of DNA ends, thus preventing self re-ligation. 20
µl of the digestion reaction was treated with 2 µl (2 units) SAP
(Fermentas) plus 2 µl SAP 10X buffer (provided with the enzyme)
and incubated for 60 min at 37ºC, followed by inactivation of SAP at
65ºC for 20 min. Host DNA was then purified from this reaction
using the GenElute PCR Clean-Up kit (Sigma), using the columns
and reagents provided and following the manufacturers instructions,
except the final elution step was performed in 40 µl ddH2O. The
method employed in this kit is based on the purification of DNA by
high salt binding to silica gel columns that has been described
(section 2.2.2.2).
2.2.8 Ligation of overhanging DNA (step 9)
Purified insert cDNA produced in section 2.2.7.1 was transferred into
the desired host vector produced in section 2.2.7.2 via DNA ligation.
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Ligations were typically performed with an excess of insert DNA;
generally the molar ratio of vector:insert included in the ligation was
manipulated to approximately 1:3. This was calculated as follows:
For the insert prepared as in section 2.2.7.1, given that the amount
of DNA used in the initial digest reaction was 2 µg, and knowing the
size of the insert (denoted as A) and that of the plasmid from
which it had been excised (B), and assuming that the yield
efficiency of the Gel Extraction kit used is 80%, then the amount of
insert DNA recovered in 50 µl eluate will be:
a) 2 µg x (A ÷ B) x 0.8
For the vector prepared as in section 2.2.7.2, given that 2 µg DNA
was used in the initial digest reaction, and knowing the size of the
vector (D) and that of the vector minus whatever fragment has
been removed in the digest reaction (C) in order to be replaced by
the new desired insert, and assuming 80% yield efficiency of the
PCR Clean-Up kit, then the amount of linearised vector recovered in
40 µl eluate will be:
b) 2 µg x (C ÷ D) x 0.8
These calculations enable us to know the concentration of insert and
vector DNA. From this knowledge, ligation reactions were prepared
in which ~50 ng vector DNA was used. In order to determine the
amount of insert DNA to include, the relative size of vector and
insert was used to calculate the amount of insert DNA that equates
to 3 times the molar amount of vector in 50 ng. That is:
c) Number of moles of vector in 50 ng = Number of moles of
insert in 50 ÷ (ratio of sizes of vector:insert in base pairs) ng
Therefore the amount of insert DNA (in ng) calculated in sum (c),
multiplied by three to give a 1:3 ratio, was included in the reaction
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(the actual amount added in µl was calculated using the
concentration determined in sum (a)).
Thus, positive and negative control reactions were set up in 0.5 ml
tubes in a total volume of 10 µl containing: 50 ng vector DNA, plus
(positive) or minus (negative) three times the molar ratio of insert
DNA, 1 µl 10X T4 DNA ligase buffer (Fermentas), 1 µl (5 units) T4
DNA ligase (Fermentas) and ddH2O. The reaction mixture was
incubated at 16ºC for 16 h, and both positive and negative controls
were subsequently transformed into competent XL-1 bacteria as in
section 2.2.4.2.
2.2.9 Large-scale (maxiprep) isolation of recombinant
plasmid cDNA from E.coli (step 13)
Large yield plasmid preparations were obtained using previously
grown 5 ml XL-1 starter cultures obtained as previously described
by the inoculation of a single colony into 5 ml LB broth (as in section
2.2.5). Depending on the growth of the starter culture, between 100
µl  1 ml (typically ~200 µl) was used to inoculate 120 ml sterile LB
broth (containing the appropriate antibiotic) in a 500 ml conical flask.
This culture was grown overnight at 37ºC with agitation (250 rpm).
DNA was subsequently isolated from the cells using the GenElute HP
Plasmid Maxiprep kit (Sigma), using the columns and reagents
provided and following the manufacturers instructions resulting in a
3 ml eluate containing the plasmid DNA (in a 50 ml conical-
bottomed tube). Essentially, this is a large-scale version of the
method used for small-scale (miniprep) plasmid isolations that has
been described (section 2.2.5), in which cells are harvested by
centrifugation, subjected to alkaline-SDS lysis and plasmid DNA is
recovered using a high salt, silica column-based centrifugation
protocol.
The DNA was further concentrated and purified using an ethanol
precipitation protocol. 300 µl of 3 M sodium acetate (NaOAc) was
added to the 3 ml eluate (i.e. 1:10 volume ratio; final concentration
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0.3 M). 2.2 volumes (7.2 ml) ice-cold 100% ethanol was added.
Ethanol is less polar than water and acts to remove the water shell
surrounding the DNA phosphate groups, thereby exposing their
negative charge. NaOAc provides counterions (Na+) that bind to the
phosphate groups, reducing the repulsive charges between DNA
molecules such that they precipitate out of solution. The resulting
mixture was centrifuged (4000 rpm, 20 min, 4ºC), salt was removed
from the DNA pellet by washing in 1 ml ice-cold 70% ethanol, and
the solution was further centrifuged (4000 rpm, 5 min, 4ºC). The
supernatant was poured off and the DNA pellet further clarified by
centrifugation (4000 rpm, 5 min, 4ºC). The DNA pellet was air-dried
for 10-15 min and then resuspended in 100-500 µl TE buffer (10 mM
Tris-HCl [pH 7.5], 1 mM EDTA), depending on the size of the pellet.
DNA concentration and purity was estimated using a
spectrophotometer (BioPhotometer, Eppendorf) and the DNA was
sequenced (section 2.2.13). The absorption spectrum of DNA is
maximal at 260 nm. Hence, absorption at 260 nm (A260) was used
as an estimation of the DNA concentration (for double-stranded DNA,
A260 = 1 at a concentration of 50 µg/ml). Proteins strongly absorb at
higher wavelengths (280 nm), and so the ratio of absorbance at
these wavelengths (A260/280) has historically been used as an
indicator of protein contamination of DNA samples. Here, samples
with A260/280 between 1.7  1.9 were considered pure; less than 1.7
was indicative of protein contamination.
2.2.10 Gateway® cloning
Gateway cloning is based on the bacteriophage lambda (Ȝ) site-
specific recombination system, which is required for Ȝ integration
into the E.coli chromosome. In the technology, recombinant DNA
sequences of interest are flanked by Ȝ-based DNA recombination
sequences (att sites), enabling specific, directional transfer between
different vectors in vitro (Hartley et al., 2000). Here, transfer of
DNA sequences between donating entry vectors and receiving
destination vectors was performed. Recombination reactions were
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prepared in sterile 0.5 ml tubes, and typically comprised ~38 ng
destination vector, ~38 ng entry vector, 1 µl TE buffer and 0.5 µl 5X
LR Clonase II enzyme mix, in a total volume of 2.5 µl. The Clonase
mix comprises the bacteriophage and E.coli enzymes required to
catalyse recombination. The reaction was allowed to proceed at
room temperature for 2 h. 0.5 µl of the serine protease proteinase K
was then added and the reaction was incubated at 37ºC for 10 min,
in order to inactivate the recombination enzymes and stop the
reaction. The reaction mix was diluted with the addition of 7 µl TE
buffer, and 1-2 µl of this was typically used in transformations
(section 2.2.4.2).
2.2.11 PCR-based site-directed mutagenesis
Desired mutations were introduced into target cDNA sequences
using PCR-based site-directed mutagenesis (Figure 2.2). In this
method, sense and antisense primers were used that were
complementary to the same sequence on opposite strands of the
plasmid template. Primers were individually designed such that the
desired mutation was central, with ~10-15 flanking bases either
side. A minimum of 40% GC content was preferred, and primers
were terminated with 1 G or C base at each end (GC clamp) in
order to promote efficient annealing. Melting temperatures were
calculated according to the following equation:
TM (ºC) = 81.5 + 0.41(% GC) - (675/n) - (% mismatch)
where n is the length of the primer in bases; % GC is the
percentage of bases that are either guanine or cytosine; %
mismatch is the percentage of bases that do not match the parental
DNA sequence.
The PCR conditions used in section 2.2.1 were maintained except
for (i) longer extension times (typically ~1 min per kbp of plasmid
length) to allow for extension of an entire plasmid, (ii) fewer
reaction cycles (12-18) in order to enhance the mutation efficiency
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and avoid non-specific polymerisation in primer-depleted conditions,
and (iii) the use of Accuzyme DNA polymerase (Bioline, Taunton, MA,
USA), which allows extension of large PCR fragments. 20 µl of the
PCR reaction mixture was then treated with 1 µl (10 units) DpnI
(Promega) for 2 h at 37oC. DpnI is a restriction endonuclease that
cleaves GATC sequences adenomethylated by the E.coli DNA
adenine methyltransferase (Dam) enzyme. Thus, inclusion of this
step results in the digestion of unwanted parental template DNA. 5
µl of the reaction was then transformed into 100 µl XL-1 competent
cells (section 2.2.4.2), the DNA was isolated as normal (sections
2.2.5 and 2.2.9) and sequenced to confirm presence of the mutation
(section 2.2.13).
2.2.12 Generation of plasmid constructs used in the
current study
The plasmid constructs that were generated during the current
study are described here. All other constructs that were used but
are not described here were already available within the host
laboratories (see list, Table 2.1)
The basics of the plasmid backbones used here are as follows. The
pcDNA3.1 vectors comprised a cytomegalovirus (CMV) enhancer-
promoter for high level expression, upstream of the multiple cloning
site (MCS), which contained various unique endonuclease
recognition sites for insertion of transgenes. This was followed by a
Bovine Growth Hormone (BGH) polyadenylation (poly(A)) signal and
transcription termination site in order to produce mRNA transcripts
with a high stability. The vector also contained a Simian Virus 40
(SV40) origin for plasmid replication in cell lines expressing the
large T antigen, an ampicillin resistance gene and pUC origin for
bacterial selection, and an antibiotic (zeocin or neomycin) resistance
gene for selection in mammalian cell lines.
The pcDNA4/TO vector was based on the pcDNA3.1 backbone
described above, but additionally contained two copies of the
tetracycline operator (TetO2) within the CMV promoter in order to
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enable selective binding by the tetracycline repressor and inhibition
of transcription (see section 2.3.4.3).
Table 2.1 Plasmid constructs used in the current study
Plasmid Source
pDEST_ARRDC1-4-eGFP-HA This study
pDEST_TXNIP-eGFP-HA This study
p3.1_ǃarrestin1/2-YFP Nick Holliday, University of Nottingham, UK
pDEST_ARRDC2(wild-type or ƩƩ)-mCherry This study
p3.1_EEA1-GFP Harald Stenmark, Institute of Cancer Research, Oslo University
Hospital, Norway
peGFP_RAB5/7/11(wild-type) Tyson Sharp, Barts
Cancer Institute, London, UK
peGFP_RAB5/7/11(constitutively-active mutants) Simon Dawson, University of Nottingham, UK and This study
pDEST_E3ubiquitinligase-eGFP-HA Simon Dawson, University of Nottingham, UK and This study
pDEST_ARRDC2(wild-type or ǻǻ)-2FLAG Simon Dawson, University of Nottingham, UK
p3.1_HA-ubiquitin This study
p3.1_ARRDC2-vYn/vYc This study
p3.1_ǃarrestin1/2-vYn/vYc Nick Holliday, University of Nottingham, UK
p3.1/p4TO_ARRDC2-GFP This study
pDEST_ARRDC3-mCherry Simon Dawson, University of Nottingham, UK
p3.1_ssǃ2AR/ssįOR Nick Holliday, University of Nottingham, UK
pCMV_FLAG-ǃ2AR-GFP Nick Holliday, University of Nottingham, UK
p3.1_ARRDC2-HA Simon Dawson, University of Nottingham, UK
p3.1_ǃarrestin1/2-HA This study
p3.1_FLAG-ǃarrestin2 Nick Holliday, University of Nottingham, UK
pCMV_HA-įOR Nick Holliday, University of Nottingham, UK
The Gateway cloning pDEST vectors were also based on pcDNA3.1,
but were previously manipulated to incorporate Ȝ recombination
sequences (see section 2.2.10) that flanked the MCS.
2.2.12.1 ARRDC2 cloning
A previously generated mammalian expression vector carrying the
wild-type ARRDC2 cDNA (NC_000019.9) N-terminally tagged with
the haemagglutinin (HA) epitope was used as a template for the
PCR amplification (section 2.2.1) of ARRDC2 (without HA). The
oligonucleotide primers used in the PCR reaction (Table 2.2) were
designed to introduce endonuclease restriction sites to enable the
subcloning of ARRDC2 into the appropriate vectors. The sense
primer was designed to introduce a start codon (ATG) at the
beginning of the ARRDC2 sequence, a Kozak initiation site
immediately upstream of this, and an in-frame EcoRI restriction site
upstream of this. The antisense primer was designed to omit the
stop codon (to allow read-through into a C-terminal fusion) and
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Mutation target site
Mutagenic primer
Parental plasmid DNA
Mutated plasmid DNA
Denaturation of parental DNA
(95ºC, 30 sec) followed by annealing
primers (~55ºC, 45-60 sec)
Extension (68-72ºC, 1 min/kbp)
catalysed by DNA polymerase to
copy the entire plasmid (repeat
12-18 cycles)
Digestion of methylated parental
DNA using DpnI (37ºC, 2 h) to
leave newly synthesised
mutated DNA
Figure 2.2 Overview of the site-directed mutagenesis method
employed to introduce mutations to double-stranded plasmid DNA
introduce an in-frame NotI restriction site 3 of the final ARRDC2
codon. The resultant PCR amplicon comprising ARRDC2 cDNA
flanked by EcoRI and NotI sites was subsequently analysed and
cloned into pJET1.2 according to standard protocols described herein.
Standard restriction enzyme methods (Figure 2.1, steps 7-13) were
then employed to subclone ARRDC2 cDNA into pre-existing plasmids
containing the relevant epitope or fusion protein cDNAs, in order to
create the following expression vectors:
x pcDNA3.1_ARRDC2-GFP
x p4TO_ARRDC2-GFP
x pcDNA3.1_ARRDC2-vYn and pcDNA3.1_ARRDC2-vYc, where
vYn and vYc represent amino acid residues 2-173 (ǃ-strands
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18) or 156239 (ǃ-strands 811) of venus YFP, respectively
(Haider et al., 2011; Kilpatrick et al., 2010).
Table 2.2 Primers used to amplify ARRDC2 for subcloning into
various vectors
Parameter Sense primer Antisenseprimer
Sequence 5-
ATAGAATTCGCCACCATGCTAT
TCGACAAGGTGAAAGC-3
5-
TAGCGGCCGCTGGCAAGTCAT
GCAGCGCGGCCTC-3
TM 82.2 90.8
% GC content 45 71
Length 38 34
EcoRI (sense) and NotI (antisense) sites are underlined; Kozak sequence is in bold;
TM, melting temperature (
oC). TM = 81.5 + 0.41(% GC content)  675/N, where N
is the primer length.
2.2.12.2 RAB7Q67L
The RAB7Q67L mutant was generated by site-directed mutagenesis
in the pre-existing plasmid, GFP-RAB7 in pEGFP (Clontech; a gift
from Dr Tyson Sharp, School of Biomedical Sciences, University of
Nottingham), according to standard protocols (section 2.2.11). The
forward and reverse mutagenic primers are denoted in Table 2.3,
and confirmation of the altered RAB7 sequence is shown in Figure
2.3.
Table 2.3 Properties of RAB7Q67L mutagenic primers
Parameter RAB7Q67Lprimers
Sense sequence 5-GGGACACAGCAGGACTGGAACGGTTCCAGTCTCTCG-3
Antisense sequence 5-CGAGAGACTGGAACCGTTCCAGTCCTGCTGTGTCCC-3
TM 85.0
% GC content 61
Length 36
Mutant was generated in pDEST_GFP-RAB7. Mutated residue is in bold; Tm, melting
temperature.
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Figure 2.3 Sequencing chromatogram indicating the generation of
the RAB7Q67L mutant
Chromatogram generated using Chromas 2. Arrow indicates the altered
residue, changing wild-type RAB7 codon 67 CAG (Q) to CTG (L).
2.2.12.3 ǃ-arrestin2-HA
A plasmid expressing ǃ-arrestin2 C-terminally fused with the HA
epitope was generated using the pre-existing pcDNA3.1_ǃ-
arrestin2-vYc background (Kilpatrick et al., 2010), where vYc is
flanked by NotI and XbaI restriction sites. A HA linker was
generated by annealing 5-phosphorylated primers designed to
comprise the HA coding sequence flanked by NotI and XbaI
overhanging sites (Figure 2.4). In a thin-walled 200 µl PCR tube
(Scientific Laboratory Supplies) a final concentration of 500 nM of
each oligonucleotide primer was mixed with 10 µl 10X T4 DNA ligase
buffer (Fermentas), and adjusted to a total volume of 100 µl with
ddH2O. The tube was placed in a thermocycler block (Mastercycler
gradient, Eppendorf), and the primers were specifically annealed by
heating to 95 ºC followed by cycling down at increments of 10 ºC
every 5 min, until they were maintained at 4 ºC until use. The
pcDNA3.1_ǃ-arrestin2-vYc plasmid was digested with NotI/XbaI
(section 2.2.7.2) and the HA linker ligated in place of the removed
vYc fusion (section 2.2.8).
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Forward: 5  GGCCGCGGTACCCCTACGACGTGCCCGACTACGCCTAAT  3
Reverse: 5  CTAGATTAGGCGTAGTCGGGCACGTCGTAAGGGTACCGC  3
NotI
XbaI
NotI overhang
XbaI overhang
Figure 2.4 HA linker primers designed for the generation of ǃ-
arrestin2-HA
Primers were designed to incorporate the HA epitope coding sequence
(underlined) followed by a stop codon (bold) between overhanging NotI
and XbaI sites (indicated). An additional two residues (GG in forward
primer) were included in order to maintain the HA read sequence in-frame
with ǃ-arrestin2. Primers were 5-phosphorylated in order to ligate into the
appropriate vector.
2.2.13 DNA sequencing analysis
All newly synthesised constructs were analysed by DNA sequencing,
carried out by the Biopolymer Synthesis and Analysis Unit (BSAU) in
the School of Biomedical Sciences (University of Nottingham), using
an automated DNA sequencer.
2.3 Cell culture and transfection
2.3.1 Cell growth and storage conditions
HEK-293TR (Invitrogen) and U2OS (donation from Dr Tyson Sharp)
cells were cultured in Dulbeccos modified Eagles medium (DMEM,
Sigma) supplemented with 10% (v/v) foetal bovine serum (FBS;
Sigma). Cells were maintained in T75 flasks (Sarstedt) under
humidified conditions in 5% CO2 at 37ºC. Primary cells used (aortic
endothelial; pulmonary artery endothelial; aortic smooth muscle;
bronchial epithelial; bronchial smooth muscle) were from single
donors (Lonza, Slough, UK) and were cultured by Marlene Groenen.
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When cells reached 80-90% confluence, they were passaged by
trypsinisation. Medium was removed and the cells were washed with
sterile Dulbeccos phosphate buffered saline (PBS; Sigma).
Trypsinisation was then performed by the addition of 2 ml trypsin.
For HEK-293 cells a standard concentration of 0.25% trypsin (w/v)
in Versene was used; U2OS cells were observed to be more strongly
adherent, so 2X concentration (0.5% w/v) of trypsin was used. Cells
were incubated in trypsin solution at 37ºC for approximately 1 min,
ensuring that the incubation time did not exceed 2-3 min to avoid
trypsin damaging cell surface proteins. Cells were dislodged by
gentle tapping of the side of the T75 flask, and trypsin was then
deactivated by the addition of ~8 ml medium to the cells. The cell
mixture was transferred to a sterile universal tube, and was
centrifuged at 1000 rpm for 5 min. The supernatant was removed
and the cell pellet resuspended in 5-10 ml medium, and an
appropriate volume of the cell suspension was transferred to a new
T75 flask containing ~20 ml fresh medium and incubated as above.
In order to freeze stocks of cells for future use, the above
passaging protocol was followed until resuspension of the cell pellet.
At this point, cells were instead resuspended in an appropriate
volume of freezing solution (10% v/v DMSO in FBS), and 1 ml
aliquots were transferred to sterile cryovials. Cryovials were placed
in a polystyrene container in a -80ºC freezer for at least 24 h for
gradual freezing, and were subsequently transferred to a liquid
nitrogen container for long-term storage.
2.3.2 Cell counting
Where required, the number of cells in a suspension was estimated
by counting using a haemocytometer. A small volume of cell
suspension was removed and loaded into the counting chamber of a
haemocytometer. The total number of cells in each of two of the
counting windows (comprising 25 squares (1 mm2) with a chamber
depth of 0.1 mm; 0.1 µl volume) was counted; the mean of these
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two was multiplied by 104 to give the approximate number of cells
per ml.
2.3.3 Seeding cells and transfection using
Lipofectamine reagent
For various experiments, cells were seeded at defined densities
(following counting; section 2.3.2 above) onto the appropriate
experimental plate and, where required, cells were transfected with
the necessary DNA constructs the following day (summarised in
Table 2.4).
For the seeding of HEK-293 cells onto glass coverslips, prior
treatment of the coverslips was required to facilitate cell adhesion.
To do this, sterile coverslips in 6-well plates were treated with 10
µg/ml poly-L-lysine (Sigma) for ~1 h at room temperature.
Coverslips were then washed once with PBS followed by cell seeding.
In contrast, U2OS cells were observed to be more adherent and so
poly-L-lysine treatment was not required.
Transfections were performed the day after cell seeding, at which
cells were generally around 70-80% confluent. DNA was introduced
to cells via conjugation to Lipofectamine reagent (Invitrogen),
according to the manufacturers instructions, with the amounts of
DNA and Lipofectamine scaled as indicated in Table 2.4.
Table 2.4 Cell seeding and transfection conditions
Culture vessel
(surface area, cm2)
Number of cells seeded
(perwell where
appropriate)
Amount of DNA added
perwell (µg)
Amount of lipofectamine
added perwell (µl)
T25 flask (25) ~1 x106 2 18
6-well plate (10) 1  2 x105 on coverslips
2  4 x105 on whole well
1
1
9
9
MatTek dish (10) 2 x105 1 9
24-well plate (2) 5 x104  1 x105 n/a n/a
96-well plate (0.3) 2  4 x104 0.05 0.45
2.3.4 Generation and maintenance of stable cell lines
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2.3.4.1 Mixed populations
Cells stably expressing a desired plasmid construct were generated
by transfection in a T25 flask (according to Table 2.4), followed by
passage the following day (at a split ratio of 1:10) into a fresh T25
flask in medium supplemented with the appropriate selection
antibiotic, corresponding to the eukaryotic resistance gene
expressed by the plasmid in question. The selection concentrations
used were: blasticidin 5 µg/ml; zeocin 800 µg/ml; G418 800 µg/ml.
Selection of transfectants was then allowed to proceed; over 1  2
weeks in selection medium, non-transfected cells died off, leaving
antibiotic-resistant colonies expressing the desired plasmid. These
were then passaged into T75 flasks for scaling up, analysed
appropriately (by Western blotting and/or microscopy), and a subset
of cells frozen down for future use. Once selected and passaged into
T75 flasks, lower antibiotic concentrations were used to maintain the
selection pressure: blasticidin 2.5 µg/ml; zeocin 100 µg/ml; G418
200 µg/ml.
2.3.4.2 Clonal populations
In some cases, the percentage of cells expressing the correct
transgene in mixed stable populations was not sufficient for the
purposes of experiments performed here. In order to obtain a more
homogeneous population of transgene-expressing cells, a dilution
cloning protocol was used. This involved the seeding of a previously
obtained mixed stable cell population onto 96-well plates (Costar,
Corning Life Sciences, Amsterdam, Netherlands) at an approximate
density of 1 cell per well (antibiotic concentrations were maintained
throughout). Thus, cell colonies obtained from this protocol would
be derived from a single parental cell (i.e. clonal). Colony growth
was analysed to ensure that each well only contained a single colony
(wells in which 2 separate colonies were observed were excluded
from the protocol). Confluent colonies were scaled-up by passage
from 96-well plates onto 24-well plates and then 6-well plates, with
a subset of the cells also seeded onto 96-well plates (Greiner
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655090, Greiner Bio-One, Stonehouse, UK) for analysis of plasmid
expression of fluorescent proteins using an ImageXpress Micro
imaging platereader (Molecular Devices, Sunnyvale, CA, USA).
Clones demonstrating sufficient percentage expression were further
scaled up through passage onto T75 flasks, and clonal populations
were then frozen down and maintained as appropriate (as in section
2.3.4.1).
2.3.4.3 Inducible expression of ARRDC2-GFP
For the inducible expression of ARRDC2-GFP in U2OS cells, a dual
clonal cell line expressing pcDNA6/TR (Invitrogen) and ARRDC2-GFP
cDNA in the pcDNA4/TO vector (p4TO_ARRDC2-GFP) was produced.
The pcDNA4/TO vector contains two tetracycline operator sites
(TetO2) within a cytomegalovirus (CMV) promoter; in the absence of
tetracycline, the tetracycline repressor (TetR; encoded by
pcDNA6/TR) binds to the TetO2, repressing expression of the gene
of interest. However, upon addition of tetracycline to the cells,
tetracycline binds to the TetR, causing it to dissociate from the
TetO2, thus allowing transcription.
U2OS cells were first stably transfected (section 2.3.4.1) with
pcDNA6/TR, and this line (denoted U2OSTR) was subjected to the
dilution cloning protocol (section 2.3.4.2). Clonal U2OS lines
expressing TetR were identified by transient transfection with
p4TO_ARRDC2-GFP, followed by treatment at 24 h with 1 µg/ml
tetracycline, and assessment of inducible ARRDC2-GFP expression at
48 h on the ImageXpress Micro platereader.
p4TO_ARRDC2-GFP was then stably transfected onto the U2OSTR
line, and the resulting population subjected to another round of
dilution cloning.
For experiments utilising ARRDC2-GFP inducible expression,
U2OSTR ARRDC2-GFP cells were seeded onto the appropriate
culture vessel 48 h prior to the experiment, and normal culture
medium was replaced with medium supplemented with or without 1
µg/ml tetracycline at 24 h.
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2.4 Immunofluorescence confocal microscopy
The following section describes the use of various protocols for the
preparation of cells for analysis by confocal microscopy.
2.4.1 Cell fixing/mounting
The standard protocol used for the fixing of cells expressing gene(s)
of interest, and/or stained as appropriate, was as follows. Cells on
glass coverslips were transfected as appropriate (section 2.3.3). The
next day, the cells were washed once with PBS, followed by fixation
in 3% (w/v) paraformaldehyde (PFA) in PBS for 10 min. Cells were
then washed twice in PBS for 5 min, followed by mounting inverted
onto a microscope slide in PBS:glycerol (1:1). Any air bubbles were
removed by carefully pressing down on the coverslip, coverslips
were sealed around the edge using clear nail varnish, and slides
were stored in the dark at 4ºC prior to confocal analysis.
2.4.2 Immunostaining
In some cases, detection of the subcellular localisation of proteins
that themselves lacked a fluorescent tag was required (in the
current thesis, this included the detection of exogenous ARRDC2-
2FLAG, endogenous ARRDC2 and endogenous LAMP1). To do this,
an epitope within the protein of interest was detected through the
use of a specific primary antibody; the primary antibody was then
detected using a fluorescently labelled secondary antibody, thus
allowing visualisation of the protein of interest.
All manipulations were performed at room temperature. Cells on
glass coverslips were washed and fixed as in section 2.4.1, followed
by two 5 min washes (25 mM glycine/PBS, to quench the fixative).
Cell membranes were permeabilised in 0.05% (v/v) Triton X-
100/PBS for 5 min, followed by two 5 min washes in PBS. In
experiments where membrane permeabilisation was omitted as a
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control, the Triton X-100 step was replaced by incubation with PBS
alone. Saturation of nonspecific sites (blocking) was then performed
by incubation in 1% (w/v) bovine serum albumin (BSA, Sigma) in
PBS (blocking solution) for 60 min. Cells were labelled by
incubation with the appropriate concentration of primary antibody in
blocking solution for 90 min, followed by rigorous washing in
blocking solution (3 x 2 min; 1 x 15 min; 1 x 5 min). Primary
antibody was detected by incubation with the appropriate
fluorophore-conjugated secondary antibody (for example, 1:1000
goat anti-mouse IgG conjugated to Alexa Fluor(AF)-488) in blocking
solution for 45 min, followed by rigorous washing (3 x 2 min in
blocking solution; 1 x 15 min in PBS; 1 x 5 min in PBS). Cells were
then post-fixed in 3 % (w/v) PFA/PBS for 15 min in order to cross-
link the antibodies used, followed by two 5 min washes in quenching
solution and a final 5 min wash in PBS prior to mounting (section
2.4.1).
The primary and secondary antibodies used in each experiment
and their concentrations are denoted in the respective figure
legends in the results chapters.
2.4.3 Transferrin labelling
Where transferrin labelling was required, medium on cells on glass
coverslips was replaced with medium containing 250 ng/µl AF-633-
conjugated transferrin (Sigma) for 15 min at 37ºC, followed by cell
fixing/mounting as in section 2.4.1. In experiments involving drug
treatments (e.g. 1 h treatment with agonist), the transferrin step
was included in the final 15 min of the drug treatment protocol;
medium plus the appropriate agonist was supplemented with 250
ng/µl AF-633 transferrin followed by fixing/mounting as normal.
2.4.4 LysoTracker labelling
For the labelling of acid compartments (lysosomes) in live cells, cells
on 35 mm MatTek dishes (MatTek Corp, Ashland, USA) were
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transfected as appropriate. The next day, cell medium was replaced
with 0.1% (w/v) BSA in HEPES buffered saline (HBS; 10 mM HEPES,
10 mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM
sodium pyruvate and 1.3 mM CaCl2, pH 7.45) containing 100 nM
LysoTrackerTM Red DND-99 (Invitrogen) for 15-30 min at 37ºC. Cells
were then imaged live in the same medium using a Zeiss LSM 510
laser scanning microscope (Carl Zeiss, Welwyn, UK).
2.4.5 Confocal imaging
Confocal images were obtained using either Zeiss LSM 510 or 710
laser scanning microscopes (Carl Zeiss) using a 63x Plan-
Apochromat NA 1.4 oil objective. Fluorophores were excited with
Argon 488 nm (GFP, YFP, AF-488), diode-pumped solid state (DPSS)
561 nm (AF-546), Helium-Neon 594 nm (mCherry) and Helium-
Neon 633 nm (AF-633, AF-647, LysoTrackerTM Red DND-99) laser
lines. Detection was as follows: band pass 505-550 nm for GFP, YFP
and AF-488; band pass 566-680 nm for AF-546; band pass 599-696
nm for mCherry; long bandpass of 650 nm for AF-633, AF-647, and
LysoTrackerTM Red DND-99. However, for experiments in which
three channels were excited (using, for example, GFP, AF-546 and
mCherry) the filter for detection of AF-546 had to be reduced
(typically to between 566-580 nm) to avoid bleed-through from the
mCherry channel. The pinhole diameter was set to 1 Airy unit for
the longest wavelength. An Airy unit (calculated automatically by
within the Zeiss software) corresponds to the theoretical size of the
Airy disc  the inner, best-focussed circle of light detected within a
diffraction pattern  based on the excitation wavelength and
numerical aperture (NA). Thus, setting to 1 Airy unit theoretically
gives the best signal:noise ratio. Detector gain and amplifier offset
were adjusted to ensure that images were not saturated, and
equivalent settings were maintained between the capture of images
that were to be compared. In colocalisation experiments, images
were regularly checked for bleed-through between channels. Typical
experimental procedures involved the collection of at least six
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images per condition, with experiments repeated independently at
least in duplicate, typically in triplicate.
2.4.6 Quantification of confocal images
2.4.6.1 Colocalisation of fluorescent channels
Zeiss LSM Image Examiner or ZEN 2009 Light Edition were used to
quantify the extent of colocalisation of two fluorescent channels
from confocal images of cells expressing or labelled with 2
spectrally distinct fluorophores. The image analysis software
produced plots of two channel intensities against each other, where
distinctly colocalised or non-colocalised channels produced
characteristic plots (for example see Figure 2.5A,B). Threshold
fluorescence intensities, above which level fluorescence was deemed
specific (above background), were determined as mean intensity +
2x standard deviation for a background region. This was a manually
selected region within the cell cytoplasm that represented
background, nonspecific staining/labelling. These threshold
intensities were set as crosshairs on the plot of channel intensities
(Figure 2.5C) in the image analysis software. Thus, the
colocalisation coefficients determined were defined as:
number of pixels in region 3 (colocalised) ÷ total number of specific
pixels for a given channel (see example in Figure 2.5C)
The coefficient thus ranges from 0 (no colocalisation) to 1 (all pixels
colocalise).
Where necessary, plasma membrane staining was excluded from
this analysis in order to solely determine colocalisation of
internalised species. To do this, the above process was followed,
except once thresholds were determined an image region of interest
(ROI) was drawn manually that enclosed the cytoplasm but
excluded the plasma membrane staining (determined using the
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plasma membrane staining of the relevant protein fusion present in
the experiment, for example, plasma membrane staining of ssǃ2AR).
The plot of channel intensities thus only included pixels within this
region; setting crosshairs and calculating coefficients for this plot
was performed as above.
2.4.6.2 Platereader granularity analysis
Recycling of internalised ssǃ2AR was assessed by high content,
quantitative analysis using the ImageXpress Ultra confocal
platereader (Molecular Devices Corporation (MDC), CA, USA). Cells
stably expressing ssǃ2AR were seeded onto 96-well plates (Greiner
655090, Greiner Bio-one, Stonehouse, UK). 24 h later, cells were 80
 90 % confluent: ssǃ2AR was labelled by replacing cell medium
with 0.1 µM AF-488 conjugated SNAPsurface benzyl guanine (BG)
(SNAPsurface BG-AF488, New England Biolabs; NEB, Hitchin, UK) in
serum-free DMEM/0.1 % BSA for 10 min. SNAP ligand was removed
with two washes in HBS, followed by incubation with vehicle or 10
µM isoprenaline (in serum-free DMEM/0.1 % BSA) for 1 h at 37 ºC.
Cells were washed twice with serum-free DMEM/0.1 % BSA, and
then incubated in this media with or without 1 µM propanolol for 5 
60 min at 37 ºC (wash step to measure recycling). At room
temperature, cells were then washed once in PBS, followed by
fixation in 3 % (w/v) PFA/PBS for 10 min. Cells were washed again
in PBS, nuclei were stained by incubation with 2 µg/ml Hoechst
(H33342) dye in PBS for 10 min, followed by washing twice in PBS.
Images were acquired immediately from four central sites per well
on the ImageXpress Ultra, using a Plan Fluor 40x NA0.6 extra long
working distance objective. Fluorophores were excited with 405 nm
(H33342) and 488 nm (BG-AF488) laser lines.
For the quantitative detection of internalised ssǃ2AR (and hence
the ability to measure ssǃ2AR recycling as a decrease in internalised
receptor present following washout of agonist), a granularity
algorithm application module was used (MetaXpress 2.0 software,
MDC) (Watson et al., 2012). In the analysis, vesicles were
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Figure 2.5 Quantification of colocalisation from confocal images
Examples of highly colocalised (A) and non-colocalised (B) images are
shown (right panels). Corresponding channel intensity plots obtained from
Zeiss LSM Image examiner are shown (left panels). In (C), the method of
quantification is indicated. Crosshairs were set as mean intensity + 2x
standard deviation for a manually selected background region within the
cell, and colocalisation coefficients for a given channel were calculated as
indicated in the formula.
specified as compartments between 2  15 µm in diameter (488 nm
image); nuclei were specified as between 6  15 µm (405 nm
image). The threshold intensity for classification of vesicles was set
with reference to the plate negative and positive controls (vehicle,
10 µM isoprenaline 1 h, respectively). Several parameters
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normalised to cell count (determined by number of nuclei stained
with H33342) were obtained (vesicle count, area, intensity per cell),
for triplicate wells (12 sites per data group). These provided similar
results; the data presented herein are vesicle average intensities per
cell, normalised (%) to plate negative and positive controls (as
above).
2.4.7 Bimolecular fluorescence complementation
(BiFC)
In the same way as enzymes such as ǃ-galactosidase, fluorescent
proteins can be split into non-active fragments. Fusing the
fragments to interacting proteins of interest brings the fragments
together, leading to association, refolding and subsequent
chromophore maturation (Figure 2.6) (Kerppola, 2008). Thus, BiFC
is used as an assay for protein-protein interactions in cells  a
fluorescent signal is indicative of an association  and may provide
spatial and temporal information regarding interactions. However, it
is important to note that BiFC is irreversible, giving the potential for
trapping of otherwise transient interactions with potential
downstream functional consequences.
BiFC was used to detect interactions between ARRDC2 and ǃ-
arrestins in intact cells. Accordingly, cells were transiently
cotransfected with ARRDC2 plus ǃ-arrestin, each fused with a
respective YFP fragment. The ability of ǃ-arrestins to homo-
oligomerise was exploited as a positive control (cotransfection of ǃ-
arrestin2-Yn plus ǃ-arrestin2-Yc); singly transfected cells 
presumed to be non-fluorescent  were included as negative
controls.
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Association Folding Maturation
1 min 60 min
Figure 2.6 Principle of BiFC
A fluorescent protein (for example, enhanced YFP) is split into two non-
fluorescent N- and C-terminal fragments (N and C). The fragments are
fused to two proteins of interest (shown in blue and green) that are able to
interact reversibly (association) until the fluorescent protein fragments
refold to form a ǃ-barrel structure (t1/2 = 1 minute; folding). The
fluorescent protein chromophore then develops over a longer time-scale to
generate a fluorescent BiFC complex (t1/2 = 60 minutes; maturation).
Adapted from (Rose et al., 2010).
2.5 Immunoprecipitation and immunodetection
2.5.1 Preparation of U2OS cell extracts
Cells on 6-well plates were transfected as appropriate. 24-48 h later,
cells were washed twice with ice-cold PBS, followed by lysis in ice-
cold radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl
[pH 7.6], 150 mM NaCl, 1% (w/v) Nonidet P (NP)-40, 1% (w/v)
sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulphate (SDS))
supplemented with a protease inhibitor cocktail containing 4-(2-
Aminoethyl)-Benzenesulphonyl Fluoride (AEBSF), Aprotinin, E-64,
Bestatin, Leupeptin and Pepstatin (Melford Laboratories, Suffolk,
UK). Typically, 2-4 wells were used for each separate
transfection/treatment condition, and 200-250 µl lysis buffer was
used per well. Cells were incubated in lysis buffer at 4ºC for 5 min,
followed by removal of cells using a cell scraper. Complete lysis was
ensured by mixing lysates on a rotator at 4ºC for 30 min. They were
then briefly sonicated to shear genomic DNA, and clarified by
centrifugation at 13,000 rpm at 4ºC for 15 min in order to pellet the
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cell debris. Supernatant (cell lysate) was retained and protein
concentration was estimated using a bicinchoninic acid (BCA)
protein assay (Smith et al., 1985), using pre-diluted BSA solutions
(between 2-20 µg/µl) as standards. Cell lysates were either used
immediately (sections 2.5.2, 2.5.3) or stored at -20 ºC for future
use.
2.5.2 Immunoprecipitation
In order to specifically isolate HA- or FLAG-tagged proteins (and
their interacting partners) from transfected U2OS cells, pull-down
experiments (immunoprecipitation) using anti-HA (mouse
monoclonal anti-HA-agarose; Sigma) or anti-FLAG (mouse
monoclonal anti-FLAG M2 affinity gel; Sigma) agarose beads were
performed. Agarose bead suspension (20 µl anti-HA, 15 µl anti-FLAG,
per immunoprecipitation) in 1.5 ml tubes was washed in 1 ml ice-
cold RIPA buffer, followed by centrifugation at 2000 rpm for 1 min
(low centrifugation speed was used to ensure that agarose beads
were not crushed by higher pressures) and subsequent removal of
the supernatant, taking care not to dislodge the agarose beads. This
step was repeated for a total of two washes. Cell lysates, equalised
for protein content (see BCA assay above), obtained as in section
2.5.1, were added to the washed agarose beads; typically 500 µl  1
ml lysate was added per immunoprecipitation. Protein binding to the
agarose was allowed to proceed by mixing on a rotator at 4 ºC
overnight. The following day, the suspension was centrifuged (2000
rpm, 1 min) and the supernatant carefully discarded as previously.
Non-specific binding to the agarose was then removed by washing
(5 min at 4 ºC with end-end mixing) in a high salt buffer (RIPA
buffer as above except containing 500 mM NaCl) followed by three
washes in standard RIPA. Each wash step was separated by
centrifugation and careful discarding of supernatants as above. After
the final wash step residual traces of RIPA buffer were carefully
removed using a narrow-bore pipette tip. Agarose beads and their
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associated protein complexes were subsequently processed and
analysed as detailed below (section 2.5.3).
2.5.3 Protein separation by denaturing SDS-PAGE
and Western blotting
One-dimensional, reducing sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed using the Laemmli
method (Laemmli, 1970). The Geneflow OmniPAGE (Geneflow,
Staffordshire, UK) gel system was used. Protein samples (typically
15-20 µg of cell lysate, or agarose beads from immunoprecipitation;
section 2.5.2) were mixed with sample loading buffer to a final
concentration: 62.5 mM Tris-HCl (pH 6.8), 5 % (v/v) glycerol, 1 %
(w/v) SDS, 0.5 mM EDTA, 100 mM dithiothreitol (DTT), 1 % (v/v) ǃ-
mercaptoethanol, 0.0025 % (w/v) bromophenol blue. Samples were
incubated at 80 ºC for 10 min before loading onto 10  12.5 %
polyacrylamide gels (prepared in-house) alongside a molecular
weight marker (PageRuler Prestained Protein Ladder, 10  170 kD,
Fermentas). Immunoprecipitate samples, following incubation at 80
ºC, were additionally centrifuged for 1 min at 2000 rpm in order to
pellet the agarose beads; the supernatant was loaded onto gels.
Samples were separated by electrophoresis at constant voltage
(~150 V) for 1  1.5 h in a running buffer (25 mM Tris, 192 mM
glycine, 0.01 % [w/v] SDS) until the bromophenol blue dye front
just eluted from the bottom of the gel.
The protein gel apparatus was dismantled and the gel was placed
alongside a sheet of nitrocellulose membrane of equivalent area
(BioTrace NT nitrocellulose membrane; Pall Corporation, Portsmouth,
UK) that was pre-soaked in Western transfer buffer (25 mM Tris,
192 mM glycine, 20 % [v/v] methanol). Protein transfer to the
membrane was carried out in the blotting tank containing transfer
buffer at constant voltage (10  20 V) for between 2  5 h at room
temperature. Membranes were removed and incubated with blocking
solution (5 % [w/v] skimmed milk powder in TTBS [Tris-buffered
saline containing 0.1 % Tween 20]) at 4 ºC overnight to block non-
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specific sites. Subsequent manipulations were performed at room
temperature. Membranes were incubated with primary antibody at
the appropriate concentration in 1 % (w/v) skimmed milk
powder/TTBS (1 % SMP) for 2 h. Membranes were washed three
times with TTBS for 10 min each, followed by incubation with the
appropriate secondary antibody in 1 % SMP for 45  60 min. The
membranes were then washed as above, followed by replacement of
the final wash with TBS and imaging using the LI-COR Odyssey
imager (LI-COR Biosciences, Nebraska, USA).
Primary antibodies used in immunoblotting were anti-HA (rabbit
monoclonal; Sigma), anti-FLAG (rabbit polyclonal anti-ECS [DDDDK];
Bethyl Laboratories, Texas, USA) and anti-GFP (mouse monoclonal
JL-8, Clontech, CA, USA). Secondary antibodies for use with the LI-
COR system were donkey anti-rabbit or anti-mouse infrared dye
(IRDye) 800CW (LI-COR Biosciences).
2.5.4 Development of an anti-ARRDC2 antibody
Prior to the start of the current project, the host laboratory had
ordered an anti-ARRDC2 antibody raised in rabbit using a small
presumed antigenic peptide corresponding to a region in the
ARRDC2 C-terminus (Genosphere, Paris, France). However, no anti-
ARRDC2 immunoreactivity was detectable using this antibody in
Western blotting experiments (data not shown). Another antibody
was produced by the same method (Genosphere), this time using
the peptide YSEEDPNPLLGDMRP as antigen. This sequence,
corresponding to amino acid residues 388  402 of human ARRDC2,
was chosen on the basis of several criteria. Estimation of ARRDC2
protein hydrophobicity using two established algorithms (Hopp et al.,
1981; Kyte et al., 1982) indicated that the region containing
residues 388  402 scores relatively low, especially using the Kyte
and Doolittle analysis (Figure 2.7A,B). Low hydrophobicity in this
region suggested that it may be solvent exposed on the protein
surface and therefore may represent a good target for potential
antigenic sites. The region has an average score when the
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percentage of accessible residues are estimated (Figure 2.7C),
further suggesting that it may at least not be buried in the native
protein and therefore may be available for antibody interaction.
Additionally, the ARRDC2 388  402 residue sequence is unique to
ARRDC2; although homologous sequences exist in ARRDC3,
ARRDC4 and TXNIP (Figure 2.8), the highest sequence identity
within this region is 46 %, between ARRDC2 and ARRDC3 sequences.
Hence, it was hypothesised that the antibody produced may
specifically recognise ARRDC2. Lastly, the antigenic peptide was
chosen to include a tyrosine residue (corresponding to ARRDC2 Y388)
as this aromatic residue has long been thought to enhance antigen
specificity and immunogenicity (Fuchs et al., 1963). Testing of the
resultant antibody is described in the first results chapter (section
3.2.3.1).
2.6 3H-cAMP accumulation
2.6.1 Column Preparation
Dowex columns were prepared using Dowex AG 50 50W-X4 resin
(hydrogen form) mesh 200-400 (BioRad), which was made into
slurry with ddH2O (50:50, volume:volume) and 2.4 ml placed into
Poly-prep columns (BioRad). Prior to each experiment, the columns
were regenerated with the addition of 10 ml HCl followed by two
washes with 10 ml ddH2O. Alumina columns were prepared by the
addition of 0.6 g of Neutral alumina WN-3 (Sigma) to Poly-prep
columns. Prior to each experiment, the columns were regenerated
with two washes of 10 ml 0.1 M imidazole (Sigma).
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Figure 2.7 ARRDC2 protein sequence analysis
(A) Kyte & Doolittle hydrophobicity plot (window = 9). (B) Hopp & Woods
hydrophobicity plot (window = 9). (C) % accessible residues analysis. All
analyses performed using ExPasy ProtScale tool.
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ARRDC1 YEQSCGGVEPSLTPES---
ARRDC2 ----YSEEDPNPLLGDMRP
ARRDC3 ----YSEIDPNPDQSADDR
ARRDC4 ----YSEVDPHPSDVEESQ
TXNIP ----YTEVDPCILNNNVQ-
:*
Figure 2.8 Multiple sequence alignment of the ARRDC2 antigenic
peptide with similar Į-arrestin sequences
ARRDC2 protein sequence corresponding to amino acid residues 388  402
was aligned with similar sequences in ARRDC3, ARRDC4 and TXNIP, as
shown using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). No
similar sequences were identified in whole sequence alignments with
ARRDC5, Vps26 or ǃ-arrestin1/2. *, fully conserved residue; :, stongly
similar residues.
2.6.2 3H-cAMP accumulation assay
The assay used was Dowex-Alumina chromatography based on a
column-based method developed elsewhere (Donaldson et al.,
1988). Cells (typically U2OSTR ARRDC2-GFP) were seeded onto 24-
well plates (Table 2.4) in normal DMEM plus FBS, followed 24 h later
by replacement of the media with media supplemented with or
without 1 µg/ml tetracycline, as appropriate. 24 h later, cells were
confluent (>90%) and the experiment was performed. Media was
removed and the cells were loaded with 3H-adenine by incubating
with 500 µl serum-free DMEM containing 1 µl 3H-adenine (550-925
Gigabecquerel [GBq]/mmol) per well at 37 ºC for 2 h. 3H-adenine-
containing media was removed and the cells were washed with 1 ml
serum-free DMEM. Cells were then incubated in 1ml of 1 mM 3-
isobutyl-1-methylxanthine (IBMX; a phosphodiesterase inhibitor) at
37 ºC for 15 min. Agonists, in 10 µl serum-free DMEM, were then
added and incubated for a further 5 h at 37 ºC. The reaction was
stopped by the addition of 50 µl concentrated HCl per well. 1 µl 14C-
cAMP (>8.1 GBq/mmol) was diluted in 5 ml ddH2O, and 100 µl of
this was added to each well as a standard. The samples were frozen
down for storage (-20 ºC) and thawed prior to running columns. 100
µl of the 14C-cAMP mix was also added to each of three scintillation
vials, which were used as 100% recovery controls.
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2.6.3 3H-cAMP and 14C-cAMP recovery
Samples were thawed, and the entirety of the contents of each well
was transferred to the corresponding Dowex column and allowed to
drip through. The passage of nucleotides through the columns is
delayed as the molecules become adsorbed onto the resin. The
columns were then washed with 3 ml ddH2O, thereby eluting the
most negatively charged molecules (e.g. ADP, ATP; two or three
phosphate groups, respectively) which are repelled by the
negatively charged Dowex. This leaves the less negatively charged
AMP and cAMP (one phosphate) still in the Dowex. The Dowex
columns were then placed over the Alumina columns, and 6 ml
ddH2O was added to each Dowex column, thus eluting the cAMP (3H-
cAMP, 14C-cAMP and unlabelled cAMP) from the Dowex into the
alumina columns. The alumina columns were then placed over
scintillation vials and 5 ml 0.1 M imidazole was added to each
column, eluting the cAMP into the vials. 8 ml scintillation fluid was
added to each vial and the 100% recovery vials. All vials were
counted on a ǃ-counter capable of dual counting 3H and 14C
simultaneously.
2.6.4 Dual detection of ǃ-particle emission
14C and 3H both decay by emitting high-energy electrons (ǃ-
particles) from the nucleus. These are measured by the detection of
photons of light which are released when the ǃ-particles collide with
molecules in the scintillation fluid. Counting of the photons produced
gives counts per minute (cpm) which, in comparison to a control
radioactive sample, are corrected to disintegrations per minute
(dpm). Dual counting of 14C and 3H relies on the fact that the ǃ-
particles emitted from 14C have more energy than those from 3H,
enabling the counter to recognise the photons produced by each
isotope as a distinct species.
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2.6.5 3H-cAMP accumulation data analysis
The 14C-cAMP dpm from the 100% recovery vials was averaged;
this was the expected 14C-cAMP count if the columns were 100%
efficient. As an estimate of the efficiency of each column, a
recovery fraction was calculated as:
Recovery = individual column 14C-cAMP count (dpm)
fraction mean 100% recovery vial 14C-cAMP count (dpm)
3H-cAMP count for each column was then corrected for the column
efficiency as follows:
Corrected 3H-cAMP = individual column 3H-cAMP count (dpm)
Recovery fraction
These corrected dpm counts were then plotted against agonist
concentration to give response curves. 24-well plates were
organised such that each experimental condition was performed in
triplicate or duplicate. Each plate had two basal (no drug) and two
maximally stimulated (10 µM isoprenaline) wells, and data were
normalised such that for each plate the basal and maximal
responses represented 0 and 100% responses, respectively.
2.7 Data analysis
All numerical data were presented as the mean ± S.E.M., and
statistical analyses and data presentation were performed using
GraphPad Prism v5.01. The statistical significance of three or more
data sets compared to a single control data set was determined
using one-way ANOVA followed by Tukey post-hoc test for multiple
comparison of means. A two-way ANOVA was used to compare data
sets with two or more variables. Statistical significance (P) values
are stated in the figures and within the text where appropriate; P <
0.05 was considered significant.
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3 Subcellular localisation of ARRDC2
3.1 Introduction
The human Į-arrestins are relatively uncharacterised in terms of
their subcellular localisation. Only Vps26  a retromer component
associated with endosomes/TGN (Bonifacino et al., 2008)  and
TXNIP  thought to localise to the nucleus (Saxena et al., 2009) 
are reasonably documented in terms of their distribution. For the
ARRDCs, only a few reports exist to date that have studied their
localisation in cultured cells, and in some cases the data presented
are contradictory (summarised in Table 3.1). Hence, initial studies
investigated ARRDC localisation, focussing on ARRDC2. This
information would then be used to develop a hypothesis for a
potential role of ARRDC2 within the relevant subcellular system.
Several markers known for their targeting to specific
compartments within the endocytic system were used to clarify
ARRDC2 localisation. The major stages within the endocytic system
following clathrin-mediated endocytosis are described below (see
Figure 3.1), highlighting the components that were used as markers
in the current investigation.
Table 3.1 Published localisation data for human ARRDCs
ARRDC Localisation Cell line(s) Reference
ARRDC1 Largely PM, no intracellular HEK-293 Nabhan et al., 2010
Punctate (vesicular) cytoplasmic HEK-293 Rauch and Serrano, 2011
Largely PM, no intracellular HEK-293T, HeLa, A549 Nabhan et al., 2012
ARRDC2 No data
ARRDC3 Largely PM, no intracellular HEK-293 Nabhan et al., 2010
PM, endosomes and lysosomes HeLa, COS-7, CHO, HEK-293 Oka et al., 2006
PM and punctate cytoplasmic HEK-293 Patwari et al., 2009
ARRDC4 Punctate (vesicular) cytoplasmic PAE Vina-Vilasseca et al., 2011
PM and punctate cytoplasmic HEK-293 Patwari et al., 2009
ARRDC5 No data
Clathrin-mediated endocytosis
The best characterised route for endocytosis of materials such as
membrane proteins and lipids is the clathrin-mediated pathway
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(McMahon et al., 2011). Cargo receptor endocytosis may be
constitutive (for example, transferrin receptor; TfR) or ligand-
stimulated (exemplified classically by EGFR; many GPCRs are also in
this category  see section 1.2.2).
Endocytosis proceeds through five main stages, defined
temporally and by the molecular machineries involved. The first
stage (initiation) involves the nucleation of plasma membrane
subdomains that contain FCH (FES CIP4 homology) domain only
(FCHO), Eps15 and intersectin proteins, which selectively bind
phosphatidylinositol-4,5-bisphosphate (PI4,5P2), a lipid enriched
within the inner leaflet of the plasma membrane.
FCHO/Eps15/intersectins generate initial membrane curvature, later
to be stabilised by clathrin (Henne et al., 2010). In the second stage
(cargo selection), AP2 is recruited via interaction with PI4,5P2 and
Eps15/intersectins. AP2 acts as a cargo adaptor, either directly
interacting with transmembrane cargo (e.g. TfR) or indirectly via
accessory proteins (e.g. ǃ-arrestins as adaptors for GPCR
recruitment). Next (coat assembly), clathrin is recruited via
interactions with AP2 and accessory proteins. Polymerisation of
clathrin triskelia forms a lattice coat, the structure of which further
induces membrane curvature leading to an invaginated clathrin-
coated pit (CCP). BAR domain-containing proteins (amphiphysin,
endophilin, SNX9) have a preference for curved membranes; they
bind to the neck of the invaginating CCP, positively inducing further
curvature that squeezes the neck. This leads to the next stage
(scission): the GTPase dynamin is recruited to the neck and
catalyses scission, producing a clathrin-coated vesicle (CCV). Finally,
the clathrin coat is disassembled (uncoating) by the ATPase heat
shock cognate 70 (HSC70) and its cofactor, auxilin (McMahon et al.,
2011).
CCV targeting to early endosomes
Following endocytosis, CCVs undergo heterotypic fusion with early
endosomes; early endosomes then undergo homotypic fusion. These
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Figure 3.1 Summary of the endocytic system in mammalian cells
Schematic showing the major intracellular compartments following clathrin-
mediated cargo endocytosis. Plasma membrane cargo proteins, such as the
transferrin receptor (TfR), are internalised through the formation of
clathrin-coated pits (CCP) that contain RAB5, which invaginate and bud off
to generate clathrin-coated vesicles (CCV). RAB5 is present on CCVs and
early endosomes (EE), promoting fusion via the early endosomal tether
protein, EEA1. Cargo sorting in EEs determines the itinerary of recycling
versus lysosomal trafficking. TfR undergoes recycling to the plasma
membrane, either by a direct (rapid) route regulated by RAB4, or indirectly
via perinuclear recycling endosomes (RE), involving RAB11 and RAB4 (slow
recycling). Cargo in EEs destined for the lysosome is instead sorted into
late endosomes/multivesicular bodies (LE/MVB) which contain RAB7; these
compartments mature into lysosomes which contain degradative enzymes
for the hydrolysis of sorted proteins. Lysosomes also contain RAB7 as well
as lysosome-associated membrane protein 1 (LAMP1), and are acidic (pH
~4.5), enabling their visualisation using pH-sensitive dyes such as
LysoTracker.
events are mediated by the RAB GTPase, RAB5.
RAB proteins are a family of small GTPases (>60 members in
humans) that control multiple aspects of vesicle trafficking including
budding, uncoating, fusion and cargo selection (Stenmark, 2009).
RABs are specifically associated with distinct intracellular
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membranes by the insertion of geranylgeranyl groups covalently
attached to RAB cysteine residues. They cycle between an inactive,
cytosolic form (guanosine diphosphate (GDP)-bound) and an active,
membrane-associated form (guanosine triphosphate (GTP)-bound).
Exchange of GTP for GDP is catalysed by guanine nucleotide
exchange factors (GEFs), and the GTP-bound form is preferentially
bound by various RAB effectors; GTP hydrolysis (accelerated by
GTPase-activating proteins; GAPs) provides energy for processes
including vesicle budding, uncoating and fusion.
RAB5 localises specifically to the plasma membrane, CCVs and
early endosomes. At the plasma membrane, RAB5 can mediate
cargo selection; for example, direct RAB5 binding to GPCR C-tails
has been observed (Seachrist et al., 2003). CCV-early endosome
fusion is mediated by RAB5 in concert with its effector, early
endosomal antigen 1 (EEA1). EEA1 localises specifically to early
endosomes via a zinc-binding FYVE finger within its C-terminus
(Stenmark et al., 1996). FYVE-dependent targeting involves binding
to phosphatidylinositol-3-phosphate (PI3P), which is enriched in
early endosomes. EEA1 contains two RAB5-binding domains at the
N- and C-termini and functions as a dimer (Simonsen et al., 1998);
it has thus been proposed that EEA1 tethers RAB5-containing CCVs
and early endosomal membranes, thereby facilitating fusion. In the
current study, RAB5 and EEA1 were utilised as markers of the early
stages of the endocytic system (predominantly CCVs and early
endosomes).
The sorting endosome: recycling pathways
Cargo within early endosomes can return directly to the plasma
membrane (rapid recycling), be trafficked through an intermediate
recycling endosome (also called the perinuclear recycling
compartment) before returning to the plasma membrane (slower
recycling), or be sorted into the MVB/late endosome pathway for
lysosomal degradation. Sorting through these different pathways is
complex, but is well characterised in terms of the specific RAB
proteins that define each compartment: RAB4 regulates rapid
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recycling (van der Sluijs et al., 1992), whereas RAB11 mediates
slow recycling through recycling endosomes (Ullrich et al., 1996), as
well as retrograde sorting from endosomes to the Golgi. Here,
RAB11 was used as a marker of recycling endosomes.
Within this system, endocytosed transferrin was also used as an
early/recycling endosomal marker. Transferrin is a plasma
glycoprotein that is responsible for the transport of iron within the
blood. Transferrin binds up to two Fe3+ ions, delivering them into
cells via binding and co-internalisation with its receptor (TfR). The
mechanism of delivery involves the dissociation of iron from
transferrin once within endosomes, since the affinity of iron for
transferrin is low at the acidic endosomal pH. However, transferrin
affinity for TfR is high at acidic pH; thus, transferrin-TfR remain
associated and recycle to the plasma membrane where, due to the
low affinity of transferrin for TfR at neutral pH, transferrin is
released to scavenge more iron (Dautry-Varsat, 1986). TfR
endocytosis and the fusion of subsequent CCVs-endosomes are
mediated by RAB5, and TfR can recycle via both RAB4-dependent
(rapid) and RAB11-dependent (slow) pathways (Zerial et al., 2001);
thus, transferrin/TfR has long been used as a standard marker for
endocytic recycling.
These pathways can be perturbed by the expression of mutant
versions of RAB proteins. For example, expression of constitutively-
active GTP-bound RAB5Q79L promotes homotypic vesicle fusion,
resulting in enlarged ring-like structures that contain early
endosomal cargo such as transferrin, whose recycling is reduced
(Stenmark et al., 1994; Wegener et al., 2010). Constitutively-active
RAB11 (RAB11Q70L) similarly stimulates vesicle fusion, but within
the slow recycling/retrograde pathways, thereby attenuating the
transport of transferrin and markers of early endosome-to-Golgi
(trans-Golgi network 38; TGN38), but not affecting lysosomal
transport (Wilcke et al., 2000). Thus, expression of RAB5Q79L and
RAB11Q70L was used here to inhibit transport through early and
recycling endosomes, respectively.
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Lysosomal trafficking
As described in section 1.2.3, sorting of cargo to the lysosome
involves ESCRT-mediated incorporation into MVBs/late endosomes,
followed by fusion of late endosomes with lysosomes. RAB7 is
specifically targeted to late endosomes/lysosomes, and mediates
late endosome maturation and fusion with lysosomes. The
segregation of RAB5 to early endosomes and RAB7 to late
endosomes is enabled by an elegant switch mechanism. RAB5
recruits the RAB7 GEF, Vps39, leading to RAB7 activation and
recruitment; RAB7 recruits a RAB5 GAP up until a critical point,
where RAB5 is inactivated and removed (Stenmark, 2009). RAB7
was used as a late endosomal/lysosomal marker here. Similar to
the RAB5 and RAB11 mutants described above, constitutively-active
RAB7Q67L perturbs late endosomal dynamics, resulting in enlarged
MVB structures that contain lysosomal markers such as cathepsin D
(Bucci et al., 2000). RAB7Q67L has been used here to enhance
visualisation of traffic through late endosomes/MVBs.
Protein degradation within the lysosome is catalysed by lysosomal
acid hydrolases, the activity of which is dependent upon an acidic
lumenal pH (lysosome pH ~4.5, compared to cytosol pH 7.2).
Lysosomal acidity is maintained by vacuolar H+ ATPases, which
pump protons into the lysosome. Lysosome-associated membrane
protein 1 (LAMP1) is a ubiquitous integral membrane glycoprotein
that is highly enriched in the limiting membrane (outer membrane
surrounding MVBs) of late endosomes/lysosomes (Chen et al.,
1985). Extensive glycosylation on the lumenal face of LAMP1 may
protect the membrane from degradation by lysosomal acid
hydrolases (Kundra et al., 1999), and LAMP1 also facilitates
lysosome acidification redundantly with LAMP2 (Eskelinen et al.,
2003). Hence, LAMP1 has been used here as a lysosomal marker.
Additionally, the acidity of lysosomes has been exploited in the
design of LysoTracker probes (Invitrogen); these are fluorophores
that are linked to a weak base, thereby targeting them to
compartments with low pH (lysosomes). Such probes are used in
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the live-cell labelling of lysosomes: here LysoTracker Red DND-99
was used.
3.2 Results
3.2.1 Subcellular localisation of exogenously
expressed ARRDCs in U2OS cells
Initial experiments aimed to visualise exogenous, fluorescent
protein-tagged ARRDCs (especially ARRDC2) in cell lines. HEK-293
cells (immortalised human cell line commonly used in the host
laboratory) were first tested for this application. Transient
transfection of HEK-293 cells with ARRDC2 constructs (for example,
ARRDC2-GFP) resulted in extremely low percentage transfection
efficiencies, and those cells that did express the transgene were
frequently morphologically abnormal with rounded shape and
indistinct structure. To circumvent this problem, stable HEK-
293TRex cells were generated that expressed tetracycline-inducible
ARRDC2-GFP (in pcDNA4TO plasmid). Cells induced to express
ARRDC2-GFP with tetracycline also exhibited altered phenotypes
such as multinucleation and high overexpression suggestive of
cytotoxicity (Figure 3.2). Dilution cloning of mixed stable HEK-
293TRex ARRDC2-GFP cells was performed to obtain a more
homogeneous population of pcDNA4TO-ARRDC2-GFP transfected
cells; cells were selected for their ARRDC2-GFP expression levels
and morphology that appeared normal. This approach produced
several stable clonal lines that displayed high percentage (>90%),
low level expression of ARRDC2-GFP in a cytoplasmic, punctate
pattern. However, expression of the ARRDC2-GFP transgene was
rapidly lost over just 2-4 cell passages. Low percentage transfection
efficiency and morphological abnormalities were observed for
alternatively tagged ARRDC2 constructs (for example ARRDC2-HA,
data not shown); hence this was not caused by the GFP tag.
Additionally, transient expression of GFP or YFP-tagged alternative
proteins such as ǃ-arrestins in HEK-293 cells was high efficiency and
109
resulted in an expected ǃ-arrestin distribution (not shown),
suggesting that the ARRDC2 transgene was the cause of the
abnormalities in these cells. Overall these observations suggested
that exogenous expression of ARRDC2 in HEK-293 cells may
adversely affect cell phenotype, leading to cytotoxicity and loss of
transgene expression. Thus, an alternative approach was adopted in
order to assess ARRDC2 expression in a system representative of
native ARRDC2.
The human cell line, U2OS (osteosarcoma-derived), was tested for
its ability to tolerate exogenous ARRDC2. Transient U2OS
transfection resulted in much higher percentage expression of
ARRDC2 constructs (typically ~40-60%), and cells expressing
ARRDC2 (or other ARRDCs, see below) were morphologically
indiscernible from non-transfected cells. Therefore, U2OS cells were
used in most subsequent experiments. The subcellular localisation of
all human ARRDCs was analysed, excluding ARRDC5, which has the
least sequence similarity to the rest (ARRDC5 lacks the variable C-
terminal region containing PPxY motifs; see Figure 1.4). Plasmids
encoding ARRDCs C-terminally tagged with eGFP-HA were
transiently expressed in U2OS cells on coverslips, and the cells were
fixed and imaged using confocal microscopy. The three ARRDCs with
highest homology, ARRDC2/3/4, all shared a highly similar
subcellular pattern, although each was expressed separately
(although note later experiment in which ARRDC2/3 colocalised
when coexpressed, Figure 3.8). Their expression pattern was that of
plasma membrane localisation, as well as a large number of discrete
intracellular puncta reminiscent of vesicles (Figure 3.3A). In each
case, the puncta were distributed throughout the cytoplasm;
congregation at a particular area (for example, the perinuclear
compartment) was not observed. In some cases  seen sporadically
for each of ARRDC2/3/4  the intracellular puncta were especially
large, suggestive of aberrantly oversized vesicles, perhaps due to
the overexpression of proteins that have roles in the function and/or
formation of the vesicles in question. Thus, ARRDC2/3/4 are
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targeted to cytoplasmic vesicular compartments and the plasma
membrane in U2OS cells.
20 µm
H33342 H33342GFP GFP
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Figure 3.2 Expression of ARRDC2-GFP in HEK-293TRex cells
Confocal microscopic images of stable HEK-293TRex cells expressing
tetracycline-induced ARRDC2-GFP. Cells were seeded onto poly-L-lysine-
coated coverslips, treated the next day with tetracycline (1 µg/ml) for 24 h
and then fixed, nuclei stained (1 µg/ml H33342, 10 min), mounted on
slides and imaged.
ARRDC2 ARRDC3 Merge
Figure 3.8 Coexpression of ARRDC2 and ARRDC3
Confocal microscopic images of stable U2OSTR ARRDC2-GFP cells
expressing tetracycline-induced ARRDC2-GFP, transiently cotransfected
with a plasmid expressing ARRDC3-mCherry. In the merged image,
ARRDC2 is shown in green, ARRDC3 in red. Image is representative of two
independent experiments. Scale bar = 10 µm.
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Fusion with large fluorescent proteins such as GFP (~28 kD) and
its derivatives (mCherry used here) has the potential to produce
artefacts in the observed protein distribution, for example by
masking sorting signal(s) within the protein of interest. ARRDC2
alternatively tagged with two copies of a much smaller epitope
(FLAG tag: DYKDDDDK) was used to compare to transient ARRDC2-
GFP, as well as ARRDC2-mCherry and tetracycline-inducible
ARRDC2-GFP. Transiently expressed ARRDC2-mCherry, ARRDC2-
2FLAG (immunostained with anti-FLAG antibody) or ARRDC2-GFP, or
ARRDC2-GFP expressed upon tetracycline induction in the stable line
U2OSTR pcDNA4TO-ARRDC2-GFP, all showed the same overall
pattern of localisation to the plasma membrane and cytoplasmic
puncta (Figure 3.3B). This suggests that the presence of large GFP-
based C-terminal tags does not affect ARRDC2 subcellular targeting.
ARRDC1-eGFP-HA was expressed in a similar pattern to
ARRDC2/3/4-eGFP-HA mentioned above, with plasma membrane
and cytoplasmic puncta apparent (Figure 3.3A). Additional diffuse
ARRDC1 staining was often observed throughout the cytosol, which
was not consistently seen for ARRDC2/3/4. Therefore, ARRDC1 is
also targeted to vesicular structures in U2OS cells, but may exhibit
subtle differences in distribution to ARRDC2/3/4.
As a comparison, TXNIP-eGFP-HA and ǃ-arrestin2-YFP were
transiently expressed in U2OS cells. TXNIP has been reported to
localise to the nucleus (Saxena et al., 2009). This was observed
here: TXNIP-eGFP-HA was strongly expressed within the nucleus,
but was also sporadically found in punctate cytoplasmic
compartments (Figure 3.3A). The ǃ-arrestins are well known for
their diffuse cytosolic distribution (i.e. not membrane-associated) in
cells in recombinant systems. This same distribution was seen here
for ǃ-arrestin2-YFP in U2OS cells (Figure 3.3A). Thus, TXNIP and ǃ-
arrestin2 subcellular targeting in U2OS cells was consistent with
previously published observations.
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Figure 3.3 Exogenous expression pattern of arrestin clan proteins
in U2OS cells
Confocal microscopic images: (A) U2OS cells transiently transfected with
plasmids expressing ARRDC1/2/3/4 or TXNIP fused with eGFP-HA, or ǃ-
arrestin2 C-terminally fused with YFP; (B) U2OS cells expressing ARRDC2
fused with the indicated construct. ARRDC2-FLAG was stained using mouse
anti-FLAG antibody (1:200 dilution) detected with AF-488-conjugated anti-
mouse secondary antibody (1:1000). Transient GFP represents
transiently expressed ARRDC2-GFP; Inducible GFP represents stable
U2OSTR ARRDC2-GFP cells expressing tetracycline-induced ARRDC2-GFP.
Representative images from at least two independent experiments are
shown. Scale bar in all images = 10 µm.
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3.2.2 ARRDC2 is dynamically localised to the endo-
lysosomal system
3.2.2.1 Colocalisation of ARRDC2 with compartment-specific
markers
Several Į-arrestins in lower eukaryotes have been implicated in
cargo protein sorting in the endo-lysosomal pathway (Herrador et
al., 2009; Lin et al., 2008; Nabhan et al., 2010; Nikko et al., 2009;
Nikko et al., 2008; Shi et al., 2006), and early reports suggest
human ARRDCs may also localise to the endocytic system (see
section 1.4.3.3 and Table 3.1). Therefore, it was hypothesised that
the ARRDC2-positive intracellular puncta observed in Figure 3.3 may
represent a component of this system. To test this, the distribution
of transiently expressed, fluorescent protein-tagged ARRDC2 in
U2OS cells was analysed in combination with known endocytic
markers (detailed in section 3.1). The extent of ARRDC2
colocalisation with each marker was assessed as described (section
2.4.6).
ARRDC2-positive cytoplasmic puncta were largely distinct from
transferrin-labelled early/recycling endosomes or EEA1-labelled
early endosomes (colocalisation coefficients of 0.111±0.022,
0.137±0.030 for ARRDC2-mCherry colocalisation with AF-633-
conjugated transferrin or EEA1-GFP, respectively, Figures 3.4 and
3.6). Furthermore, colocalisation of ARRDC2 with the early
endosomal marker, RAB5, or the recycling endosomal marker,
RAB11 was rarely observed (0.136±0.034, 0.155±0.045 coefficients
for ARRDC2-mCherry colocalisation with GFP-RAB5 or GFP- RAB11,
respectively, Figures 3.4 and 3.6). However, sporadic colocalisation
of ARRDC2-positive puncta with RAB5 or transferrin (including
plasma membrane-localised transferrin) was infrequently observed
over several experiments.
In contrast, a much higher proportion of ARRDC2 colocalised with
immunostaining for the lysosomal marker, LAMP1 (0.430±0.041
colocalisation coefficient for ARRDC2-mCherry with LAMP1
immunostaining, P < 0.001 when compared to ARRDC2
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Figure 3.4 ARRDC2 does not colocalise with markers of
early/recycling endosomes
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ARRDC2-mCherry plus GFP-tagged EEA1, RAB5 or
RAB11, or co-stained with 250 ng/µl AF-633-conjugated transferrin for 15
min, as indicated. In merged images, ARRDC2-mCherry is shown in red,
marker is shown in green. Infrequent colocalised puncta are highlighted
with arrows. Images are representative from at least two independent
experiments. Scale bar = 10 µm.
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Figure 3.5 ARRDC2 colocalises with markers of late
endosomes/lysosomes
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ARRDC2-mCherry plus GFP-RAB7, or co-
immunostained using rabbit anti-LAMP1 antibody (1:500) detected with
AF-633-conjugated anti-rabbit secondary antibody (1:1000); or with
ARRDC2-GFP plus co-staining with LysoTrackerTM Red DND-99 (100 nM,
15-30 min), as indicated. In merged images, ARRDC2-mCherry or
ARRDC2-GFP is shown in red; the indicated marker is in green. Images are
representative from at least two independent experiments. Scale bar = 10
µm.
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Figure 3.6 Quantification of ARRDC2 colocalisation with
compartment-specific markers
Colocalisation analysis of confocal images (example images shown in
Figures 3.4 and 3.5) from U2OS cells transiently transfected with ARRDC2
constructs plus the indicated compartment-specific marker. ARRDC2-GFP
colocalisation with ARRDC2-mCherry (leftmost bar) is also indicated as a
positive control. Colocalisation calculations were performed as described in
section 2.4.6.1. Data are mean ± SEM of 5-10 cells analysed for each of 
2 independent experiments. Statistical comparisons are with respect to
transferrin (TFN) data. ***P < 0.001, one-way ANOVA plus Tukey test.
colocalisation with transferrin, Figures 3.5 and 3.6). ARRDC2
colocalisation was also higher with acidic compartments (i.e.
lysosomes) stained with LysoTracker Red DND-99 (0.586±0.068
colocalisation coefficient for ARRDC2-GFP with LysoTrackerTM, P <
0.001) and with the late endosomal/lysosomal marker, RAB7
(0.330±0.053 coefficient for GFP-RAB7 colocalisation with ARRDC2-
mCherry, P < 0.001, Figures 3.5 and 3.6). As a positive control,
ARRDC2 colocalisation with itself was assessed (ARRDC2-GFP
colocalisation with ARRDC2-mCherry): a colocalisation coefficient of
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0.822±0.021 was measured (Figure 3.6, cell images not shown).
Thus, the higher proportion of colocalisation measured with LAMP1,
LysoTrackerTM and RAB7 (coefficients between 0.330  0.586)
equates to genuine colocalisation indicative of the presence of
ARRDC2 within these compartments. Collectively, these data
suggest that ARRDC2 is distinct from early and recycling endosomes
in U2OS cells, and may be predominantly targeted to late
endosomes/lysosomes, as well as the plasma membrane.
It is worth noting that a reduction in ARRDC2 plasma membrane
localisation was often observed upon coexpression with endosomal
markers, especially RAB GTPases (Figures 3.4 and 3.5), in
comparison to the strong plasma membrane targeting seen in cells
overexpressing ARRDC2 alone (Figure 3.3). Thus, overexpression of
endosomal proteins may have driven an altered ARRDC2 distribution,
although this was controlled for in the use of markers that did not
perturb the system (Transferrin, LysoTracker, LAMP1
immunostaining).
3.2.2.2 Effect of constitutively-active RAB mutants on the
localisation of ARRDC2
Since ARRDC2 is found both at the plasma membrane and in late
endosomes/lysosomes, it was hypothesised that ARRDC2 may traffic
through the endocytic system between these compartments.
Expression of constitutively-active RAB7 (GFP-RAB7Q67L) resulted
in the accumulation of ARRDC2-mCherry within enlarged GFP-
RAB7Q67L-positive vesicles, supporting the proposition that
ARRDC2 traffics to the late endosome/lysosome (Figure 3.7, middle
row). Interestingly, expression of constitutively-active RAB5 (GFP-
RAB5Q79L) also caused accumulation of ARRDC2-mCherry within
enlarged GFP-RAB5Q79L-positive vesicles (Figure 3.7, top row). A
constitutively-active RAB11 mutant (GFP-RAB11Q70L) had no effect
on ARRDC2-mCherry distribution; ARRDC2-mCherry was distinct
from GFP-Rab11Q70L-positive vesicles (Figure 3.7, bottom row).
Together, these data suggest that ARRDC2 predominantly localises
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to late endosomes/lysosomes but may traverse between the plasma
membrane, early/late endosomes and lysosomes.
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Figure 3.7 ARRDC2 accumulates in enlarged RAB5Q79L- or
RAB7Q67L-positive endosomes
Confocal microscopic images of U2OS cells transiently transfected with
ARRDC2-mCherry plus GFP fusions of mutant RAB5Q79L, RAB7Q67L or
RAB11Q70L, as indicated. In merged images, ARRDC2 is shown in red, RAB
mutant is shown in green. Insets show higher magnification image of
boxed zone, indicating ARRDC2 accumulation within the relevant RAB
mutant endosomes. Images are representative from at least two
independent experiments. Scale bar = 10 µm.
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3.2.3 Analysis of endogenous ARRDC2 expression in
primary and immortalised human cell lines
3.2.3.1 Validation of anti-ARRDC2 antibody
In order to detect endogenous ARRDC2 expression, a polyclonal
antibody was raised in rabbit against a selected peptide
corresponding to residues 388  402 of the ARRDC2 primary
sequence (described in section 2.5.4). This antibody was tested for
its use in immunostaining and immunoblotting experiments.
U2OSTR cells expressing tetracycline-induced ARRDC2-GFP were
subjected to immunostaining using the anti-ARRDC2 antibody. Anti-
ARRDC2, detected using an AF-633-conjugated anti-rabbit
secondary antibody, showed plasma membrane and punctate
cytoplasmic staining that was highly colocalised with ARRDC2-GFP
(Figure 3.9A, top panel). No immunostaining was observed in a
control lacking the anti-ARRDC2 primary antibody (Figure 3.9A,
bottom panel), removing the possibility that the staining seen was
due to background caused by non-specific secondary antibody
labelling. The ARRDCs, in particular ARRDC2/3/4, exhibit a degree of
similarity including at the level of primary sequence. However, the
peptide region of ARRDC2 chosen to raise the anti-ARRDC2 antibody
was distinct from other ARRDC members (Figure 2.8). Nevertheless,
the specificity of the anti-ARRDC2 antibody in detecting ARRDC2
alone, and not other ARRDCs, was tested. As shown in Figure 3.9C,
no anti-ARRDC2 immunostaining was detected in U2OS cells
transiently expressing ARRDC1/3/4-eGFP-HA or the less closely
related TXNIP-eGFP-HA or ǃ-arrestin1/2-YFP. In contrast, positive
control cells transiently expressing ARRDC2-eGFP-HA showed anti-
ARRDC2 immunostaining that mirrored the ARRDC2-eGFP-HA
distribution. Thus, the anti-ARRDC2 antibody raised detects
exogenous, overexpressed ARRDC2 when used in the
immunostaining of intact U2OS cells, and does not exhibit
detectable cross-reactivity in this context with other ARRDC
members, TXNIP, or ǃ-arrestins.
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Figure 3.9 Anti-ARRDC2 immunostaining and immunoblotting
(A) Confocal microscopic images of stable U2OSTR ARRDC2-GFP cells
expressing tetracycline-induced ARRDC2-GFP (488 channel; green in
merged image), stained with rabbit anti-ARRDC2 antibody (1:200 dilution)
detected using AF-633-conjugated anti-rabbit secondary antibody (1:1000;
633 channel, red in merged image). Bottom row shows a control in which
the same immunostaining protocol was performed in the absence of anti-
ARRDC2 primary antibody. (B) Lysates from U2OS cells transiently
transfected with a plasmid expressing ARRDC2-2FLAG were separated by
12.5% SDS-PAGE and analysed by Western blotting. Left panel shows
blotting with anti-FLAG antibody (1:5000); right panel with anti-ARRDC2
(1:1000) detected using IRDye 800CW anti-rabbit secondary antibody
(1:10,000). Molecular weight markers are indicated in kD. (C) Confocal
microscopic images of U2OS cells transiently transfected with
ARRDC1/2/3/4 or TXNIP C-terminally fused with eGFP-HA, or ǃ-arrestin1/2
C-terminally fused with YFP (all shown in 488 channel, top row), stained
with rabbit anti-ARRDC2 antibody (1:200) detected using AF-633-
conjugated anti-rabbit secondary antibody (1:1000; 633 channel, bottom
row). Scale bar in all images = 10 µm.
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The ability of the antibody to detect ARRDC2 in Western
immunoblotting was also tested. Whole cell protein lysates from
U2OS cells transiently expressing ARRDC2 C-terminally fused with
two copies of the FLAG epitope (ARRDC2-2FLAG) were obtained.
Western immunoblotting using an anti-FLAG antibody detected a
presumed ARRDC2-2FLAG band at ~55 kilodaltons (kD) (ARRDC2 is
predicted to be approximately 44 kD; this difference in size will be
commented on in Chapter 4), as well as several higher molecular
weight bands (see Chapter 4; Figure 3.9B, left panel). However,
immunoblotting the same lysate using the anti-ARRDC2 antibody did
not detect any bands corresponding to FLAG-identified ARRDC2,
other than potentially at the interface between the stacking and
running gels, as suggested by faint immunoreactivity at the top of
the gel (Figure 3.9B, right panel). Using different concentrations of
anti-ARRDC2 (down to a dilution of 1:500; not shown) did not
improve detection of ARRDC2-2FLAG. Hence, although able to
detect ARRDC2 in intact cell immunostaining, the anti-ARRDC2
antibody developed is not able to detect ARRDC2 in the context of
Western immunoblotting.
3.2.3.2 Analysis of ARRDC2 expression in U2OS and HEK-293
cells
The anti-ARRDC2 antibody was next employed in immunostaining to
determine whether ARRDC2 is expressed endogenously in several
human cell lines. This was first tested in the immortalised cell lines,
U2OS and HEK-293, when overexpressing ARRDC2-GFP
(tetracycline-induced expression in U2OSTR; transient expression in
HEK-293T). In both U2OS and HEK-293T cells, as mentioned above
(see Figure 3.9A), ARRDC2-GFP was detectable using the anti-
ARRDC2 antibody (Figure 3.10A). However, in cells not expressing
the ARRDC2-GFP transgene (see adjacent cells in both U2OS and
HEK-293T images), no anti-ARRDC2 immunostaining was detected.
Thus, it appears that neither U2OS nor HEK-293 cells express
detectable levels of endogenous ARRDC2 protein.
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3.2.3.3 Analysis of ARRDC2 expression in human primary cells
Anti-ARRDC2 immunostaining was next performed in several human
primary cell lines (aortic endothelial; pulmonary artery endothelial;
aortic smooth muscle; bronchial epithelial; bronchial smooth
muscle). ARRDC2 immunoreactivity was apparent in human aortic
endothelial cells, pulmonary artery endothelial cells and aortic
smooth muscle cells (Figure 3.10B). Given the validation of the anti-
ARRDC2 antibody used  especially that it is specific to ARRDC2 and
does not cross-react with other arrestin family proteins (section
3.2.3.1)  these results suggest that ARRDC2 is expressed within
these cells. Some possible diffuse, weak ARRDC2 immunoreactivity
was detectable in bronchial epithelial cells, but no clear signal was
detectable in bronchial smooth muscle cells (Figure 3.10B). This
suggests that ARRDC2 is not expressed in bronchial smooth muscle
cells but may be expressed in bronchial epithelial cells, although this
cannot be convincingly concluded from the faint staining seen.
These data suggest that ARRDC2 may be expressed in human aortic
endothelial cells, pulmonary artery endothelial cells and aortic
smooth muscle cells, but that its expression may be cell-type
specific.
In aortic endothelial cells, ARRDC2 immunostaining was clearly
observed at the plasma membrane, as well as appearing to be
present throughout the cytoplasm, most of which was diffuse in
pattern although occasionally more discrete puncta were observed
(Figure 3.10B). No staining was seen in a control lacking the
ARRDC2 primary antibody. This excluded the possibility that the
immunostaining observed was due to non-specific secondary
antibody labelling. An additional control was performed in which the
same immunostaining protocol was followed except for omission of
the permeabilisation step (0.05% Triton X-100, see section 2.4.2)
normally required to allow antibody entry to the cell interior via
permeabilisation of the plasma membrane. Without permeabilisation,
little or no immunostaining was observed, indicating that, as
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Figure 3.10 Immunofluorescence analysis of endogenous ARRDC2
expression in immortalised and primary human cell lines
(A) Confocal microscopic images: top row (U2OS) shows stable U2OSTR
ARRDC2-GFP cells expressing tetracycline-induced ARRDC2-GFP (488
channel; green in merged image), stained with rabbit anti-ARRDC2
antibody (1:200 dilution) detected using AF-633-conjugated anti-rabbit
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secondary antibody (1:1000; 633 channel, red in merged image); bottom
row (HEK-293T) shows HEK-293T cells transiently transfected with
ARRDC2-GFP (488 channel; green in merged image), stained with rabbit
anti-ARRDC2 antibody as above. (B) Confocal microscopic images of
primary human cells (Ao En, Aortic Endothelial; PA En, Pulmonary Artery
Endothelial; Ao SM, Aortic Smooth Muscle; Br Ep, Bronchial Epithelial; Br
SM, Bronchial Smooth Muscle) stained with rabbit anti-ARRDC2 antibody
(1:200) detected using AF-488-conjugated anti-rabbit secondary antibody
(1:1000; top row). Controls in which the same immunostaining protocol
was performed in the absence of anti-ARRDC2 primary antibody (middle
row) or Triton X-100 permeabilisation step (bottom row) are indicated.
Corresponding phase images are shown in insets. Scale bars = 20 µm.
expected, detection of the intracellular immunostaining seen
required permeabilisation, excluding the possibility of non-specific
extracellular plasma membrane labelling. Pulmonary artery
endothelial cells also showed ARRDC2 immunostaining at the plasma
membrane (Figure 3.10B). There also appeared to be some degree
of diffuse staining in the cytoplasm of these cells. Again, when the
controls lacking primary antibody or permeabilisation step were
performed, no ARRDC2 immunostaining was observed, suggesting
that the ARRDC2 immunoreactivity seen was specific. As mentioned,
aortic smooth muscle cells also showed a degree of ARRDC2
immunoreactivity (Figure 3.10B). ARRDC2 immunostaining in these
cells appeared to be diffusely distributed throughout the cytoplasm
and possibly at the plasma membrane, although definitively showing
this, even in confocal sections, was difficult due to the flat nature of
the cells. Indeed, the diffuse presumed cytoplasmic staining may
actually represent plasma membrane, since confocal microscopy
may not be able to resolve cytoplasm between two close plasma
membrane sheets in these cells. Again, however, no immunostaining
was detectable in the primary antibody-deficient control, and very
little immunostaining was present when permeabilisation was
omitted, suggesting that the anti-ARRDC2 labelling seen was
specific.
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3.3 Discussion
3.3.1 ARRDCs localise to the endocytic system
Several reports in lower eukaryotes have localised the Į-arrestins to
the plasma membrane and/or cytoplasmic vesicular compartments,
either through direct observation (Guetta et al., 2010; Herrador et
al., 2009; Hervas-Aguilar et al., 2010; Lin et al., 2008; O'Donnell et
al., 2010) or by inference from their reported roles within the
endocytic system (Hatakeyama et al., 2010; Nikko et al., 2009;
Nikko et al., 2008). The few studies on human ARRDCs have made
broadly the same conclusions, although in some cases reports on a
single ARRDC have been contradictory (see Table 3.1). Here,
transiently expressed ARRDC1-4 in U2OS cells all distributed in a
broadly similar manner: that is, at the plasma membrane and in
punctate structures reminiscent of vesicles throughout the
cytoplasm. One group has recently reported that ARRDC1 and
ARRDC3 localise exclusively to the plasma membrane without any
intracellular patterning (Nabhan et al., 2012; Nabhan et al., 2010).
However, elsewhere punctate cytoplasmic staining for ARRDC1
(Rauch et al., 2011) and ARRDC3 (Oka et al., 2006; Patwari et al.,
2009) has been reported, as was observed here. Overall, the plasma
membrane and vesicular pattern seen here for the human ARRDCs
is largely in agreement with the limited available literature.
It is notable that the approach used for tagging ARRDC2  at the
C-terminus  enabled visualisation of ARRDC2 without affecting its
subcellular targeting. This approach was chosen since ARRDC2 has
an extended C-tail that, based on known ǃ-arrestin structures, is
predicted to form a flexible structure (Aubry et al., 2009; Han et al.,
2001), in contrast to the ARRDC2 (and other ARRDCs) N-terminus
that forms the start of the predicted arrestin N-domain, part of the
arrestin ǃ-sandwich fold that is hypothesised to be essential for
ARRDC2 structure and function. The lack of apparent effect of
various C-terminal tags (e.g. 2FLAG, ~2 kD; eGFP, ~28 kD) upon
ARRDC2 localisation supports the idea that the ARRDC2 C-terminus
may be unessential for subcellular targeting.
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3.3.2 ARRDC2 is dynamically localised within the
endocytic system, predominantly to late
endosomes/lysosomes
Next, the nature of the ARRDC2-positive cytoplasmic puncta noted
above was investigated. In U2OS cells, colocalisation studies using
exogenous ARRDC2 expressed in combination with compartment-
specific markers convincingly indicated that ARRDC2 is largely
confined to late endosomes/lysosomes (in addition to the plasma
membrane) and is not found within early or recycling endosomes.
However, a low degree of colocalisation of ARRDC2 with early
endosomal markers (RAB5; transferrin plasma membrane staining,
for example) was detected, and the ARRDC2 expression pattern was
highly colocalised with that of ARRDC3 (see Figure 3.8), a protein
previously reported to localise to transferrin-positive endosomes, as
well as lysosomes (Oka et al., 2006). Such reports  of a protein
appearing to variably localise to distinct endocytic structures 
have contributed to the developing view of an endocytic system that
has a degree of plasticity. It is important to emphasise that the
supposed specific, restricted targeting of proteins such as the RAB
GTPases to particular endocytic domains is more complex than often
indicated. For example, as described in section 3.1, the segregation
of RAB5 to early endosomes versus RAB7 on late endosomes is the
result of a switch mechanism involving competition between RAB5-
and RAB7-related factors (McMahon et al., 2011). This likely
produces a concentration gradient of each RAB protein; for example,
high-to-low concentration of RAB5 in early-to-late endosomes,
respectively. Thus, RAB5 is not likely to be completely absent from
later endosomal structures, making the observation of sporadic
ARRDC2 colocalisation with RAB5 and other early endosomal
markers unsurprising.
RAB proteins are essential to the function of their respective
endosomes, critically regulating endosomal budding, fusion and
maturation, and the flux of cargo through each compartment.
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Perhaps unsurprisingly, overexpression of RABs can perturb the
trafficking towards these pathways; for example, RAB5
overexpression leads to increased flux of cargo such as the TfR
through the endocytic and early endosomal pathways (Bucci et al.,
1992). The analysis of ARRDC2 distribution in relation to
endogenous RAB GTPases (for example, using anti-RAB
immunostaining) would be a preferred method, and would
strengthen the case for the ARRDC2 localisation described here
being representative of the native system. However, this limitation
was controlled for by using alternative markers that do not perturb
trafficking (LAMP1, LysoTracker, Transferrin), thereby
complementing the RAB GTPase overexpression data.
The fact that ARRDC2 is targeted to the plasma membrane in
addition to late endosomes/lysosomes, and sporadically appears
within compartments labelled with early endosomal markers,
suggested that ARRDC2 may traverse, at least transiently, the
earlier stages of the endocytic system. This was further supported
by the observed accumulation of ARRDC2 within enlarged
endosomes induced by the overexpression of a constitutively active
mutant of the early endosomal GTPase, RAB5 (RAB5Q79L). Whether
the dynamic movement of ARRDC2 through the endocytic pathway
is a feature of its in situ function, or merely reflective of the delivery
of nascent ARRDC2 to its site of action (i.e. late
endosomes/lysosomes) via the plasma membrane/early endosomes,
is unclear from these data. In this context it is worth noting that
several lysosomal proteins (including RAB7 and LAMP1), when newly
synthesised, are thought to be delivered to the lysosome via this
same route, and are also found within RAB5Q79L-positive enlarged
endosomes (Wegener et al., 2010). Therefore, caution must be
taken before concluding that the function of ARRDC2 involves
movement between different components of the endocytic pathway,
although the concurrent presence of ARRDC2 at the plasma
membrane in the absence of targeted perturbations of the endocytic
system (seen for exogenous and endogenous [section 3.3.3]
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ARRDC2; not seen, for example, for RAB7/LAMP1) further hints that
this may be the case.
Possible future experiments that may illuminate upon the question
of dynamic ARRDC2 movement (retrograde versus anterograde
trafficking) include the use of photoswitchable fluorescent protein
variants. Photoswitchable GFP and related fluorescent proteins have
been engineered that are protonated in response to a pulse of
ultraviolet (UV) irradiation (405 nm), leading to isomerisation and
photoconversion of the chromophore, typically from green to red
wavelengths (Brejc et al., 1997; Chudakov et al., 2004). UV-induced
photoswitching of tagged ARRDC2 at defined regions (for example at
the plasma membrane or in co-labelled lysosomes) would enable
analysis of its trafficking in and out of these compartments as has
been performed, for example, in assessing the movement of
proteins to and from defined vesicular clusters (Fang et al., 2010).
This approach could also be combined with total internal reflection
fluorescence (TIRF) microscopy (Mattheyses et al., 2010) to image
dynamic events at or close to the plasma membrane with high
resolution.
3.3.3 Detection of endogenous ARRDC2
In order to study endogenous ARRDC2, an antibody was raised
against a short peptide sequence unique to ARRDC2 (section 2.5.4).
This antibody detected exogenously expressed ARRDC2 in intact cell
immunofluorescence staining in U2OS or HEK-293 cells, and did not
cross-react with any other human ARRDCs, TXNIP, or ǃ-arrestins in
this system. However, the antibody was unable to detect
overexpressed ARRDC2 in Western immunoblotting. The reason for
this is unknown, although it may be that the antibody binds to an
epitope within the ARRDC2 protein whose structural integrity is
important to the interaction, and whose integrity may be lost under
the denaturing conditions used in SDS-PAGE.
The anti-ARRDC2 antibody was used to investigate endogenous
ARRDC2 expression pattern in several immortalised and primary
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human cell types. No ARRDC2 immunostaining was detectable in the
U2OS and HEK-293 lines, suggesting that ARRDC2 is not expressed
in these cell types. However, several primary cell types (aortic
endothelial; pulmonary artery endothelial; aortic smooth muscle)
showed specific ARRDC2 immunostaining; other primary cells did
not (bronchial epithelial; bronchial smooth muscle cells). As far as is
known from current literature, there is no data available on the
endogenous expression of ARRDC2 in human tissues, although
expressed sequence tag (EST) database information suggests that
the ARRDC2 gene is widely (but not ubiquitously) expressed
(http://www.ncbi.nlm.nih.gov/unigene). Thus, this is a novel
demonstration: that ARRDC2 protein is expressed in human aortic
endothelial, pulmonary artery endothelial and aortic smooth muscle
cells. It is notable that ARRDC2 expression may be tissue specific;
for example, although expression was detected in some smooth
muscle cells (aorta) it was not in others (bronchial).
Each primary cell type used here that expressed ARRDC2 showed
some degree of plasma membrane immunostaining, in addition to
possible diffuse cytoplasmic staining; very little evidence of punctate
vesicular localisation was obtained. This appeared to be in contrast
to the exogenous expression data presented, where punctate
vesicular structures were easily observed (sections 3.3.1 and 3.3.2).
It is possible that exogenous overexpression of ARRDC2 may lead to
enhanced flux through the endocytic pathway to lysosomes (where
most exogenous ARRDC2 was detected). That is, the subcellular
targeting seen for ARRDC2 may represent an exaggeration of the
native system, as may be the case in any study that uses
exogenously overexpressed proteins. However, it is important to
note that the apparent flat nature of the primary cells used rendered
the resolution of cellular substructures difficult (see next paragraph).
Furthermore, endosomes/lysosomes are relatively small structures
(typically around 100-200 nm), and the expression level of
endogenous proteins (such as ARRDC2) within them is likely to be
lower than in the overexpressed system, making their definitive
identification above the level of cytoplasmic background difficult.
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Hence, it remains likely that the proposed late endosomal/lysosomal
localisation of ARRDC2 will represent the native situation. Indeed,
subsequent data presented in the current thesis (Chapters 4 and 5)
attest to a potential role for ARRDC2 in the endocytic system in
support of this claim.
The recent development of an anti-ARRDC2 antibody enabled
these studies on endogenous ARRDC2 in primary cells. Further
characterisations using this system would be essential to define a
physiologically relevant function for ARRDC2. First, it would be
desirable to clarify the endogenous expression observed here, for
example by using reverse transcriptase PCR (RT-PCR) to detect
Arrdc2 mRNA expression in the relevant primary lines, and by
including an additional control in the primary cell immunostaining
protocol (co-incubation with the antibody-raising peptide in order to
specifically compete out anti-ARRDC2 binding to the presumed
endogenous protein). Subsequent experiments would aim to more
convincingly determine the localisation of endogenous ARRDC2
using, for example, 3D reconstruction analysis of confocal images
(enabling greater resolution in the z direction). This may well reveal
that the putative diffuse cytoplasmic staining seen actually
represents plasma membrane staining, unable to be resolved due to
the closeness of the plasma membrane sheets in the flat cells used.
The use of alternative primary cell types whose intracellular
compartments are more readily visualised could potentially add
credence to the vesicular targeting seen in the exogenous studies.
Additionally, an approach to uncovering a physiological role for
ARRDC2 in GPCR regulation would be to assess whether ARRDC2
distribution is affected by stimulation of primary cells with various
GPCR agonists (at endogenously expressed or transfected GPCRs),
which may indicate ARRDC2-GPCR recruitment.
In summary, human ARRDCs are targeted to intracellular vesicular
compartments and the plasma membrane. In the case of ARRDC2,
the compartments represent components of the endocytic pathway,
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predominantly late endosomes/lysosomes. ARRDC3 likely localises
to similar endocytic compartments, evidenced by a high degree of
ARRDC3-ARRDC2 colocalisation. The appearance of ARRDC2
throughout the endocytic system points to a potential dynamic role
therein, and ARRDC2 flux through the system is indicated by the
ability of RAB GTPase mutants to block ARRDC2 within early or late
endosomes. Immunostaining indicates that ARRDC2 is expressed by
some human cell types (aortic endothelial; pulmonary artery
endothelial; aortic smooth muscle), but that its distribution may be
tissue-specific. Broadly, the distribution seen within these primary
cells  especially plasma membrane targeting  supports the
proposed endocytic targeting of ARRDC2, suggesting that it may
have a physiologically relevant role within this system.
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4 ARRDC2 is a ubiquitin ligase
adaptor
4.1 Introduction
Ubiquitination is increasingly being recognised as a critical signal
that regulates intracellular cargo protein sorting pathways (Acconcia
et al., 2009; Hislop et al., 2011; Raiborg et al., 2009). In addition to
the direct ubiquitination of cargo proteins for their lysosomal
trafficking, ubiquitination of components of the ESCRT sorting
machinery regulates their function (Hoeller et al., 2006), as is also
evident for ubiquitin ligase adaptors (Macdonald et al., 2011). This
may also be true for arrestins: ǃ-arrestins and Į-arrestins have also
been reported to be regulated by ubiquitination (Shenoy et al., 2007)
(Becuwe et al., 2012; Gupta et al., 2007; Hatakeyama et al., 2010;
Kee et al., 2006; Lin et al., 2008; Rauch et al., 2011). In the case of
Į-arrestins ubiquitination may be performed by the NEDD4 family
ligase with which they interact.
As described in section 1.2.3, E3 ubiquitin ligases determine the
specificity of ubiquitination, and are divided into RING finger and
HECT domain families. The RING E3 ligases are scaffolds that bind
E2s (ubiquitin-conjugating enzymes), recruiting them to the vicinity
of substrates and activating the direct transfer of ubiquitin
(Deshaies et al., 2009). In contrast, HECT E3 ligases contain a
conserved Cys residue that forms an intermediate thioester bond
with ubiquitin before transferring it to the substrate (Rotin et al.,
2009). The Cys residue is within the C-terminal region of the HECT
domain, a bilobal structure whose N-terminal region contacts the E2
enzyme. The HECT domain is present in the C-terminal portion of all
HECT E3 ligases. In addition to this characteristic domain, HECTs
have multiple other domains within their N-terminus that delineate
them into the HERC, NEDD4 and other HECTs subfamilies. For the
NEDD4 family, these include a C2 domain in the extreme N-
terminus and two to four WW domains (Figure 4.1A). The C2
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domain interacts with phospholipids (possibly in a Ca2+-dependent
manner), targeting NEDD4 family ligases to membrane
compartments such as the plasma membrane and endosomes
(Dunn et al., 2004; Lu et al., 2011). An autoinhibitory role for the
C2 domain has also been reported for the NEDD4 ligase SMURF2,
whereby an intramolecular interaction between the C2 and HECT
domains reduces the HECT catalytic activity (Wiesner et al., 2007).
WW domains are protein-protein interaction domains that contain
two conserved Trp residues. The WW domains bind to proline-rich
sequences (such as PPxY motifs) in substrate proteins or adaptors
(Sudol et al., 1995), and provide the major means for recognising
substrates or being targeted to them.
Although they share a common HECT domain, NEDD4 ligases have
various unique roles. These include the regulation of cell signalling
(NEDD4, SMURF1/2, AIP4), protein trafficking (NEDD4, NEDD4L)
and viral budding (NEDD4, WWP1). For example, SMURF1 and
SMURF2 negatively regulate signalling induced by transforming
growth factor ǃ (TGFǃ), a key regulator of processes including
proliferation, differentiation and apoptosis. TGFǃ binding to its
receptor activates signal transduction via various intracellular Smad
proteins, the termination of which also involves other, inhibitory
Smads. Smads contain PPxY motifs, enabling them to bind to
SMURF1/2, an association that leads to ubiquitination and
degradation of Smads themselves, TGFǃ receptor or TGFǃ-induced
transcription factors (Inoue et al., 2008).
Several NEDD4 family ligase roles in intracellular trafficking and
viral budding have been described in Chapter 1. The impact of
ubiquitination upon GPCR signalling and trafficking was also touched
upon therein. RING finger and HECT domain ligases have been
implicated in GPCR ubiquitination and regulation, both of which may
be mediated by arrestins. For example, ǃ-arrestin2 recruits the
RING E3 ligase, Mdm2, to agonist-stimulated ǃ2AR, leading to
ubiquitination of the receptor and arrestin, and thus to enhanced
ǃ2AR lysosomal degradation (Shenoy et al., 2001). ǃ-Arrestins have
also been reported to bind the NEDD4 family members NEDD4 and
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AIP4, interactions that may similarly influence the ubiquitination and
turnover of GPCRs and other cell-surface cargo (Bhandari et al.,
2007; Shenoy et al., 2008; Simonin et al., 2010). ǃ-Arrestins do not
contain PPxY motifs, and the mechanisms underlying these
interactions are unclear. As has been described in Chapter 1, many
Į-arrestin-NEDD4 family ligase interactions have been uncovered,
the majority of which are thought to be mediated by a canonical
PPxY motif-WW domain mechanism.
Therefore, the background to the current chapter is the emerging
role for Į-arrestins as adaptors for NEDD4 E3 ligases in intracellular
trafficking. The observation that ARRDC2 is targeted to the
endocytic system (Chapter 3) in which the NEDD4 E3 ligases carry
out many of their functions suggested that ARRDC2 may fit into this
paradigm, together with the PPxY motifs located in the ARRDC2 C-
terminus that may enable an interaction. Hence, the potential ability
of ARRDC2 to scaffold NEDD4 E3 ligases was investigated. Whether
ARRDC2 itself is subject to ubiquitination was also determined.
4.2 Results
4.2.1 PPxY motif-dependent interaction of ARRDC2
with multiple members of the NEDD4 family of HECT
E3 ubiquitin ligases
To test for ARRDC2 interaction with all nine NEDD4 family E3 ligases
present in man, ARRDC2-2FLAG and individual ligases C-terminally
tagged with eGFP-HA (ligase-eGFP-HA) were transiently expressed
either alone or in combination in U2OS cells. Protein lysates from
these cells were incubated with anti-HA agarose beads in order to
immunoprecipitate the ligase-eGFP-HA fusions. Western
immunoblotting was then performed on whole cell lysates or
immunoprecipitates to assess for the presence of
coimmunoprecipitated ARRDC2-2FLAG (n  2).
ARRDC2-2FLAG was efficiently expressed, as evidenced by an
anti-FLAG immunoreactive band at ~55 kD in lysates obtained from
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ARRDC2-2FLAG transfections, not present in lysate lacking ARRDC2-
2FLAG transfection (Figure 4.1, bottom panel). ARRDC2 is predicted
to be ~44 kD which, combined with two copies of the FLAG epitope,
would only be expected to total ~46 kD. The disparity between this
and the observed size of the ARRDC2-2FLAG band is discussed in
section 4.2.3. The eGFP-HA-tagged NEDD4 family ligases were also
efficiently expressed in transient transfections (evidenced by
microscopy; see, for example, Figure 4.3) and several were
detected in immunoprecipitates blotted using an anti-HA antibody
(Figure 4.1, middle panel). For example, WWP2 is predicted to be
~99 kD; plus eGFP-HA (~29 kD) would equal ~128 kD, the
approximate size that is seen on the blot. However, detection of
several of the ligases on immunoblotting was weak or absent,
possibly due to poor exposure of the HA epitope or inefficient
transfer of the large proteins from gel to nitrocellulose. Nevertheless,
coimmunoprecipitation of ARRDC2-2FLAG was observed with
multiple NEDD4 family members (Figure 4.1, top panel). The
immunoprecipitate derived from cells transfected with ARRDC2-
2FLAG alone (without ligase-eGFP-HA) showed only a very faint
anti-FLAG immunoreactive band at ~55 kD. This is possibly
indicative of background nonspecific ARRDC2-2FLAG binding to the
anti-HA agarose, despite multiple wash steps (see section 2.5.2).
However, a much stronger ARRDC2-2FLAG band was observed for
immunoprecipitates obtained from lysates in which NEDL1, AIP4,
WWP2 or SMURF1 (tagged with eGFP-HA) were coexpressed with
ARRDC2-2FLAG, suggesting that these ligases associate with
ARRDC2. In addition to the strong coimmunoprecipitation of
ARRDC2 with the above four ligases, ARRDC2-2FLAG bands also
appeared to be present in the NEDL2, NEDD4, WWP1 and SMURF2
immunoprecipitates that were stronger than the control ARRDC2-
2FLAG immunoprecipitate lacking ligase-eGFP-HA. Therefore,
specific ARRDC2 interactions with NEDL2, NEDD4, WWP1 and
SMURF2 were also detected. Immunoprecipitation with the
remaining ligase, NEDD4L, gave a weak ARRDC2-2FLAG band that
could not be convincingly distinguished from the background control,
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Figure 4.1 Coimmunoprecipitation of ARRDC2 with the NEDD4
family of HECT E3 ubiquitin ligases
(A) Generalised domain organisation of the NEDD4 family of HECT E3
ligases. All members contain an N-terminal C2 domain, a C-terminal HECT
domain, and two to four WW domains. (B) U2OS cells were transiently
cotransfected with plasmids expressing ARRDC2-2FLAG and/or the
indicated ligase tagged with eGFP-HA. Cell lysates (2.5% input) and
immunoprecipitates (IP) obtained by incubation with anti-HA agarose were
separated by 12.5% SDS-PAGE and analysed by Western blotting using
anti-HA or anti-FLAG antibodies (both at 1:5000 dilution), as indicated,
detected using IRDye 800CW anti-rabbit secondary antibody (1:10,000).
Molecular weight markers are shown in kD.
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suggesting that ARRDC2 may not interact with NEDD4L. NEDD4L-
eGFP-HA appeared to be expressed in this experiment, as evidenced
by the presence of a band at over 130 kD (NEDD4L is estimated to
be ~105 kD; eGFP-HA ~29 kD). Together, these data suggest that
ARRDC2 is able to interact with several members of the NEDD4
family of E3 ligases, with the possible exception of NEDD4L.
The regions of ARRDC2 required for interaction with NEDD4 family
ligases were investigated. Interaction with NEDL1 and WWP1 was
tested: as seen above, coimmunoprecipitation of wild-type ARRDC2-
2FLAG was detected with either NEDL1- or WWP1-eGFP-HA (Figure
4.2B, C, top panels). However, a mutant ARRDC2 in which the Tyr
residues of both PPxY motifs were mutated to Ala (denoted
ARRDC2ǻǻ¶) failed to coimmunoprecipitate with NEDL1 or WWP1;
although faint ARRDC2ǻǻ-2FLAG bands were detectable, they were
no stronger than the background level in the absence of NEDL1- or
WWP1-eGFP-HA. These results indicated that the PPxY motifs of
ARRDC2 are required for its binding to NEDL1 and WWP1. For
NEDL1, single PPxY motif mutants of ARRDC2 were also tested for
their ability to coimmunoprecipitate following ligase pull-down
(Figure 4.2B). Mutation of the first PPxY motif (ARRDC2Y342A)
resulted in a similar abrogation of coimmunoprecipitation with
NEDL1 as the ARRDC2ǻǻ double PPxY mutant. Mutation of the
second PPxY motif (ARRDC2Y388A) also seemed to reduce detected
coimmunoprecipitation compared to wild-type ARRDC2, but did not
appear to completely remove NEDL1 binding, as evidenced by some
residual ARRDC2Y388A-2FLAG present in the immunoprecipitate
that was stronger than the background level. This suggested that
both ARRDC2 PPxY motifs may contribute to its binding to NEDL1,
but that the first PPxY motif (corresponding to Tyr342) may be most
important. It is notable that the apparent amount of NEDL1-eGFP-
HA present, detected by blotting with anti-HA, varied between
conditions and was markedly lower in the ARRDC2ƩƩ WUDQVIHFWHG
sample; thus, comparisons between the level of ARRDC2 pull-down
in different samples must be made with caution.
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Figure 4.2 ARRDC2 interaction with NEDL1 and WWP1 is dependent
on the presence of ARRDC2 PPxY motifs
(A) Domain organisation of ARRDC2: the two PPxY motifs are shown,
indicating that constructs used in which Tyr342 is mutated to Ala, Tyr388 is
mutated to Ala, or both residues are mutated to Ala are denoted as 342,
388 or ǻǻ, respectively. (B, C) U2OS cells were transiently
cotransfected with plasmids expressing ARRDC2-2FLAG and/or NEDL1-
eGFP-HA or WWP1-eGFP-HA, as indicated. Cell lysates (2.5% input) and
immunoprecipitates (IP) obtained by incubation with anti-HA agarose were
separated by 12.5% SDS-PAGE and analysed by Western blotting using
anti-HA or anti-FLAG antibodies (both at 1:5000 dilution), as indicated,
detected using IRDye 800CW anti-rabbit secondary antibody (1:10,000).
Molecular weight markers are shown in kD.
4.2.2 ARRDC2 overexpression alters the subcellular
distribution of several NEDD4 family ligases
Next, the role of ARRDC2 interaction with NEDD4 family ligases in
determining ARRDC2 and/or ligase subcellular localisation was
investigated by confocal microscopy. First, the distribution of
ARRDC2 wild-type (wt) or PPxY motif double mutant (ǻǻ) fused to
mCherry was analysed in transiently transfected U2OS cells. The
distribution of ARRDC2ƩƩ was indistinguishable from ARRDC2wt;
both were found within cytoplasmic vesicular structures and at the
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plasma membrane (Figure 4.3A), as previously seen for various
ARRDC2wt fusion proteins (section 3.2.1), although the precise
identity of the ARRDC2ƩƩ-positive vesicles was not determined.
The distribution of all nine NEDD4 family ligases (fused to eGFP-
HA), alone or in combination with ARRDC2wt/ǻǻ-mCherry, was also
assessed by transient transfection of U2OS cells and confocal
microscopy. WWP1 was diffusely localised throughout the cytosol
when expressed alone, with no punctate vesicular structures
observed (Figure 4.3A). However, when coexpressed with
ARRDC2wt, in addition to diffuse staining, WWP1-positive puncta
were frequently observed, and these were highly colocalised
(0.563±0.039 coefficient for WWP1-eGFP-HA colocalisation with
ARRDC2wt-mCherry, n = 3) with ARRDC2wt puncta (Figure 4.3B,
left panel). In contrast, ARRDC2ƩƩ overexpression did not affect
WWP1 distribution; WWP1 remained diffusely distributed without
any observable puncta upon coexpression with ARRDC2ƩƩ (Figure
4.3B, right panel). No obvious change in ARRDC2wt/ƩƩ distribution
was observed when coexpressed with WWP1 in comparison to
ARRDC2wt alone. These observations further supported the PPxY-
dependent interaction of ARRDC2 with WWP1 (section 4.2.1), and
suggested that this interaction may affect the subcellular
distribution of WWP1.
A similar effect, albeit less marked, of ARRDC2 overexpression
was observed for SMURF1, another ligase found to
coimmunoprecipitate with ARRDC2 (Figure 4.1B). SMURF1 was also
diffusely distributed when expressed alone in U2OS cells, without
any cytoplasmic puncta observed (Figure 4.3A). Coexpression with
ARRDC2wt resulted in the sporadic appearance of SMURF1 puncta
that colocalised with ARRDC2wt (Figure 4.3D, left panel). The
SMURF1-positive puncta were seen less frequently than for WWP1,
and their identification was hampered by the high level of diffuse
cytosolic SMURF1 staining that remained. Nevertheless, SMURF1-
positive puncta did appear to be induced by ARRDC2wt
overexpression and again, this was not seen upon coexpression with
ARRDC2ƩƩ)LJXUH'ULJKWSDQHO7KXVinteraction with
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Figure 4.3 ARRDC2 may associate with NEDD4 family ubiquitin
ligases in living cells
Confocal microscopic images of U2OS cells: (A) transiently transfected
with plasmids expressing ARRDC2-mCherry (wild-type, wt; or PPxY mutant,
ƩƩ), WWP1-eGFP-HA, AIP4-eGFP-HA, SMURF1-eGFP-HA or NEDL1-eGFP-
HA. (B, C, D, E) transiently cotransfected with plasmids expressing
ARRDC2-mCherry (wild-type, WT; or PPxY mutant, ƩƩand WWP1, AIP4,
SMURF1 or NEDL1 tagged with eGFP-HA, except for in E, where ARRDC2
:7 ƩƩ VKRZQ LV the construct tagged with 2x FLAG epitope (ARRDC2-
2FLAG), stained using mouse anti-FLAG antibody (1:200) detected with AF-
633-conjugated anti-mouse secondary antibody (1:1000). In merged
images, ARRDC2 is shown in red; the indicated ligase is in green. Images
are representative of at least two independent experiments. Scale bar = 10
µm.
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Figure 4.4 ARRDC2 overexpression does not affect NEDD4, NEDD4L,
WWP2, NEDL2 or SMURF2 distribution
Confocal microscopic images of U2OS cells: (A) transiently transfected
with plasmids expressing NEDD4, NEDD4L, WWP2, NEDL2 or SMURF2 N-
terminally fused with eGFP-HA. (B, C, D, E, F) transiently cotransfected
with plasmids expressing ARRDC2-mCherry (wild-type, WT; or PPxY
mutant, ƩƩand NEDD4, NEDD4L, WWP2, NEDL2 or SMURF2 tagged with
eGFP-HA. In merged images, ARRDC2 is shown in red; the indicated ligase
is in green. Images are representative of at least two independent
experiments. Scale bar = 10 µm.
146
ARRDC2 may also influence the localisation of SMURF1.
AIP4, another ligase that coimmunoprecipitated strongly with
ARRDC2 (Figure 1B), localised to punctate cytoplasmic vesicles and
the plasma membrane when expressed alone in U2OS cells (Figure
4.3A). In this case, the coexpression of ARRDC2wt had no obvious
effect upon AIP4 distribution; AIP4 remained localised to
cytoplasmic puncta and the plasma membrane (Figure 4.3C, left
panel). However, ARRDC2wt did colocalise highly with AIP4-positive
puncta (0.519±0.012 coefficient for ARRDC2wt-mCherry
colocalisation with AIP4-eGFP-HA). Furthermore, although AIP4
remained punctate in distribution upon ARRDC2ǻǻ coexpression, the
AIP4 puncta did not appear to colocalise with ARRDC2ǻǻ; AIP4- and
ARRDC2ǻǻ-positive vesicles were largely distinct (Figure 4.3C, right
panel; 0.146±0.005 ARRDC2ǻǻ-mCherry colocalisation coefficient
with AIP4-eGFP-HA, p = 0.009, upaired t test). This differential
colocalisation of AIP4 with variants of ARRDC2 (colocalised with
ARRDC2wt; not with ARRDC2ǻǻ) suggests that AIP4 distribution
may be influenced by ARRDC2.
ARRDC2 overexpression did not affect the distribution of the
remaining six NEDD4 family ligases. For example, NEDL1 was
localised diffusely throughout the cytosol but was also sporadically
present within discrete punctate compartments when expressed
alone in U2OS cells (Figure 4.3A). Although the NEDL1 puncta
occasionally colocalised with coexpressed ARRDC2wt, there was no
discernable effect upon NEDL1 distribution, and colocalisation with
ARRDC2ǻǻ was also observed (Figure 4.3E). Of the remaining five
NEDD4 family ligases, NEDL2, NEDD4L, WWP2, and SMURF2 were
all diffusely distributed when expressed alone, and this distribution
was unaffected by overexpression of ARRDC2 (Figure 4.4). When
expressed alone, NEDD4 was localised diffusely throughout the
cytoplasm, but also appeared in punctate cytoplasmic structures and
at the plasma membrane (Figure 4.4A); this distribution was also
unaffected by overexpression of ARRDC2 (NEDD4-positive puncta
sporadically colocalised with both ARRD&ZWƩƩ when coexpressed
[Figure 4.4B]). Hence, although ARRDC2 overexpression is capable
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of affecting NEDD4 family ligase (WWP1, SMURF1 and AIP4)
subcellular distribution, this is not ubiquitous to all NEDD4 family
members.
4.2.3 ARRDC2 is modified by ubiquitin independent of
ARRDC2-NEDD4 family ligase interaction and
lysosomal function
As mentioned in section 4.2.1, on Western immunoblots, transiently
expressed ARRDC2-2FLAG appeared as an anti-FLAG
immunoreactive band at ~55 kD, around 10 kD higher than would
be expected for monomeric, unmodified ARRDC2-2FLAG protein.
The reason for this disparity is unclear, although it is possible that
ARRDC2 may be modified by ubiquitination. A single ubiquitin
moiety adds ~8 kD to the molecular weight of a protein. Hence, the
predominant form of ARRDC2 may be monoubiquitinated, which
would explain the major band detected at ~55 kD. Further to this,
additional more slowly migrating bands were detectable above the
molecular weight of ARRDC2-2FLAG at discrete intervals (for
example, see Figure 4.5A, bottom panel). These additional bands
are suggestive of further ubiquitinated forms of ARRDC2, indicating
that ARRDC2 may be multi- and/or polyubiquitinated. Whether
ARRDC2 is indeed ubiquitinated was tested by the transient
expression of ARRDC2-2FLAG with or without ubiquitin N-terminally
tagged with HA (HA-ubiquitin) in U2OS cells. Resulting protein
lysates were incubated with anti-HA agarose beads in order to
immunoprecipitate HA-ubiquitin; Western immunoblotting was
performed on whole cell lysates or immunoprecipitates to assess for
the presence of coimmunoprecipitated ARRDC2-2FLAG.
ARRDC2wt coimmunoprecipitated with ubiquitin; although, as in
previous coimmunoprecipitation experiments, a low level of
background ARRDC2wt-2FLAG binding to the anti-HA agarose was
evident by the presence of faint anti-FLAG immunoreactive bands
at~55 kD in the HA-ubiquitin-negative immunoprecipitate, a much
stronger band was observed for ARRDC2wt-2FLAG when
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Figure 4.5 ARRDC2 ubiquitination is independent of its PPxY motifs
and is unaffected by lysosomal inhibition
(A) U2OS cells were transiently cotransfected with plasmids expressing
ARRDC2-2FLAG wild-type (wt) or PPxY mutant (ǻǻ) and/or HA-ubiquitin, as
indicated. (B) U2OS cells were transiently cotransfected with plasmids
expressing ARRDC2-2FLAG wild-type and/or HA-ubiquitin, as indicated. In
addition, cells were treated plus/minus 1 µM Bafilomycin A1 (inhibitor of
lysosomal function) for 24h prior to cell lysis. In both A/B, cell lysates (5%
input) and immunoprecipitates (IP) obtained by incubation with anti-HA
agarose were separated by 12.5% SDS-PAGE and analysed by Western
blotting using anti-HA or anti-FLAG antibodies (both at 1:5000 dilution), as
indicated, detected using IRDye 800CW anti-rabbit secondary antibody
(1:10,000). Molecular weight markers are shown in kD.
HA- ubiquitin was coexpressed (Figure 4.5A, top panel).
Furthermore, a number of more slowly migrating bands were
detected above the ~55 kD band. These observations indicate that
ARRDC2 may be modified by ubiquitin, predominantly involving
monoubiquitination but also multi- and/or polyubiquitination.
The ability of ARRDC2 to interact with NEDD4 family E3 ligases
has been previously shown (section 4.2.1). NEDD4 ligases have
been implicated in the ubiquitination of Į-arrestins (Becuwe et al.,
2012; Gupta et al., 2007; Hatakeyama et al., 2010; Kee et al., 2006;
Rauch et al., 2011), and it is notable that overexpression of several
NEDD4 ligases (NEDL1 and WWP2 in particular) appeared to result
in an increase in the intensity of high molecular weight ARRDC2
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bands detected in immunoprecipitates, suggestive of an
enhancement of ARRDC2 ubiquitination (Figure 4.1, top panel).
Therefore, it was hypothesised that ARRDC2 ubiquitination may be
dependent upon ARRDC2-ligase interaction. However, the
ARRDC2ƩƩ PPxY motif mutant coimmunoprecipitated with ubiquitin
in a comparable manner to ARRDC2wt (Figure 4.5A, top panel). It is
worth noting that an alternative interpretation of the
coimmunoprecipitation of ARRDC2 and ubiquitin is that ARRDC2
binds to ubiquitin, rather than being modified by the covalent
attachment of it, as has been suggested elsewhere (Rauch et al.,
2011). This possibility underlines the importance of subsequent
alternative approaches to measuring ARRDC2 ubiquitination (see
section 4.3).
As mentioned (section 4.1), ubiquitination (especially
polyubiquitination) of protein substrates within the endocytic system
is frequently used as a signal for their targeting to the lysosome for
degradation. Hence, it is possible that the ubiquitination of ARRDC2
detected here serves this purpose for the turnover of the protein. To
address this, the expression and ubiquitination of ARRDC2-2FLAG
was assessed in cells treated with or without the vacuolar-type
ATPase inhibitor, bafilomycin A1, which prevents the acidification
and maturation of endosomes, thereby blocking transport from late
endosomes to lysosomes (van Weert et al., 1995). ARRDC2
expression and ubiquitination (as detected by
coimmunoprecipitation as above) were comparable in cells treated
or untreated with bafilomycin A1 (Figure 4.5B); that is,
accumulation of ubiquitinated ARRDC2 was not detected upon
lysosomal inhibition. It is noted that in these experiments an
expected high molecular weight smear of ubiquitinated proteins was
only weakly detected and the characteristic low molecular weight
band (~10 KDa) of unconjugated ubiquitin was not seen in anti-HA
blots, suggesting that ubiquitin may have been poorly expressed.
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4.3 Discussion
Coimmunoprecipitation demonstrated that ARRDC2 is able to
interact, at least indirectly, with multiple members of the NEDD4
family of HECT E3 ubiquitin ligases. The ARRDC2 C-terminal PPxY
motifs must be present in order to detect coimmunoprecipitation
with NEDD4 ligases (demonstrated here for NEDL1 and WWP1). This
suggests that the ARRDC2-ligase interaction may be direct,
involving ARRDC2 PPxY motif contact with ligase WW domains, in
agreement with the emerging paradigm for Į-arrestin-NEDD4 family
ligase interactions. Coimmunoprecipitation also indicated that
ARRDC2 is modified by ubiquitin. Mutation of ARRDC2 PPxY motifs
did not appear to affect its ubiquitination, suggesting that the
modification is independent of ARRDC2 interaction with NEDD4
ligases. Finally, ARRDC2 ubiquitination was detected regardless of
lysosomal function, suggesting that the modification may have some
function other than targeting ARRDC2 for lysosomal degradation.
4.3.1 ARRDC2 interaction with NEDD4 family ligases
Many Į-arrestins have been reported to interact with NEDD4 family
ligase members (Andoh et al., 2002; Hatakeyama et al., 2010;
Herrador et al., 2009; Lin et al., 2008; Nabhan et al., 2010; Nikko
et al., 2008; Rauch et al., 2011). In particular, Rauch and Martin-
Serrano (2011) investigated the interaction of several NEDD4
ligases with human ARRDCs, including ARRDC2. Using a yeast two-
hybrid screen, they showed that ARRDC2 is capable of binding
WWP1, WWP2 and NEDD4, and furthermore showed using GST pull-
downs that ARRDC2 can directly interact with WWP1, WWP2, NEDD4
and AIP4. These observations are in agreement with the
coimmunoprecipitation data presented here, and collectively argue
strongly for the ability of ARRDC2 to directly interact with NEDD4
family ubiquitin ligases.
The interaction of ARRDC2 with NEDD4 ligases was found to be
PPxY motif-dependent (shown here for interactions with NEDL1 and
WWP1), as has been shown for many other Į-arrestin-NEDD4 ligase
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interactions (Andoh et al., 2002; Hatakeyama et al., 2010; Herrador
et al., 2009; Lin et al., 2008; Nabhan et al., 2010; Rauch et al.,
2011). ARRDC2 contains two PPxY motifs in its C-tail. Mutation of
both PPxY motifs abolished ARRDC2 interaction with NEDL1 (and
WWP1), whereas some residual NEDL1 binding was detectable with
single ARRDC2 PPxY mutants. This suggests that both PPxY motifs
contribute to the ARRDC2-ligase interaction. This is in agreement
with other studies where Į-arrestin interaction with ligases is
reduced, but not completely abolished, by mutation of single PPxY
motifs (Lin et al., 2008; Nabhan et al., 2010). The discovery that
ARRDC2 binds several NEDD4 ligases via its PPxY motifs strongly
suggests that the interaction is mediated canonically by the ligase
WW domains. However, mutation of individual ligase WW domains
and analysis of the impact upon ARRDC2 coimmunoprecipitation
would be needed to directly demonstrate this.
The relevance of ARRDC2-NEDD4 family ligase interactions to any
molecular or physiological mechanisms has not been addressed
elsewhere to date. In the case of ARRDC1, interaction with ligases 
notably WWP1  and ubiquitination by those same ligases may
provide a link between the ligases and the ESCRT machinery during
PPxY-dependent viral budding (Rauch et al., 2011). For ARRDC3,
PPxY-dependent interaction with NEDD4 has been suggested to
recruit NEDD4 to the agonist-stimulated ǃ2AR, thereby mediating
receptor ubiquitination and downregulation (Nabhan et al., 2010).
Thus, ARRDC-NEDD4 family ligase interactions may serve to recruit
the ligases to specific subcellular localisations and/or substrate
proteins, where their ubiquitination of substrates is required under
particular conditions.
Data presented here suggest that this is true for ARRDC2: that is,
the interaction of ARRDC2 with NEDD4 family ligases can influence
the localisation of the ligases, and thus may determine their site of
action. This was shown for WWP1 and SMURF1, both of which
exhibited a diffuse cytosolic distribution when expressed alone but,
when coexpressed with ARRDC2wt, also became localised to
punctate structures that colocalised with ARRDC2wt. Importantly,
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WWP1 or SMURF1 redistribution was not induced upon coexpression
with ARRDC2ǻǻThe ARRDC2 PPxY motifs were demonstrated to be
required for its interaction with WWP1; although not tested here,
based on the amount of literature supporting PPxY motif-WW
domain interactions it is expected that this is also the case for the
ARRDC2-SMURF1 interaction. Thus, the ARRDC2 PPxY motif-
dependent redistribution of WWP1 and SMURF1 to a more punctate
pattern is likely to be a result of direct interaction with ARRDC2 and
recruitment to vesicular compartments in which ARRDC2 resides.
An effect of ARRDC2 overexpression upon AIP4 distribution was
also potentially detected, since AIP4 puncta colocalised with
ARRDC2wt but not ARRDC2ƩƩ. This suggests that interaction with
ARRDC2 may also determine the precise localisation pattern of AIP4.
Hypothetically, it is conceivable that when expressed alone, AIP4
localises to discrete vesicular compartments (for example,
endosomes) that are separate from ARRDC2-positive compartments
(i.e. lysosomes) such that, upon overexpression of ARRDC2ƩƩ, the
two populations are not colocalised; overexpressed ARRDC2wt,
however, is able to interact with AIP4 and recruits it to ARRDC2wt-
positive lysosomes. This assumes that ARRDC2ƩƩ is targeted to the
lysosome in the same way as ARRDC2wt. Although ARRDC2wt and
ARRDC2ƩƩ exhibited the same overall pattern of distribution 
plasma membrane plus cytoplasmic puncta  additional experiments
such as co-staining specific compartments (for example with
transferrin or LysoTracker) would be needed to clarify this.
Regarding the impact of the ARRDC2-AIP4 interaction, the reverse
hypothesis is also possible: namely that AIP4 causes ARRDC2
redistribution. Again, additional experiments using compartment-
specific co-staining of AIP4- and ARRDC2-containing puncta would
be required to distinguish these two possibilities.
With reference back to the localisation studies on ARRDC2
(Chapter 3), the fact that ARRDC2ǻǻ retains the ability to target to
vesicular compartments (although as noted above, the nature of
these compartments is unknown) suggests that ARRDC2 is not
targeted to membranes by its association with NEDD4 ligases, but
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by some other unknown mechanism. In contrast, a recent report
showed that deletion of the PPxY motif-containing C-terminus of
ARRDC4 abolishes its membrane targeting, resulting in a diffuse
cytosolic pattern of distribution (Vina-Vilaseca et al., 2011).
However, since a large portion (the last 68 amino acids) of the
ARRDC4 C-terminus was deleted, it is unclear whether this effect is
due to the lack of NEDD4 ligase binding. It could be that other
residues within this region form membrane contacts (directly or
indirectly), or that the C-tail is essential for the overall structure of
the protein which, when disrupted, is unable to support the same
molecular interactions.
It is worth noting that the strategy for assessing ARRDC2
interactions with NEDD4 family ligases involved the use of ligases
that were C-terminally tagged with eGFP-HA, both in microscopic
localisation studies and immunoprecipitations. This approach was
chosen in order to avoid disrupting the N-terminal phospholipid-
binding C2 domain, which is known to be required for correct
subcellular targeting (Dunn et al., 2004; Lu et al., 2011). However,
since the completion of the current project it has become clear that
the extreme C-terminus of NEDD4 ligases contains a conserved
phenylalanine residue that is critical for substrate ubiquitination
(Salvat et al., 2004). Disrupting this activity may not have affected
the ligase subcellular targeting, making the conclusions of the
localisation experiments reported here unaltered. But for
immunoprecipitation experiments altered ligase activity and possibly
conformation may have affected the results; it would therefore be
ideal to replicate the results using alternative methods (ligases
fused to HA alone; immunoprecipitation of endogenous ligases).
4.3.2 ARRDC2 ubiquitination
Coimmunoprecipitation of ARRDC2 with ubiquitin demonstrated that
ARRDC2 can be modified by ubiquitin. The presence of sequential
higher molecular weight bands on ARRDC2 Western blots upwards
of the major ARRDC2 band suggested that this may involve multi-
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or polyubiquitination, as has been seen for ARRDC1 (Nabhan et al.,
2012). However, the predominant form of ARRDC2 may be
monoubiquitinated, since the major ARRDC2 band detected on
Western blots was consistently ~10 kD larger than the predicted
molecular weight of monomeric, unmodified ARRDC2. A similar
observation has been made for the yeast Į-arrestin, ART1, which
appeared on Western blots as a weak band corresponding to
unmodified ART1 plus a stronger band ~8 kD larger in size (Lin et
al., 2008). Pull-down of ART1 and anti-ubiquitin immunoblotting
confirmed that this major band was an ubiquitinated form of ART1,
presumably monoubiquitinated. For ARRDC2 this could be similarly
tested by pull-down of ARRDC2 followed by immunoblotting with an
antibody targeted against ubiquitin (and analysis of the size of the
resultant bands). Such an approach would also provide a more
meaningful assessment of the proportion of ARRDC2 that is modified
by the attachment of endogenous ubiquitin, information that is not
available from the above experiment in which total, overexpressed
ubiquitin was immunoprecipitated, and any ARRDC2 bound to it was
detected.
Inhibition of lysosomal function by the addition of bafilomycin A1
did not appear to affect the level of ARRDC2 protein or its
ubiquitination status, suggesting that the ARRDC2 ubiquitination
detected may not represent a signal for lysosomal sorting and
degradation. Rather, it is tempting to speculate that the
ubiquitination of ARRDC2 may directly influence its function  as is
the case for other Į-arrestins (Becuwe et al., 2012; Rauch et al.,
2011)  within the endo-lysosomal system. Given the influence of
NEDD4 family ligases upon sorting processes within this system,
that ARRDC2 interacts with several NEDD4 family members (section
4.2.1), and that other Į-arrestins are reported to be ubiquitinated
by NEDD4 family ligases (Becuwe et al., 2012; Hatakeyama et al.,
2010; Rauch et al., 2011), it was hypothesised that the
ubiquitination of ARRDC2 may be carried out by NEDD4 family
ligases. However, it was shown here that the ARRDC2ǻǻ mutant,
which does not interact with NEDD4 family ligases (demonstrated
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here for NEDL1 and WWP1), retains its ability to
coimmunoprecipitate efficiently with ubiquitin. As mentioned above,
the experimental approach used  pull-down of ARRDC2 with
overexpressed ubiquitin  may yield positive coimmunoprecipitation
results that exaggerate the real situation.
Nonetheless, this result suggests that NEDD4 family ligase
interaction is not required for ARRDC2 ubiquitination, implying that
other ligases may be responsible. This would not be the first time
that a PPxY motif-containing ubiquitin ligase adaptor has been
reported to be ubiquitinated independent of a known NEDD4 family
ligase interaction (Edwards et al., 2009). However, it is in contrast
to several reports on other Į-arrestins. ART1, as mentioned above,
is monoubiquitinated, and this modification was abolished by
mutation of the two ART1 PPxY motifs (Lin et al., 2008). The human
Į-arrestin ARRDC1 is ubiquitinated: this is enhanced by the
overexpression of WWP1, and abolished by the overexpression of a
catalytically inactive WWP1 mutant or the deletion of the ARRDC1
PPxY motif-containing C-terminus (Rauch et al., 2011). Thus, the
ubiquitination of ARRDC2 by a non-NEDD4 family ligase would
represent a new mechanism of Į-arrestin regulation. It would be
important to perform the reverse ARRDC2-ubiquitin pull-down
experiment described above before making this conclusion. Indeed,
as noted in section 4.2.3, overexpression of several NEDD4 ligases
(NEDL1 and WWP2) appeared to increase the intensity of high
molecular weight ARRDC2 bands, suggestive of an enhancement of
ARRDC2 ubiquitination. Thus, the combination of more sensitive
approaches such as observing the effect of NEDD4 ligase siRNA
knockdown or catalytic mutant overexpression on ARRDC2
ubiquitination would be required to convincingly demonstrate that
NEDD4 ligases are not responsible.
In summary, the endocytic targeting of ARRDC2 was described in
Chapter 3. This has been supported by the discovery that ARRDC2
can interact with several members of the NEDD4 ubiquitin ligase
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family, ubiquitous regulators of signalling and trafficking within the
endocytic system. Interaction with NEDD4 ligases requires ARRDC2
PPxY motifs, suggesting that the mechanism involved may be
similar to that used by several other Į-arrestins. Moreover,
interaction with ARRDC2 can influence the subcellular targeting of
several NEDD4 ligases (notably WWP1, SMURF1), providing a basis
for the hypothesis that ARRDC2 may represent an adaptor for
specific NEDD4 ligase ubiquitination events. ARRDC2 itself can be
ubiquitinated, a modification that may influence ARRDC2 in situ
function, rather than lysosomal targeting. Biochemical experiments
hint that the predominant form of ARRDC2 may be
monoubiquitinated, in addition to higher order ubiquitin oligomers.
Preliminary data suggest that this modification may not be carried
out by NEDD4 ligases, although additional experiments will be
needed to clarify the ligase(s) responsible.
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5 Putative role for ARRDC2 in GPCR
regulation
5.1 Introduction
The GPCRs used in the current study were the Rhodopsin/class A
receptors, ǃ2AR and įOR.
ǃ2AR is perhaps the most widely studied GPCR, and much of the
knowledge gleaned from ǃ2AR studies has shaped the understanding
of GPCR signalling and regulatory mechanisms. ǃ2AR responds to
the endogenous catecholamine agonists, adrenaline and
noradrenaline (Goldstein, 2001). Adrenaline and, to a lesser extent,
noradrenaline, are secreted in response to sympathetic nervous
system (SNS) stimulation of the adrenal medulla.
Adrenaline/noradrenaline act peripherally to stimulate both Į- and
ǃ-adrenoceptors, producing physiological effects including enhanced
cardiac output and skeletal muscle vasodilation, characteristic of the
fight-or-flight stress response. They also act upon the lungs to
produce airway relaxation, hence the use of adrenoceptor agonists
(at the ǃ2AR) to treat asthma. Noradrenaline also acts centrally as a
neurotransmitter to regulate cognitive functions such as arousal,
mood and memory (Ramos et al., 2007; Sara, 2009). Such
knowledge has led to the use of compounds which alter
noradrenaline physiology, for example in the treatment of
depression (tricyclic antidepressants inhibit noradrenaline re-uptake,
as do amphetamine/cocaine).
The canonical pathway for ǃ2AR signalling involves agonist-
dependent coupling to Gs, which activates adenylyl cyclase leading
to increased production of cAMP and the subsequent activation of
PKA, which phosphorylates various target proteins. At high agonist
concentrations, ǃ2AR also couples to inhibitory Gi proteins in a
manner dependent on receptor phosphorylation by PKA, which
induces a switch in coupling from Gs to Gi (Daaka et al., 1997; Liu et
al., 2009). As has been described (Chapter 1), ǃ2AR also undergoes
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agonist-dependent phosphorylation by GRKs, leading to ǃ-arrestin
association and desensitisation, as well as clathrin-mediated
endocytosis. Agonist-stimulated ǃ2AR is subject to ubiquitination,
originally thought to be carried out by the RING E3 ligase, Mdm2,
which is recruited by ǃ-arrestin (Shenoy et al., 2001) although
NEDD4 appears to be a more likely candidate for the ligase
responsible (Nabhan et al., 2010; Shenoy et al., 2008). ǃ2AR falls
into group A (section 1.2.4) of GPCRs that are transiently
phosphorylated and ubiquitinated, from which ǃ-arrestin rapidly
dissociates. Thus, ǃ2AR is used here as a model GPCR that is
targeted to early/recycling endosomes upon internalisation (Moore
et al., 2004; Seachrist et al., 2000), leading to rapid recycling to the
plasma membrane (Pippig et al., 1995; Shenoy et al., 2003) and
hence inefficient lysosomal sorting and degradation; reductions in
ǃ2AR levels of just ~10 and ~25% are detected upon isoprenaline
stimulation (10 µM) for 3 and 24h, respectively (Nabhan et al., 2010;
Shenoy et al., 2003).
Opioid receptors are divided into four subtypes based on their
pharmacological responsiveness to a variety of opioid ligands: mu-,
kappa-, delta- and nociceptin/orphanin-opioid receptors (µ-, ț-, į-
and N-opioid receptors) (Waldhoer et al., 2004). įOR is expressed
in the brain and mediates analgesic and antidepressant responses to
opiates; specifically, endogenous įOR peptide ligands include
various enkephalin derivatives. These can be mimicked by
therapeutic agonists (for example, morphine  although note that
morphine preferentially activates µOR), the chronic application of
which is well known to cause tolerance, presumably through
receptor downregulation. įOR is a Gi/Go-coupled receptor: įOR
activation leads to inhibition of adenylyl cyclase and presynaptic
Ca2+ channels (Law et al., 2000). The mechanism of desensitisation
and endocytosis of įOR is highly similar to that of ǃ2AR, involving
ligand-dependent phosphorylation by GRKs, recruitment of ǃ-
arrestins and coupling to the clathrin-mediated endocytic machinery
(von Zastrow, 2010). Thus, įOR is internalised into homologous
early endosomal compartments to ǃ2AR (Tsao et al., 2000).
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However, from here, the fate of įOR is markedly distinct from ǃ2AR;
the įOR undergoes sorting into the lysosomal pathway, leading to
efficient proteolysis and downregulation; whereas, as described
above, just ~10% of ǃ2AR is degraded over 3 h agonist stimulation,
for įOR this rises to 50% (Tsao et al., 2000). Under the GPCR
classification system described (section 1.2.4), įOR is a group B
GPCR whose phosphorylation and ubiquitination is thought to be
more prolonged, leading to more stable ǃ-arrestin association,
intracellular retention and lysosomal trafficking. Despite this
definition, the mechanism of įOR segregation into the lysosomal
pathway remains incompletely understood. Experiments indicate
that GPCR-associated sorting proteins (GASPs) are required,
although their precise role remains undefined (Whistler et al., 2002).
Surprisingly, lysosomal sorting can occur in mutant įOR receptors
devoid of ubiquitin-targeted cytoplasmic lysine residues (Tanowitz et
al., 2002), yet still requires components of the ESCRT machinery
(Hislop et al., 2004), which is normally involved in MVB sorting of
ubiquitinated cargoes (section 1.2.3). It appears that įOR
ubiquitination  performed by the NEDD4 family ligase AIP4  plays
a regulatory, rather than obligatory role in įOR degradation by
enhancing the efficiency of receptor incorporation into ESCRT-
mediated ILVs (Henry et al., 2011). Here, įOR is used as a model
GPCR that undergoes efficient lysosomal trafficking and degradation.
If ARRDC proteins are involved in GPCR regulation  as supported
by aforementioned studies on ARRDC3  one mechanism by which
this might occur is via oligomerisation with ǃ-arrestins. Homo-
oligomerisation of visual arrestin is well established, and is thought
to perform a regulatory role in limiting the proportion of active
monomer available in retinal cells (Kim et al., 2011; Schubert et al.,
1999). Homo- and hetero-oligomerisation of ǃ-arrestins has also
been reported using methods including coimmunoprecipitation and
resonance energy transfer (Storez et al., 2005), and may be
supported at physiological concentrations by the presence of the
cytosolic lipid, inositol hexakisphosphate (IP6) (Hanson et al., 2007).
The homodimerisation interface of ǃ-arrestin2 was mapped using a
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spot peptide array, and it was found that this same surface defines
the ERK1/2 signalling platform (Xu et al., 2008). This led to the
suggestion that ǃ-arrestin dimers  similar to visual arrestins  may
represent inactive storage forms in which signalling interactions are
masked, and that disruption of dimerisation upon receptor
association is required for their scaffolding functions. However, ǃ-
arrestin2 binding to the alternative partner, JNK3, was unaffected by
mutations that disrupted dimerisation (Xu et al., 2008), and
interaction with Mdm2 has been reported to require ǃ-arrestin2
dimerisation (Boularan et al., 2007), suggesting that ǃ-arrestin
dimers may be functionally relevant, perhaps determining the
specific subset of downstream effectors with which ǃ-arrestin can
interact. Furthermore, the apparent involvement of both ǃ-arrestins
in various signalling pathways suggests that heterodimerisation of
ǃ-arrestins could play an important role (Defea, 2008). Moreover,
the ability of arrestins to act as dimers or higher order oligomers is
conceptually plausible. The potential for GPCR oligomerisation has
been noted (section 1.1.4), and it has been recognised that the
association of arrestin and GPCR dimers might provide the extensive
surface required for the scaffolding of the apparent multitude of
arrestin effectors (Gurevich et al., 2008a). The ability of arrestin
family proteins to hetero-oligomerise would provide yet another
level of complexity to this system.
The current chapter investigates a potential role for ARRDC2 in the
regulation of GPCRs, focussing on ǃ2AR and įOR. This was prompted
by several lines of evidence, including (i) the similarity of Į-arrestins,
including ARRDC2, to the canonical GPCR regulatory adaptors, the
ǃ-arrestins; (ii) the reported involvement of other Į-arrestins,
notably ARRDC3, in GPCR regulation (see section 1.4.3) (iii) the fact
that ARRDC2 is specifically targeted to the endocytic system,
including the plasma membrane (Chapter 3), the environment in
which GPCRs function and are regulated by trafficking; (iv) the
detection of ARRDC2 ubiquitination and interactions with NEDD4
family ubiquitin ligase members (Chapter 4), both of which
represent important determinants of multiple cargo trafficking
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processes, including those involving GPCRs. As mentioned, the
potential for homo- and hetero-oligomerisation of ARRDC2 with
arrestin members was also investigated.
5.2 Results
5.2.1 ARRDC2 regulation of a prototypic recycling
receptor: ǃ2AR
5.2.1.1 ARRDC2 colocalises with internalised ǃ2AR
As a preliminary indicator for the involvement of ARRDC2 in ǃ2AR
regulation, the colocalisation of coexpressed fluorescent protein
fusions of ARRDC2 and ǃ2AR was assessed in U2OS cells. In these
experiments, ǃ2AR was fused with either C-terminal GFP (ǃ2AR-GFP)
or extracellular N-terminal SNAP tag (plus N-terminal signal
sequence; ssǃ2AR). The expression pattern and agonist
responsiveness of these fusions in U2OS cells was first validated.
ǃ2AR-GFP or ssǃ2AR were efficiently expressed in transiently
transfected cells. In the absence of agonist stimulation expression
was largely confined to the plasma membrane, whereas agonist
stimulation (isoprenaline, 10 µM, 1 h) resulted in receptor
internalisation into cytoplasmic vesicles (Figure 5.1). Hence, the
expression pattern and responsiveness of the ǃ2AR fusions in U2OS
cells was in agreement with that widely known for ǃ2AR (Kallal et al.,
1998). Coexpression of ARRDC2 constructs with ǃ2AR (ARRDC2-
mCherry with ǃ2AR-GFP; ARRDC2-GFP with ssǃ2AR labelled with AF-
633-conjugated SNAP ligand) had no obvious effect upon the
distribution of either protein in unstimulated conditions (Figure
5.2A,B, top panels); ǃ2AR-GFP/ssǃ2AR remained largely at the
plasma membrane, ARRDC2-mCherry/ARRDC2-GFP retained the
punctate intracellular distribution (with some plasma membrane
staining) that has already been described (Chapter 3). Agonist
stimulation, as seen above, caused ǃ2AR internalisation into
cytoplasmic vesicles; interestingly, ARRDC2 puncta exhibited a high
degree of colocalisation with internalised ǃ2AR (Figure 5.2A,B,
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bottom panels; for example, a coefficient of 0.672±0.023 was
measured for ARRDC2-mCherry colocalisation with ǃ2AR-GFP, n = 5).
Figure 5.1 Exogenous expression of ǃ2AR constructs in U2OS cells
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ǃ2AR tagged with GFP (ǃ2AR-GFP) or SNAP tag
(ssǃ2AR), treated with isoprenaline (ISO, 10 µM, 1h) or without (Control),
as indicated. ssǃ2AR was visualised by labelling with 0.1 µM SNAPsurface
BG-AF546 prior to the experiment. Images are representative of at least
three independent experiments. Scale bar = 20 µm.
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Figure 5.2 ARRDC2 colocalises with agonist-stimulated ǃ2AR
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ARRDC2-mCherry plus ǃ2AR-GFP (A), or with
ARRDC2-GFP plus ssǃ2AR (B). Cells were treated with isoprenaline (ISO,
10 µM, 1h) or without (Control), as indicated. ssǃ2AR was visualised by
labelling with 0.1 µM SNAPsurface BG-AF633 prior to the experiment. In
merged images, ǃ2AR is in green, ARRDC2 is in red. Images are
representative of at least three independent experiments. Scale bar = 10
µm.
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Figure 5.3 Internalised ǃ2AR is found within transferrin-positive
early endosomal/recycling compartments in U2OS cells
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ǃ2AR-GFP (A) or ssǃ2AR (B) were treated with
isoprenaline (ISO, 10 µM, 1h or 8h, as indicated) or without (Control), as
indicated. In addition, cells were co-stained with 250 ng/µl AF-633-
conjugated Transferrin for the final 15 min of the plus/minus isoprenaline
incubation, or co-immunostained post-fixing using rabbit anti-LAMP1
antibody detected with AF-633-conjugated anti-rabbit secondary antibody,
as indicated. ssǃ2AR was visualised by labelling with 0.1 µM SNAPsurface
BG-AF546 prior to the experiment. In merged images, ǃ2AR-GFP is in green,
ssǃ2AR is in blue and transferrin/LAMP1 (Marker) is in red. Images are
representative of at least three independent experiments. Scale bar = 10
µm.
5.2.1.2 ARRDC2/ǃ2AR colocalisation involves compartmental
ARRDC2 redistribution
The observation that ARRDC2 colocalises with agonist-stimulated,
internalised ǃ2AR was interesting given that ARRDC2 has been found
to reside within late endosomal/lysosomal compartments (Chapter 3)
and that, in contrast, ǃ2AR is widely believed to rapidly recycle to
the plasma membrane via early/recycling endosomes (Parent et al.,
2009; Shenoy et al., 2003). Indeed, experiments performed here
confirmed that in U2OS cells, agonist-stimulated, internalised ǃ2AR
(10 µM isoprenaline, 1 h) was found within transferrin-positive
early/recycling endosomes and was distinct from LAMP1-labelled
lysosomes (Figure 5.3). Moreover, high-content imaging indicated
that the receptor was efficiently recycled (Figure 5.4). Cells stably
expressing ssǃ2AR were stimulated for 1 h with 10 µM isoprenaline,
followed by two rinse washes and a final wash step of between 5 
60 min in serum-free DMEM/0.1 % BSA with or without 1 µM
propanolol, a ǃ2AR antagonist. Although there was only an ~11 %
reduction in isoprenaline-stimulated ssǃ2AR internalisation over a 30
min wash period without propanolol, inclusion of propanolol 
assumed to compete for binding to ssǃ2AR with isoprenaline, which
may not be fully removed in the wash steps  resulted in a ~64 %
reduction in internalisation over the same time-scale, and an ~89 %
reduction over the full 1 h. This result is contrasted with the profile
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Figure 5.4 Internalised ǃ2AR recycles rapidly to the cell surface
ssǃ2AR recycling to the plasma membrane following agonist stimulation
was quantified by granularity analysis of IX Ultra platereader images (see
section 2.4.6.2). U2OS cells stably expressing ssǃ2AR on 96-well plates
were labelled with 0.1 µM SNAPsurface BG-AF488, followed by incubation
with vehicle or 10 µM isoprenaline (ISO; in serum-free DMEM/0.1 % BSA)
for 1 h at 37 ºC. Cells were washed twice with serum-free DMEM/0.1 %
BSA, and then incubated in this media with or without 1 µM S-propanolol
for 5  60 min at 37 ºC (wash) before fixation. The pooled granularity
data plotted are average intensities per cell, normalised to 10 µM ISO
control responses without a wash step. Data are the mean ± S.E.M. of 4
experiments performed in triplicate. Representative images are shown
above of cells without isoprenaline stimulation (No ISO), stimulated for 1
h with no wash (ISO 1h), 1 h wash without propanolol (ISO 1h recycle
1h no prop) or 1 h wash plus propanolol (ISO 1h recycle 1h + prop), as
indicated.
of GPCR 120 (GPR120), a non-recycling receptor that exhibited less
than 25 % recycling over a 30 min period, assessed using the same
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method (Watson et al., 2012). Thus, ǃ2AR is efficiently recycled to
the plasma membrane in the U2OS system used.
The nature of these compartments containing internalised ǃ2AR
and ARRDC2 was analysed by additional co-staining for either
transferrin-positive early/recycling endosomes or LAMP1-positive
lysosomes. In cells coexpressing ǃ2AR-GFP and ARRDC2-mCherry,
ARRDC2-mCherry localised to late endosomes/lysosomes in the
absence of agonist (0.543±0.018, ARRDC2-mCherry colocalisation
coefficient with LAMP1, and 0.182±0.011 with transferrin, P < 0.001;
Figure 5.5 top row, 5.7A), in agreement with previous localisation
data (Chapter 3). However, in cells stimulated with isoprenaline (10
µM, 1 h), ARRDC2-mCherry colocalised with transferrin
(0.426±0.013) but not with LAMP1 (0.189±0.011, P < 0.001;
Figure 5.5 bottom row, 5.7A, n = 4).
This change in ARRDC2 localisation was also observed when the
alternative constructs, ssǃ2AR and ARRDC2-GFP, were used. In
these experiments, only colocalisation with transferrin-positive
early/recycling endosomes was assessed. Nevertheless, ARRDC2-
GFP colocalisation with transferrin was similarly low in unstimulated
conditions (0.239±0.027; Figure 5.6 top row, 5.7B). Again,
stimulation with isoprenaline (10 µM, 1 h) resulted in a significant
increase in ARRDC2 localisation to early/recycling endosomes
(0.556±0.050 ARRDC2-GFP colocalisation with transferrin, P <
0.001; Figure 5.6 middle row, 5.7B). In this experiment, the effect
of 8 h isoprenaline incubation was also assessed. After 8 h
stimulation, ARRDC2-GFP colocalisation with transferrin returned to
near the level without agonist present (0.301±0.049; Figure 5.6
bottom row, 5.7B). Collectively, these data indicate that ARRDC2
colocalisation with agonist-stimulated, internalised ǃ2AR involves a
change in ARRDC2 distribution, from LAMP1-labelled late
endosomes/lysosomes to transferrin-labelled early/recycling
endosomes.
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Figure 5.5 ARRDC2 colocalisation with agonist-stimulated ǃ2AR-GFP
involves compartmental redistribution of ARRDC2
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ǃ2AR-GFP plus ARRDC2-mCherry. Cells were treated
with isoprenaline (ISO, 10 µM, 1h) or without (Control), as indicated. In
addition, cells were co-stained with 250 ng/µl AF-633-conjugated
Transferrin for the final 15 min of the plus/minus isoprenaline incubation,
or co-immunostained post-fixing using rabbit anti-LAMP1 antibody detected
with AF-633-conjugated anti-rabbit secondary antibody, as indicated.
Merged images show ǃ2AR in green, ARRDC2 in red and transferrin/LAMP1
(Marker) in blue. Images are representative of at least three independent
experiments. Scale bar = 10 µm.
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Figure 5.6 ARRDC2 colocalisation with agonist-stimulated ssǃ2AR
involves compartmental redistribution of ARRDC2
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ssǃ2AR plus ARRDC2-GFP. Cells were treated with
isoprenaline (ISO, 10 µM, 1h or 8h, as indicated) or without (Control), as
indicated. In addition, cells were co-stained with 250 ng/µl AF-633-
conjugated Transferrin for the final 15 min of the control/ISO incubation.
ssǃ2AR was visualised by labelling with 0.1 µM SNAPsurface BG-AF546 prior
to the experiment. In merged images, ARRDC2 is shown in green, ssǃ2AR
is in blue and transferrin is in red. Images are representative of at least
three independent experiments. Scale bar = 10 µm.
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Figure 5.7 Quantification of ARRDC2 compartmental redistribution
in response to agonist-stimulated ǃ2AR internalisation
Colocalisation analysis of confocal images (example images shown in
Figures 5.4 and 5.5) from U2OS cells transiently transfected with ARRDC2-
mCherry plus ǃ2AR-GFP (A), or ARRDC2-GFP plus ssǃ2AR (B). Graphs
show coefficients for ARRDC2-mCherry colocalisation with AF-633-
conjugated Transferrin or anti-LAMP1 antibody labelling (as indicated), in
cells treated with isoprenaline (ISO, 10 µM, 1h or 8h, as indicated) or
without (Control), as indicated. Colocalisation calculations were performed
as described in section 2.4.6.1. Data are mean ± SEM of 6-15 cells
analysed for each of  3 independent experiments. ***P < 0.001, one-
way ANOVA plus Tukey post test.
5.2.1.3 Effect of ARRDC2 overexpression upon ǃ2AR trafficking
and signalling
The trafficking profile of ǃ2AR and its downstream signalling in U2OS
cells were compared with or without the exogenous overexpression
of ARRDC2-GFP.
The analysis of ARRDC2-GFP colocalisation with transferrin in the
presence of ssǃ2AR (treated with or without agonist) has been
described above (section 5.2.1.2). In these experiments,
colocalisation of internalised ssǃ2AR with transferrin was also
assessed (the analysis excluded plasma membrane-localised ssǃ2AR;
see section 2.4.6), in singly transfected cells or cells co-transfected
with ARRDC2-GFP. In the absence of agonist, ssǃ2AR exhibited a
degree of constitutive internalisation (Figure 5.6 top row) which was
highly colocalised with transferrin, irrespective of ARRDC2-GFP
overexpression (0.737±0.050, 0.759±0.047 ssǃ2AR colocalised with
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transferrin in cells with/without ARRDC2-GFP, respectively; Figure
5.6 top row, 5.8). In cells without ARRDC2-GFP, upon 1h
isoprenaline stimulation, internalised ssǃ2AR colocalisation with
transferrin was moderately lowered, and after 8 h stimulation this
decrease was more pronounced (Figure 5.8). This same pattern
occurred in cells overexpressing ARRDC2-GFP, such that at each
given time-point, no significant difference between cells with or
without ARRDC2-GFP was measured. This indicated that
overexpression of ARRDC2-GFP had no major effect upon the
trafficking of internalised ssǃ2AR. However, the decrease observed
in ssǃ2AR colocalisation with transferrin between 0 and 1 h agonist
stimulation was less pronounced in cells overexpressing ARRDC2-
GFP (the apparent difference was rendered no longer significant;
Figure 5.8), hinting that ARRDC2 overexpression may have delayed
the exit of ssǃ2AR from transferrin-positive compartments. However,
this effect, if any, was extremely subtle and should not be over
interpreted given the relatively low sensitivity of measuring receptor
trafficking with the colocalisation analysis employed here. It would
require further investigation to establish whether this was a genuine
effect; that is, whether ARRDC2 has a regulatory role in ǃ2AR traffic
from transferrin-positive early/recycling endosomes, for example
using different, potentially more sensitive methods such as
knockdown of ARRDC2 expression (see section 5.3.1).
The effect of ARRDC2 overexpression upon the signalling elicited
by ǃ2AR was also investigated. ǃ2AR couples to the Gs subtype of
heterotrimeric G proteins: ǃ2AR agonist stimulation leads to the
dissociation of GĮs, which activates adenylyl cyclase resulting in the
increased formation of intracellular cAMP and activation of PKA
(Kobilka, 1992). U2OS cells express endogenous ǃARs: stimulation
with the broad-spectrum ǃAR agonist isoprenaline resulted in PKA
activation, which was sensitive to the selective ǃ2AR antagonist,
ICI118,551, indicating that U2OS cells express this subtype (Stefan
et al., 2007). Hence, a cAMP accumulation assay (see section 2.6)
was used to measure the endogenous response to isoprenaline in
U2OS cells with or without induced overexpression of ARRDC2-GFP.
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Figure 5.8 Effect of ARRDC2 overexpression upon ǃ2AR trafficking
Colocalisation analysis of confocal images (representative images shown in
Figures 5.3B and 5.5) from U2OS cells transiently transfected with ssǃ2AR
alone (No ARRDC2) or in combination with ARRDC2-GFP (Plus ARRDC2).
Graph shows coefficients for colocalisation of internalised ssǃ2AR with AF-
633-conjugated Transferrin, in cells treated with isoprenaline (ISO, 10 µM,
1h or 8h) or without (Control), as indicated. Colocalisation calculations
were performed as described in section 2.4.6.1. Data are mean ± SEM of
6-15 cells analysed for each of  3 independent experiments. *P < 0.05,
***P < 0.001, ns = not significant; one-way ANOVA plus Tukey post test.
No significant differences were measured between No ARRDC2 versus
Plus ARRDC2 data for each time-point.
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Figure 5.9 Isoprenaline-stimulated [3H]-cAMP accumulation in
U2OSTR ARRDC2-GFP cells was unaffected by ARRDC2
overexpression
The columns represent [3H]-cAMP accumulation under basal or maximal
stimulation (10 µM isoprenaline for 5 h, ISO) conditions. Data points for
each individual experiment were the mean of triplicate determinations;
these were expressed as a percentage of the maximal response to ISO in
each experiment (without tetracycline), and the means of six independent
experiments were pooled to give the data presented here, shown as pooled
means ± SEM. No significant effect of tetracycline induction was detected
(two-way ANOVA, p = 0.09). TET, non tetracycline-treated; +TET,
overnight tetracycline induction prior to experiment.
In the absence of induced ARRDC2-GFP expression, 5h isoprenaline
incubation stimulated cAMP production with a potency (pEC50) of
7.07 ± 0.13 (Figure 5.9). Overexpression of ARRDC2-GFP did not
affect isoprenaline-induced cAMP production: the pEC50 in the
presence of induced ARRDC2-GFP was 7.07 ± 0.12 and, although
the maximal response appeared elevated this did not reach
statistical significance (Figure 5.9).
5.2.1.4 Detection of associations between ǃ2AR and arrestins
by coimmunoprecipitation
The potential ability of ARRDC2 to interact with ǃ2AR was
investigated using coimmunoprecipitation, using the association of
ǃ2AR with ǃ-arrestin2 as a positive control.
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In one approach, coimmunoprecipitation of FLAG-ǃ2AR-sfGFP
(stably expressed) in cells transiently transfected with ARRDC2-HA
or ǃ-arrestin2-HA appeared to have been detected (Figure 5.10A).
Anti-HA immunoprecipitates blotted with anti-GFP antibody showed
bands for IgG heavy and light chain (at ~50 and ~25 kD,
respectively) and an unidentified presumed non-specific band at
~100 kD, present in all immunoprecipitates. In addition, a band was
detectable at ~75-85 kD, which may represent FLAG-ǃ2AR-sfGFP
(predicted to be ~75 kD). This putative FLAG-ǃ2AR-sfGFP band was
barely detectable in lysates lacking ARRDC2-HA or ǃ-arrestin2-HA
cotransfection. In cells transfected with ǃ-arrestin2-HA, the putative
FLAG-ǃ2AR-sfGFP band remained weak in unstimulated conditions,
but was markedly stronger when cells were stimulated with
isoprenaline for 5 min, whereas stimulation for 1 h resulted in a less
pronounced band, suggesting that the band seen may indeed
represent FLAG-ǃ2AR-sfGFP. In cells transfected with ARRDC2-HA,
the putative FLAG-ǃ2AR-sfGFP band was difficult to distinguish from
the background level, although it appeared stronger in cells
stimulated with isoprenaline for 1 h, suggesting that an interaction
with ARRDC2-HA may have been detected.
Experiments in which FLAG-ǃ2AR or HA-ǃ2AR were pulled down
using the relevant anti-FLAG or anti-HA agarose were also
performed. However, immunoblotting for coimmunoprecipitated
ARRDC2 or ǃ-arrestin2 fusions did not detect any bands, despite
their presence in whole cell lysates (Figure 5.10B,C, top panels).
The reverse experiments were also performed, in which ARRDC2 or
ǃ-arrestin2 was pulled down and immunoprecipitates were blotted
for ǃ2AR. In general, no ǃ2AR bands were detected using this
approach, possibly hampered by the inability to solubilise ǃ2AR;
ǃ2AR may have aggregated, resulting in it not entering gels (see
Figure 5.10C, middle panel; ǃ2AR bands seen at the interface
between stacking/running gels).
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Figure 5.10 Attempts to detect interactions between ǃ2AR and
arrestins
U2OS wild-type cells (B,C) or cells stably expressing FLAG-ǃ2AR-sfGFP (A)
were transiently transfected with plasmids expressing the indicated
constructs. Cells were treated 24 h later with/without isoprenaline (ISO, 10
µM) as indicated prior to cell lysis. Cell lysates (2.5% input) and
immunoprecipitates (IP) obtained by incubation with anti-HA or anti-FLAG
agarose (as indicated) were separated by 12.5% SDS-PAGE and analysed
by Western blotting using anti-HA, anti-FLAG or anti-GFP antibodies (all at
1:5000 dilution), as indicated, detected using IRDye 800CW anti-rabbit (HA,
FLAG) or anti-mouse (GFP) secondary antibodies (all at 1:10,000). In (A),
IgG heavy (H) and light (L) chain are highlighted, as is an unidentified
nonspecific band (*). Molecular weight markers are shown in kD.
5.2.2 ARRDC2 regulation of a lysosome-targeted
receptor: įOR
5.2.2.1 ARRDC2 colocalises with internalised įOR
The colocalisation of ARRDC2 with įOR was next assessed, using
transient transfection of plasmids expressing ARRDC2-GFP and įOR
N-terminally fused with SNAP tag (ssįOR). In U2OS cells, ssįOR
was largely targeted to the plasma membrane in unstimulated cells,
and was internalised into cytoplasmic vesicles upon įOR agonist
stimulation (1 µM DADLE, 1 h; Figure 5.11A), as expected from the
literature (Trapaidze et al., 1996). Coexpression of ARRDC2-GFP
with ssįOR had no obvious effect upon the distribution of either
protein in unstimulated conditions (Figure 5.11B top row); ssįOR
remained largely at the plasma membrane, whereas ARRDC2-GFP
retained the punctate intracellular distribution (with some plasma
membrane staining) that has been described (Chapter 3). Agonist
stimulation, as seen above, caused ssįOR internalisation into
cytoplasmic vesicles. ARRDC2 puncta exhibited a high degree of
colocalisation with internalised ssįOR (Figure 5.11B, bottom row).
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5.2.2.2 ARRDC2/įOR colocalisation also involves
compartmental ARRDC2 redistribution
The nature of the compartments containing internalised įOR and
ARRDC2 observed here was analysed by co-staining for transferrin-
positive early/recycling endosomes. In cells expressing ARRDC2-GFP
alone in the absence of agonist, ARRDC2-GFP targeting was distinct
from early/recycling endosomes (0.111±0.022 ARRDC2-GFP
colocalised with transferrin; Figure 5.13), in agreement with
ARRDC2 localisation to transferrin-negative late
endosomes/lysosomes (Chapter 3). However, in cells coexpressing
ssįOR and ARRDC2-GFP, ARRDC2-GFP colocalisation with transferrin
in the absence of agonist was moderately increased, and was further
increased by ssįOR stimulation (0.260±0.032, 0.407±0.025
colocalisation with transferrin without/with 1 µM DADLE, 1 h,
respectively, P < 0.01, P < 0.001; Figure 5.12 and 5.13). Thus,
ARRDC2 colocalisation with internalised įOR involves redistribution
of ARRDC2 from transferrin-negative to transferrin-positive
compartments, as seen for ARRDC2 colocalisation with ǃ2AR seen
above.
5.2.2.3 ARRDC2 influences įOR trafficking
The trafficking profile of įOR in U2OS cells was compared with or
without the exogenous overexpression of ARRDC2-GFP. The analysis
of ARRDC2-GFP colocalisation with transferrin in the presence of
ssįOR (treated with/without agonist) has been described above
(section 5.2.2.2). In these experiments, colocalisation of
internalised ssįOR with transferrin was also assessed, in singly
transfected cells or cells co-transfected with ARRDC2-GFP. In the
absence of agonist, ssįOR exhibited a degree of constitutive
internalisation (Figure 5.12) which was colocalised to a small degree
with transferrin, irrespective of ARRDC2-GFP overexpression
(0.310±0.027, 0.340±0.030 ssįOR colocalised with transferrin in
cells with/without ARRDC2-GFP, respectively; Figure 5.12 and 5.14).
Upon agonist stimulation (1 µM DADLE, 1 h), internalised ssįOR
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Figure 5.11 ARRDC2 colocalises with agonist-stimulated įOR
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ssįOR alone (A) or ssįOR plus ARRDC2-GFP (B).
Cells were treated with DADLE (1 µM, 1h) or without (Control), as indicated.
ssįOR was visualised by labelling with 0.1 µM SNAPsurface BG-AF546 prior
to the experiment. In merged images, ssįOR is in red, ARRDC2 is in green.
Images are representative of at least three independent experiments. Scale
bar = 10 µm.
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Figure 5.12 ARRDC2 colocalisation with agonist-stimulated įOR
involves compartmental redistribution of ARRDC2
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ssįOR alone (top two rows) or ssįOR plus ARRDC2-
GFP (bottom two rows). Cells were treated with DADLE (1 µM, 1h) or
without (Control), as indicated. In addition, cells were co-stained with 250
ng/µl AF-633-conjugated Transferrin for the final 15 min of the plus/minus
DADLE incubation. ssįOR was visualised by labelling with 0.1 µM
SNAPsurface BG-AF546 prior to the experiment. In merged images,
ARRDC2 is in green, ssįOR is in blue, Transferrin is in red. Images are
representative of at least three independent experiments. Scale bar = 10
µm.
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Figure 5.13 Quantification of ARRDC2 compartmental redistribution
in response to agonist-stimulated įOR internalisation
Colocalisation analysis of confocal images (example images shown in
Figure 5.11) from U2OS cells transiently transfected with ARRDC2-GFP with
or without ssįOR, as indicated. Graphs show coefficients for ARRDC2-GFP
colocalisation with AF-633-conjugated Transferrin, in cells treated with
DADLE (1 µM, 1h) or without (con), as indicated. Colocalisation calculations
were performed as described in section 2.4.6.1. Data are mean ± SEM of
6-9 cells analysed for each of 3 independent experiments. **P < 0.01,
***P < 0.001, one-way ANOVA plus Tukey post test.
colocalisation with transferrin was moderately increased; this
increase was enhanced by ARRDC2-GFP overexpression
(0.461±0.028, 0.618±0.028 ssįOR colocalised with transferrin in
cells without/with ARRDC2-GFP, respectively, P < 0.001; Figure
5.12 and 5.14). Hence, internalised ssįOR partially localised to
transferrin-positive compartments upon 1 h agonist stimulation, and
this appeared to be enhanced by ARRDC2-GFP overexpression.
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5.2.2.4 ARRDC2 coimmunoprecipitates with įOR
To test for ARRDC2 interaction with įOR, ARRDC2-2FLAG and įOR
N-terminally fused with HA (HA-įOR) were transiently expressed
either alone or in combination in U2OS cells, followed by anti-HA
immunoprecipitation of HA-įOR. Western immunoblotting was then
performed on whole cell lysates or immunoprecipitates to assess for
the presence of ARRDC2-2FLAG (n = 2).
Expression of HA-įOR in these experiments was unable to be
detected by anti-HA immunoblotting of lysates or
immunoprecipitates from HA-įOR-transfected cells (not shown).
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Figure 5.14 ARRDC2 influences įOR trafficking
Colocalisation analysis of confocal images (representative images shown in
Figures 5.11) from U2OS cells transiently transfected with ssįOR alone or
plus ARRDC2-GFP, as indicated. Graph shows coefficients for colocalisation
of internalised ssįOR with AF-633-conjugated Transferrin, in cells treated
with DADLE (1 µM, 1h) or without (con), as indicated. Colocalisation
calculations were performed as described in section 2.4.6.1. Data are mean
± SEM of 6-11 cells analysed for each of  3 independent experiments.
***P < 0.001, one-way ANOVA plus Tukey post test.
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Figure 5.15 Attempts at coimmunoprecipitation of ARRDC2 with
įOR
U2OS cells were transiently cotransfected with plasmids expressing HA-
įOR and/or ARRDC2-2FLAG. 24 h later cells were treated with/without įOR
agonist (DADLE, 1 µM) for the indicated time-points, followed by isolation
of cell lysates. Cell lysates (5% input) and immunoprecipitates (IP)
obtained by incubation with anti-HA agarose were separated by 12.5%
SDS-PAGE and analysed by Western blotting using anti-FLAG antibody
(1:5000), detected using IRDye 800CW anti-rabbit secondary antibody
(1:10,000). Molecular weight marker is shown on the left in kD.
This may be due to poor exposure of the HA epitope or inefficient
transfer of the protein from the gel to nitrocellulose. Nevertheless,
coimmunoprecipitation of ARRDC2-2FLAG was observed with HA-
įOR (Figure 5.15). The immunoprecipitate derived from cells
transfected with ARRDC2-2FLAG alone showed a faint anti-FLAG
immunoreactive band at ~55 kD, possibly indicative of background
nonspecific ARRDC2-2FLAG binding to the anti-HA agarose, as has
been seen previously (see Chapter 4). However, a stronger
ARRDC2-2FLAG band was observed for immunoprecipitates obtained
from lysates in which HA-įOR was coexpressed with ARRDC2-2FLAG,
suggesting that ARRDC2 may interact with įOR. This interaction
appeared to be agonist-independent, since įOR stimulation (1 µM
DADLE, 10 min or 1 h) had no detectable effect upon the level of
ARRDC2-2FLAG coimmunoprecipitation with HA-įOR. This result is
preliminary both in the sense that the experiment itself is subject to
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some caveats  the relatively high level of background nonspecific
binding of ARRDC2-2FLAG to the HA agarose and that no effect of
agonist stimulation was detected  and that it is the only approach
that was used to support an interaction. Subsequent experiments
would look to strengthen the tentative claims made here by
providing alternative lines of evidence, for example
coimmunoprecipitation in the alternative orientation (pull-down of
ARRDC2 and detection of įOR) or biophysical detection using
techniques such as BRET or BiFC.
5.2.3 Oligomerisation of arrestin family proteins
5.2.3.1 ARRDC coimmunoprecipitates with itself and with ǃ-
arrestins
To assess whether ARRDC2 may form a complex with itself and with
ǃ-arrestins, HA- or FLAG-tagged ARRDC2 and/or ǃ-arrestin1/2 were
transiently expressed in U2OS cells, followed by anti-HA
immunoprecipitation and Western blotting. As has been reported
elsewhere (Xu et al., 2008), homo-oligomerisation of ǃ-arrestin2
was observed, as detected by the coimmunoprecipitation of FLAG-ǃ-
arrestin2 with ǃ-arrestin2-HA (Figure 5.16A). Interestingly, homo-
oligomerisation of ARRDC2 was also detected by
coimmunoprecipitation of ARRDC2-2FLAG with ARRDC2-HA (despite
weak detection of ARRDC2-HA expression in immunoprecipitates 
note that immunoprecipitation was performed using anti-HA agarose;
Figure 5.16A,B). Furthermore, the coimmunoprecipitation of
ARRDC2-2FLAG with ǃ-arrestin1-HA (despite poor ǃ-arrestin1-HA
detection in immunoprecipitates) or ǃ-arrestin2-HA suggested that
ARRDC2 may form hetero-oligomers with ǃ-arrestins (Figure
5.16A,B). In the case of ARRDC2-2FLAG coimmunoprecipitation with
ǃ-arrestin2-HA, the effect of stimulation of endogenous ǃ2AR
(isoprenaline 10 µM, 10 min) on the interaction was assessed.
However, isoprenaline stimulation had no detectable effect on the
ARRDC2-ǃ-arrestin2 association (Figure 5.16B).
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5.2.3.2 ARRDC2 interacts with ǃ-arrestins in living cells
The relevance of potential ARRDC2-ǃ-arrestin interactions in intact
cells was tested by the coexpression of various ARRDC2 and ǃ-
arrestin fusion proteins in U2OS cells, followed by confocal imaging.
When expressed alone, ǃ-arrestin1-YFP or ǃ-arrestin2-YFP were
diffusely localised throughout the cytoplasm, in addition to a degree
of nuclear targeting of ǃ-arrestin1-YFP (Figure 5.17A,B), in
agreement with the known targeting of exogenous ǃ-arrestin
proteins (Goodman et al., 1996a; Hoeppner et al., 2012). However,
upon coexpression of ARRDC2-mCherry, ǃ-arrestin1-YFP became
localised to more punctate, vesicular structures that colocalised with
ARRDC2-mCherry (the effect was seen to varying degrees;
representative images are shown in Figure 5.17B). In contrast, no
effect of ARRDC2-mCherry overexpression upon ǃ-arrestin2-YFP
distribution was detected (Figure 5.17B). However, the ability of
ARRDC2 to interact with ǃ-arrestin2 was also assessed using BiFC
(described in section 2.4.7). When expressed alone, ǃ-arrestin2
fused with either N- or C-terminal YFP fragments (vYn-ǃ-arrestin2;
ǃ-arrestin2-vYc) did not exhibit any fluorescence when excited at
488 nm (Figure 5.18A). However, coexpression of vYn-ǃ-arrestin2
and ǃ-arrestin2-vYc resulted in the detection of a BiFC signal, with
diffuse staining throughout the cytoplasm, indicative of homo-
oligomerisation of ǃ-arrestin2 (Figure 5.18B). Similarly, no BiFC
signal was detected upon expression of ARRDC2-vYn alone (Figure
5.18A), but BiFC was detected upon coexpression with ǃ-arrestin2-
vYc (Figure 5.18C). The ARRDC2-ǃ-arrestin2 BiFC signal was
present in a punctate, vesicular pattern throughout the cytoplasm,
as well as possibly some plasma membrane staining. Collectively,
these data indicate that ARRDC2 can interact with ǃ-arrestins in
living cells, and suggest that these interactions may influence ǃ-
arrestin subcellular targeting.
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Figure 5.16 ARRDC2 coimmunoprecipitates with itself and with ǃ-
arrestins
U2OS cells were transiently transfected with plasmids expressing the
indicated protein constructs. In (B), cells were treated 24 h later
with/without isoprenaline as indicated prior to cell lysis. Cell lysates (2.5%
input) and immunoprecipitates (IP) obtained by incubation with anti-HA
agarose were separated by 12.5% SDS-PAGE and analysed by Western
blotting using anti-HA or anti-FLAG antibody (both at 1:5000 dilution), as
indicated, detected using IRDye 800CW anti-rabbit secondary antibody
(1:10,000). In (A), ǃ-arrestin2-HA was expressed at a much higher level
than ARRDC2-HA; hence, in order to visualise ARRDC2-HA the exposure
used saturated (blue) the ǃ-arrestin2-HA bands. Molecular weight markers
are shown on the left in kD.
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Figure 5.17 ARRDC2 may influence ǃ-arrestin1 subcellular
distribution
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ǃ-arrestin1/2-YFP alone (A) or in combination with
ARRDC2-mCherry (B), as indicated. In merged images, ARRDC2 is shown
in red; the indicated ǃ-arrestin is in green. Colocalisation of ǃ-arrestin1-
YFP/ARRDC2-mCherry is highlighted with arrows. Images are
representative of two independent experiments. Scale bar = 10 µm.
187
vYn-ǃ-arrestin2 / ǃ-arrestin2-vYc
ARRDC2-vYn / ǃ-arrestin2-vYc
ǃ-arrestin2-vYc vYn-ǃ-arrestin2 ARRDC2-vYnA
B
C
Figure 5.18 Detection of BiFC between ARRDC2 and ǃ-arrestin2
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ǃ-arrestin2-vYc, vYn-ǃ-arrestin2 or ARRDC2-vYn alone
(A) or in combination (B,C), as indicated. vYn and vYc represent N- and
C-terminal fragments of venus YFP, which alone are not fluorescent. When
brought into proximity by their fusion to interacting protein partners
vYn/vYc refold to produce a fluorescent BiFC signal. The presence of cells is
indicated in (A) by insets showing phase images. Scale bar = 10 µm.
5.3 Discussion
The aim of the current chapter was to investigate a potential role for
ARRDC2 in GPCR regulation. The data presented attest to this role,
showing that ARRDC2 is specifically recruited to GPCRs (indicated by
quantitative colocalisation), can associate with GPCRs and may
regulate them via the ability to oligomerise with ǃ-arrestins.
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5.3.1 ARRDC2: a novel GPCR regulator?
Confocal microscopy revealed that fluorescent protein-tagged
ARRDC2 colocalises with agonist-stimulated, internalised GPCRs: the
prototypic recycling receptor, ǃ2AR and the lysosome-targeted įOR.
In each case, colocalisation involved a compartmental redistribution
of ARRDC2 to early/recycling endosomes. This suggests that
ARRDC2 colocalisation with each GPCR represents a specific event.
It could be that ARRDC2 is recruited in a retrograde fashion,
redistributing from its native compartments (late
endosomes/lysosomes) to compartments containing internalised
ǃ2AR or įOR (early/recycling endosomes). Alternatively, given the
dynamic nature of ARRDC2 localisation within the endocytic system
(Chapter 3), it is possible that ARRDC2 associates with GPCRs at an
earlier stage (plasma membrane or early endosomes, for example),
an association that prevents ARRDC2 from reaching the lysosome,
resulting in the overall redistribution observed. Detailed
microscopic experiments would be required to discriminate these
possibilities, for example using ARRDC2 fused with a
photoactivatable fluorescent protein in order to follow ARRDC2
transport from and to specific compartments in living cells, and TIRF
microscopy to detect potential plasma membrane recruitment
events. A potential subtle effect of ARRDC2 overexpression upon
ǃ2AR intracellular trafficking was observed. ARRDC2 overexpression
also altered įOR trafficking, and an association between ARRDC2
and įOR was detected by coimmunoprecipitation.
ARRDC2 overexpression did not appear to have any effect upon
ǃ2AR signalling, indicated by measuring isoprenaline-stimulated
cAMP production. Due to the constraints of the current project, only
a simple concentration response approach was employed. It is worth
noting that the information gathered from this is limited; it only
indicates the effect of ARRDC2 overexpression on the total cAMP
produced over 5 h. It may be that ARRDC2 has a more time-
dependent effect, for example downregulating ǃ2AR signalling via
increased ǃ2AR degradation upon prolonged receptor activation. This
effect would not be detected using the method employed here;
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more detailed time-courses of receptor signalling, potentially
including a pre-stimulatory period (e.g. 24 h pre-incubation with
agonist in the presence/absence of ARRDC2 to detect an effect on
long-term downregulation), would be required to measure such an
effect. Moreover, the approach used is limited by the fact that only
one signalling output (cAMP production) was measured. It is
possible that ARRDC2 has a direct impact on particular aspects of
ǃ2AR signal transduction, for example the ERK/MAPK cascade, which
has been previously noted to have an arrestin (ǃ-arrestin)
component (section 1.3.1). Thus, it would also be informative to
measure ERK activation (for example by immunoblotting for
phosphorylated ERK) promoted by ǃ2AR in the presence or absence
of overexpressed ARRDC2.
A low level of constitutive ǃ2AR internalisation was detected, and
this was highly colocalised with transferrin-labelled compartments,
as expected from the known rapid recycling itinerary for ǃ2AR. Over
more prolonged periods of agonist stimulation ǃ2AR is gradually
delivered to the lysosomes for degradation (Shenoy et al., 2008).
This gradual ǃ2AR lysosomal delivery was detected here as a
sequential moderate decrease in ǃ2AR colocalisation with transferrin
as the duration of agonist stimulation increased from 1 h to 8 h
(although note that a concomitant increase in colocalisation, for
example, with lysosomal markers, was not tested). ARRDC2
colocalisation with transferrin was monitored over the same time
points and, following the initial increase from unstimulated to 1 h
agonist treatment (indicative of ARRDC2 recruitment), a decrease in
transferrin colocalisation was also observed at the 8 h time point,
potentially reflecting the delivery of ǃ2AR-associated ARRDC2 to
lysosomes. Despite these observations no prominent, sustained
effect of ARRDC2 overexpression on ǃ2AR trafficking was detected,
although ARRDC2 overexpression did appear to delay the observed
agonist-induced decrease in ssǃ2AR colocalisation with transferrin.
The lack of a marked effect of ARRDC2 overexpression on ǃ2AR
trafficking may be due to insufficient sensitivity of the system used
 quantification of colocalisation with transferrin, a broad marker for
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the recycling pathway  to detect potential subtle changes in
receptor trafficking. Moreover, the approach of overexpressing wild-
type ARRDC2 may also not be the most powerful method possible to
detect a role for the protein in question. Indeed, in a recent report
on the role of ARRDC3 in ǃ2AR regulation, overexpression of wild-
type ARRDC3 had no detectable effect in the assay used
(immunoblot analysis of ǃ2AR degradation); an effect was only
detected when a PPxY mutant ARRDC3 was overexpressed, or
ARRDC3 expression was depleted using siRNA (Nabhan et al., 2010).
Thus, more sensitive experiments (e.g. detection of ǃ2AR
degradation and ubiquitination) and alternative lines of evidence
(e.g. ARRDC2 siRNA) would be required to convincingly assess the
potential role of ARRDC2 in ǃ2AR trafficking. Similarly, the use of
siRNA may yet reveal a role for ARRDC2 in ǃ2AR signal transduction,
which was not detected using ARRDC2 wild-type overexpression.
These experiments were not performed in the current project due to
limitations on time and approaches available; assessing ǃ2AR
degradation/ubiquitination would likely require ǃ2AR
immunoprecipitation which, as described below, proved difficult;
ARRDC2 siRNA would require the detection of endogenous ARRDC2
expression, which proved unsuccessful in the cell lines used here
(U2OS, HEK-293).
įOR also exhibited a low level of constitutive internalisation in the
system used. This was largely distinct from transferrin
compartments, which may reflect the efficient targeting of įOR to
the degradative pathway, although colocalisation with lysosomal
markers was not tested. Agonist-stimulated internalisation resulted
in a moderate increase in colocalisation of internalised įOR with
transferrin. Despite its presumed efficient targeting to lysosomes,
įOR endocytosis and early trafficking is via the same transferrin-
positive pathway as ǃ2AR (Tsao et al., 2000). Hence, it is not
necessarily surprising that partial colocalisation with transferrin-
positive compartments is detected after 1 h agonist stimulation.
Overexpression of wild-type ARRDC2 increased the degree of
agonist-stimulated įOR colocalisation with transferrin. The
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implications of this result are unclear: it may reflect a positive role
for ARRDC2 in the endocytosis or early trafficking stages of įOR.
However, it would be important to further dissect these possibilities
by performing additional experiments, as has been described for
ǃ2AR above.
Coimmunoprecipitation indicated that ARRDC2 associates with
įOR, although this does not confirm a direct interaction (ARRDC2
may associate indirectly via oligomerisation with other arrestins; see
below). ARRDC2 association with įOR was detected in the absence
of agonist stimulation, and stimulation for 10 min or 1 h did not
alter the level of coimmunoprecipitation, suggesting that ARRDC2
may constitutively bind įOR. This is in contrast to the reported
agonist-dependent interaction of ARRDC3 with ǃ2AR (Nabhan et al.,
2010), although in a subsequent report significant interactions with
ǃ2AR were detected for ARRDC1, ARRDC3 and ARRDC4 in the
absence of agonist stimulation (Patwari et al., 2011). Constitutive
activity of several GPCRs has been reported, producing low levels of
agonist-independent endocytosis and recycling of receptors that
may be dependent upon constitutive association with ǃ-arrestins
(Halls et al., 2010; Pampillo et al., 2009; Pediani et al., 2005;
Terrillon et al., 2004a; Walwyn et al., 2007). These include the mu-
opioid receptor (µOR) (Walwyn et al., 2007), which is known to
heterodimerise with įOR (Snook et al., 2006). Thus, it is possible
that ARRDC2 may constitutively associate with GPCRs, such as įOR,
and that these associations are important for agonist-independent
receptor regulation. This would imply that ARRDC2 may be recruited
to GPCRs at the plasma membrane. Nevertheless, the agonist-
stimulated recruitment of ARRDC2 to įOR (potentially in
endosomes), as detected by compartmental ARRDC2 redistribution,
suggests that there may yet be an activation-dependent component
to the ARRDC2 association with įOR, as is generally thought to be
the case for ǃ-arrestin-GPCR interactions.
This result adds to the small amount of data that suggest Į-
arrestins are capable of binding GPCRs. The coimmunoprecipitation
of overexpressed proteins that has been used thus far in these
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studies has the potential to enhance the detection of such
interactions. Agonist dependency (as for the ARRDC3 and ǃ2AR
association) would be one indication of the potential physiological
relevance of the interaction. However, it is important, especially in
the absence of an agonist-dependent association, to further
characterise ARRDC associations with GPCRs, for example using GST
pull-downs to demonstrate direct binding, and through the
coimmunoprecipitation of endogenous proteins to confirm that the
results obtained from overexpressed systems are relevant to the
native proteins.
The potential association between ARRDC2 and ǃ2AR was also
investigated using coimmunoprecipitation, with the known
association between ǃ2AR and ǃ-arrestin2 as a positive control.
However, this approach failed to detect a clear association with
ARRDC2. It also largely did not detect an association with ǃ-
arrestin2, suggesting that methodological limitations may have
hampered the detection of a potential ARRDC2 interaction, rather
than the necessary lack of an interaction. The only experiment that
appeared to detect an interaction between ǃ-arrestin2 and ǃ2AR was
that using U2OS cells stably expressing FLAG-ǃ2AR-sfGFP (Figure
5.10A). Even in this case pull-down with ǃ-arrestin2-HA was not
definitive and hampered by presumed background binding of FLAG-
ǃ2AR-sfGFP to the HA agarose and the presence of high molecular
weight unidentified band(s). Nonetheless, an interaction with ǃ-
arrestin2 was detected upon agonist stimulation (10 µM isoprenaline,
5 min), and a potential interaction was detectable with ARRDC2
after 1 h agonist stimulation. However, the clarity of this result was
poor, and it is notable that no comparison was able to be made
between the apparent FLAG-ǃ2AR-sfGFP present in
immunoprecipitates and the amount present in the initial lysates,
since anti-FLAG or anti-GFP immunoblotting of whole cell lysates
failed to detect FLAG-ǃ2AR-sfGFP (not shown). The inability to detect
ǃ2AR and the lack of clear positive data may stem from the fact that
ǃ2AR appears to form insoluble aggregates that are excluded from
entering gels (see Figure 5.10C, middle panel). This issue was
193
addressed through the use of a variety of solubilisation conditions
(using sample buffer ± ǃ-mercaptoethanol; incubating samples at
room temperature, 37 ºC or 80 ºC for 3  30 min prior to gel loading)
but none of the conditions used improved the ability of ǃ2AR to enter
gels. Thus, from these data it is unclear whether ARRDC2 is capable
of interacting with ǃ2AR. To answer this question it will be necessary
to further optimise conditions for ǃ2AR coimmunoprecipitations, for
example using defined cell types and conditions that are known to
allow the immunodetection and immunoprecipitation of ǃ2AR (Xiao
et al., 2011).
The observed recruitment of ARRDC2 to internalised ǃ2AR or įOR
is similar to that seen for ARRDC3 recruitment to ǃ2AR (Nabhan et
al., 2010). It is worth considering whether ARRDC2 and ARRDC3
may act similarly, since they are the two closest mammalian Į-
arrestin homologues (protein sequence similarity = 69%). ARRDC3
was reported as targeting largely to the plasma membrane in
unstimulated cells (in contrast to the ARRDC3 distribution seen here;
see Chapter 3). Upon agonist stimulation of ǃ2AR, ARRDC3 became
localised to intracellular puncta that colocalised with internalised
ǃ2AR, as was seen here for ARRDC2. However, in both cases, the
spatiotemporal characteristics of ARRDC recruitment to GPCR are
unknown. Since ARRDC3 localised to the plasma membrane
irrespective of agonist stimulation, it is unclear whether ARRDC3
recruitment to ǃ2AR occurred at the plasma membrane or in
internalised vesicular compartments. The time-scale used for
agonist-dependent detection of ARRDC3 association with ǃ2AR by
coimmunoprecipitation (20 min) was too long to discriminate these
possibilities (Nabhan et al., 2010). Similarly, ARRDC2 partially
localised to the plasma membrane irrespective of GPCR stimulation,
and enhanced ARRDC2 plasma membrane targeting upon agonist
stimulation (e.g. 5 min ǃ2AR stimulation with isoprenaline) was
unable to be detected using confocal microscopy (data not shown).
Thus, whether the recruitment of ARRDC2 to GPCRs occurs at the
plasma membrane or in intracellular vesicles remains unknown.
Experiments designed to more sensitively define the spatial (e.g.
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TIRF at the plasma membrane) and temporal (e.g. agonist-
stimulated BRET between receptor and ARRDC2) parameters
involved would be required to answer this question.
A major function of the reported ARRDC3 interaction with ǃ2AR
was to recruit NEDD4 to ubiquitinate the receptor, targeting it for
lysosomal degradation (Nabhan et al., 2010). ARRDC2 also acts as a
NEDD4 family ligase adaptor (Chapter 4; includes ARRDC2 ability to
associate with NEDD4, the ligase responsible for ǃ2AR
ubiquitination); therefore, it is hypothesised that ARRDC2 could
similarly recruit ligase(s) to this and/or other GPCRs. This could be
tested by employing the PPxY mutant ARRDC2 (ARRDC2ǻǻ) in place
of wild-type ARRDC2 in the experiments performed here, for
example examining its effect upon receptor trafficking and signalling.
However, there is a difference between the role reported for
ARRDC3 and that observed here for ARRDC2. Whilst ARRDC3
promotes lysosomal targeting of ǃ2AR, the data presented here
suggest that ARRDC2 overexpression inhibits ǃ2AR or įOR lysosomal
trafficking. Thus, it is possible that ARRDC2 differentially affects
receptor trafficking, potentially by slowing the receptor at a rate
limiting step in lysosomal trafficking (for example during the ESCRT-
mediated process) and/or by stimulating retrograde sorting or
retrieval from degradation, in contrast to ARRDC3.
5.3.2 ARRDC2: extending the scope of arrestin family
oligomerisation?
The ability of ARRDC2 to interact with itself and with ǃ-arrestin1/2
was demonstrated using coimmunoprecipitation. Moreover,
microscopy indicated that ARRDC2 overexpression can drive ǃ-
arrestin1 from a diffuse pattern to intracellular puncta that
colocalise with ARRDC2, and a BiFC interaction between ARRDC2
and ǃ-arrestin2 was detected, also with a punctate intracellular
pattern. Thus, associations between ARRDC2 and ǃ-arrestins may
influence their function in intact cells.
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The propensity of ǃ-arrestins to homo- and hetero-oligomerise
has been documented, although the function of complexes remains
unclear (see section 5.1). The ability of Į-arrestins to oligomerise is
less well known; the only known report to date is of ARRDC1 homo-
oligomerisation, detected by coimmunoprecipitation of
overexpressed proteins (Nabhan et al., 2012). Data presented here
show that this ability extends to ARRDC2, which can homo- and
hetero-oligomerise with arrestin family members. The data
supporting this ability include the detection of a BiFC signal between
ARRDC2 and ǃ-arrestin2. BiFC has the limitation that it produces an
irreversible association, which may interfere with the function of
protein partners whose interaction would otherwise be transient
(Kerppola, 2008; Rose et al., 2010). Nevertheless, an advantage is
that BiFC specifically identifies the protein-protein complex in
question. In the case of the ARRDC2-ǃ-arrestin2 association the
BiFC signal was localised to intracellular puncta. Although in the
standard colocalisation experiments (ARRDC2 and ǃ-arrestin2
tagged with full-length fluorescent proteins) ARRDC2 did not appear
to cause ǃ-arrestin2 redistribution (this was only observed for ǃ-
arrestin1), ARRDC2 may still interact with ǃ-arrestin2 in similar
intracellular compartments. This conclusion is aided by the use of
BiFC which specifically identified ARRDC2-ǃ-arrestin2 complexes, as
opposed to simple coexpression of fluorescent protein-tagged
proteins, where differences in the relative expression levels of the
two partners may have precluded observation of any redistribution.
Future experiments would ideally investigate the mechanism of
ARRDC2 interaction with ǃ-arrestins, as well as the role that these
interactions play. Several amino acid residues in the polar core of ǃ-
arrestin2 have been shown to contribute to its self-association,
including Lys285 and Arg286; mutation of these residues substantially
reduced the detection of FRET between ǃ-arrestin2 pairs and
produced weaker coimmunoprecipitations (Xu et al., 2008).
Similarly, IP6 has been found to promote the self-association of ǃ-
arrestins (Hanson et al., 2007), and binding sites for IP6 on ǃ-
arrestin2 have been mapped (these include residues Lys233, Arg237
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and Lys251) (Gaidarov et al., 1999). It would be informative to test
whether mutation of the residues mentioned have an effect upon ǃ-
arrestin2 association with ARRDC2, which would suggest that a
similar mechanism of interaction may be involved. Although some of
the key polar core residues are conserved in ARRDC proteins, the
residues mentioned (Lys285, Arg286, Lys233, Arg237 and Lys251 in ǃ-
arrestin2) are not (Figure 1.2). Hence, it is not necessarily possible
to produce targeted mutations in ARRDC2 that correspond to those
in ǃ-arrestins and analyse their effect on oligomerisation; it is
suggested that first assessing the impact of more global ARRDC2
alterations (N- or C-terminal truncations, for example) would be an
approach to investigating the ARRDC2 regions involved.
An approach to probe the potential role of arrestin hetero-
oligomers could be to assess the ability of GPCRs to recruit ARRDC2
(using colocalisation and immunoprecipitation) in the absence of ǃ-
arrestins. Knockout mouse embryonic fibroblasts (MEFs) lacking ǃ-
arrestins (Vines et al., 2003) would be an ideal system within which
to perform these experiments. Conversely, it would be highly
desirable to demonstrate that ARRDCs such as ARRDC2 are
important for ǃ-arrestin functions. For example, are canonical ǃ-
arrestin functions such as GPCR desensitisation and internalisation
influenced by ARRDCs? Perhaps most likely (see section 6.5), is the
purported ability of ǃ-arrestins to scaffold NEDD4 family ubiquitin
ligases (Bhandari et al., 2007; Shenoy et al., 2008) actually
provided by their dimerisation partners, the ARRDCs? These
questions could be answered by manipulating ARRDCs (e.g. by
siRNA knockdown or overexpression of mutants) and examining the
effect upon the ǃ-arrestin functions described.
In conclusion, the identification of ARRDC2 as a NEDD4 family
ubiquitin ligase adaptor within the endocytic system was described
in Chapters 3 and 4. The inevitable next question was what is the
relevance of such observations; that is, what cargo(s) might
ARRDC2 regulate in its role as ligase adaptor? Given the data
presented here, it seems likely that ARRDC2 is involved in GPCR
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regulation in a similar vein to other newly identified Į-arrestin
proteins, in particular ARRDC3. This is supported by the specific
recruitment of ARRDC2 to GPCRs under stimulated conditions,
potentially involving a physical association, the impact of ARRDC2
upon the intracellular trafficking itinerary of these GPCRs and the
ability of ARRDC2 to associate with and potentially modulate the
function of the canonical GPCR regulators, the ǃ-arrestins.
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6 Conclusions and perspectives
6.1 Overview
The number of mammalian proteins harbouring a conserved arrestin
ǃ-sandwich structure has been extended beyond the classical visual
and ǃ-arrestins. Visual/ǃ-arrestin homologues have been identified
that represent earlier, ancestral proteins from which ǃ-arrestins
evolved, and have hence been designated as Į-arrestins (Alvarez,
2008). Much recent investigation has attempted to determine
whether the function of ǃ-arrestins as flexible adaptors  in
particular for the signalling and trafficking of GPCRs  is conserved
in Į-arrestins. Work on Į-arrestin orthologues in lower eukaryotes
clearly indicates conserved roles for the wider arrestin family as
adaptors for intracellular cargo trafficking. The emerging pattern is
that Į-arrestins scaffold WW domain-containing E3 ubiquitin ligases
for their recruitment to plasma membrane cargo, in order to
mediate cargo ubiquitination and endocytosis/downregulation
(Figure 1.4). In one case in fungi, the Į-arrestin cargo was a seven-
transmembrane domain receptor (Herranz et al., 2005). However,
the majority of specific cargoes regulated by yeast/fungal Į-
arrestins are transporters that are structurally unrelated to GPCRs;
indeed, endocytic downregulation of the sole yeast seven-
transmembrane domain receptor, Ste2, was unaffected by genetic
knockout of the Į-arrestin ART1, although this may be explained by
cargo selectivity of the specific Į-arrestin that was targeted (Lin et
al., 2008).
Thus, the question has remained: do mammalian Į-arrestins
interact with and regulate GPCRs, or is this a newly evolved function
unique to ǃ-arrestins? Recent data suggest that the ability to
scaffold ubiquitin ligases is retained by most mammalian Į-arrestins,
and this appears to enable them to direct diverse vesicular
trafficking processes. There are a few emerging reports that human
Į-arrestins can bind GPCRs, and hints that the ability of Į-arrestins
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to act as adaptors may impinge upon GPCR signalling and trafficking
(section 1.4.3). Within this context, the current study supports a
role for human Į-arrestins (specifically ARRDCs) as endocytic
ubiquitin ligase adaptors. Specifically, ARRDC2 is reported as an
endo-lysosomal protein targeted predominantly to the plasma
membrane and late endosomes/lysosomes. In agreement with data
elsewhere (Rauch et al., 2011), ARRDC2 interactions with several
members of the NEDD4 family of WW domain-containing E3
ubiquitin ligases were detected. For the first time, the mechanism of
these interactions was shown to critically involve ARRDC2 C-
terminal PPxY motifs, in agreement with that described for multiple
other Į-arrestin-ligase interactions. Moreover, ARRDC2
overexpression altered the subcellular targeting of several NEDD4
family ligases, suggesting that interaction with ARRDC2 may serve
to determine the ligase subcellular site of action. The question of
ARRDC interaction with GPCRs was also addressed: for the first time,
a putative interaction of ARRDC2 with a GPCR, the įOR, was
detected using coimmunoprecipitation. ARRDC2 was specifically
recruited to endosomes containing agonist-stimulated, internalised
įOR and analysis of įOR trafficking using quantification of confocal
images suggested that ARRDC2 may influence įOR intracellular
trafficking. ARRDC2 was also specifically recruited to another
prototypical GPCR, the ǃ2AR, and a subtle effect of ARRDC2
overexpression upon ǃ2AR trafficking was detected, although no
effect upon ǃ2AR signalling was observed. Additionally, indirect
evidence for the involvement of ARRDC2 in GPCR processes came
from the observed ability of ARRDC2 to hetero-oligomerise with
various arrestin family members. Coimmunoprecipitation,
coexpression studies and BiFC collectively indicated that ARRDC2
can interact with itself and with ǃ-arrestins, and that these
interactions may influence the subcellular targeting of the
interaction partners in question.
In summary, the current study has uncovered significant novel
information regarding an Į-arrestin that has been largely unstudied.
This includes the identification of ARRDC2 as a wide-spectrum
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NEDD4 family ubiquitin ligase adaptor and the clarification of the
mechanism (PPxY motif) involved, and the novel demonstration that
ARRDC2 can associate with and influence the trafficking of GPCRs.
The next section will consider the approaches used to garner such
information, commenting on their advantages and limitations, and
will highlight possible alternatives.
6.2 Experimental approach: recombinant
versus native systems
The general approach used here was of exogenous expression of
proteins fused with tags (epitopes or fluorescent proteins) in
cultured cell lines. A distinct advantage of this is that direct
comparisons can be made between protein variants  such as wild-
type versus mutant ARRDC2  overexpressed in the same system.
Moreover, conclusions based on such experiments are generally
borne out in the native system, as has been the case, for example,
in the emerging picture of the ǃ-arrestins over the past twenty
years or so. Nonetheless, the recombinant approach does have the
limitation that proteins are overexpressed, giving levels that are
higher than the endogenous proteins with the possibility for effects
on cellular functions governed by the protein in question. For
example, overexpression of ARRDC2, an apparent endocytic protein,
may cause enhancement of endocytic/vesicular functions, perhaps
driving the protein to the predominantly lysosomal distribution
observed. This is not to say that this observation is false, but rather
that ideally it must but controlled for, as has been attempted here in
the complementary analysis of endogenous ARRDC2 targeting in
primary cells. The endogenous approach also has significant
limitations, though, being more technically challenging; it requires
large numbers of primary cells that express sufficient levels of the
proteins in question (which, for ARRDC2, were not available)
combined with the ability to perturb or detect such proteins (for
example using siRNA and high affinity antibodies for endogenous
coimmunoprecipitation, again which were not readily available).
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6.3 How is ARRDC2 subcellular distribution
established?
The data described here present human ARRDCs as proteins that
are targeted to membrane-bound compartments. Co-labelling with
compartment-specific markers indicated that ARRDC2 is dynamically
targeted to the endocytic system, predominantly to late
endosomes/lysosomes, as well as the plasma membrane.
A question that arises is the mechanism by which ARRDC2 (and
other ARRDCs) is targeted to membrane compartments, and
conversely why this capability is apparently not conserved in the ǃ-
arrestins. With respect to ARRDC2, two possibilities (that are not
mutually exclusive) are that (i) ARRDC2 interacts directly with
membranes, for example binding compartment-enriched membrane
phospholipids, or (ii) ARRDC2 is indirectly targeted to membranes
via interaction with a membrane-binding partner, as has been
reported for the endosomal targeting of Vps26, which is targeted to
endosomes/TGN via interaction with Vps35 (Collins et al., 2008).
Recently, the reported plasma membrane targeting of ARRDC1 has
been shown to be dependent upon several residues in its predicted
arrestin domain (Phe88, Gly180, Asn191), the mutation of which
reduced or abolished ARRDC1 plasma membrane localisation,
leaving the protein diffusely distributed throughout the cytosol
(Nabhan et al., 2012). Interestingly, all three residues are
conserved throughout all human ARRDCs and ǃ-arrestins (see
Figure 1.2), indicating their importance, possibly in contributing to
the ǃ-sandwich fold. This would suggest that the overall structure of
the ARRDC is required for membrane targeting, hinting that
targeting may involve ARRDC interaction with membrane localised
partners, rather than direct targeting via intrinsic ARRDC lipid-
binding elements (which, based on sequence predictions, are absent
from ARRDCs). It would be informative to test whether mutation of
the equivalent residues in ARRDC2 similarly affects its membrane
targeting.
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The fact that ǃ-arrestins contain these residues and are yet
generally considered to be diffusely localised in the cytosol (in the
absence of GPCR stimulation) makes the interpretation of these
observations unclear. It is possible that the residues contribute to as
yet unidentified contacts (for example, intramolecular hydrophobic
interactions) in Į-arrestins that are not present in ǃ-arrestins,
thereby defining a distinct structure for the Į-arrestins that
promotes membrane targeting (directly or indirectly, as described
above). The prevailing dogma that ǃ-arrestins are diffusely localised
comes largely from overexpression data. However, it has been
reported that endogenous ǃ-arrestins may target to intracellular
punctate structures, possibly indicative of the ability of the native
proteins to associate with membranes (Shankar et al., 2010). It
would be interesting to explore further whether endogenous Į-
arrestin distribution is consistent with the reported exogenous data
available (see section 3.3.3) or if, similar to ǃ-arrestins,
overexpression may drive them to an alternative pattern.
The nature of membrane targeting (direct versus indirect) could
also be addressed by investigating whether Į-arrestins display
affinity for lipids (for example, using a protein-lipid overlay assay
(Dowler et al., 2002))  although, as commented above, they lack
any predicted lipid-interacting motifs  and through the systematic
identification of potential membrane-associated binding partners
(for example, using mass spectrometry analysis of interaction
partners). A more targeted approach to identifying binding partners
could be to assess whether Į-arrestins interact specifically with SH3
domains. ARRDC2/3/4 all contain a potential class I SH3-binding
motif, (R/K)XPPXXP, towards the centre of the arrestin C-domain
that may enable them to interact with SH3 domains (Alvarez, 2008),
although this possibility has not been investigated. SH3 domains are
common protein-protein interaction modules present in plasma
membrane proteins (e.g. proteins involved in clathrin-mediated
endocytosis such as endophilin (Simpson et al., 1999)) and
endosomal proteins (e.g. the ESCRT-0 component, STAM (Takeshita
et al., 1996)), and protein lysosomal targeting via a proline-rich
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motif interaction with SH3 domain-containing proteins has been
reported elsewhere (Qian et al., 2006). Thus, the ability to interact
with SH3 domains could represent a potential mechanism for
ARRDC2/3/4 membrane targeting. However, as commented in
Chapter 4, for ARRDC4, membrane targeting was shown to be
abolished by deletion of the C-terminal 68 amino acids (residues
350-418) (Vina-Vilaseca et al., 2011). These residues do not include
the putative ARRDC4 SH3-binding motif (spanning residues 273-
279); hence, in the case of ARRDC4, if it does indeed interact with
SH3 domains via this motif, it appears that this may not determine
its membrane targeting.
6.4 ARRDC2 as a NEDD4 family ubiquitin ligase
adaptor
The Į-arrestins generally contain C-terminal PPxY motifs that in
many cases have been shown to enable their interaction with
NEDD4 family ubiquitin ligases, which may serve to recruit the
ligase for ubiquitination of the Į-arrestin itself and/or associated
cargo proteins. The human ARRDCs appear to fit with this paradigm,
and here it was found that ARRDC2 too is capable of interacting with
several NEDD4 ligase family members, and that this interaction may
be important to the function of the ligases by determining their site
of action.
A question that arises from these studies is whether the observed
interaction of ARRDC2 with several NEDD4 family ligases is of
physiological relevance. The system used to test for interactions 
coimmunoprecipitation of overexpressed proteins  has the potential
to amplify the detection of associations that are actually low affinity.
Hence, although the data presented clearly argue for the ability of
ARRDC2 to interact with NEDD4 family ligases, whether all the
interactions detected occur in native cells remains unclear. However,
there are reasons to believe this may be the case. Theoretically, the
possibility for multiple NEDD4 ligase interactions is plausible.
Despite the differences in function of specific NEDD4 ligases (section
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4.1) they exhibit significant sequence similarity, especially within
the WW domains that are thought to mediate the ARRDC2
interaction. For example, related proteins WWP1 and WWP2 both
contain four WW domains. WWP1 and WWP2 exhibit 72% overall
sequence similarity, with 88% similarity across the four WW
domains. Both ligases were able to coimmunoprecipitate ARRDC2.
WWP1 and WWP2 may perform redundant roles, with both ligases
implicated in carcinogenesis, possibly via converging effects on TGFǃ
signalling (Komuro et al., 2004; Soond et al., 2011). Therefore, it is
conceivable that ARRDC2 could interact with both WWP1 and WWP2
in the native context, and could thereby mediate or influence some
of their overlapping functions.
Moreover, there are several reports of other PPxY motif-containing
proteins that bind several different NEDD4 ligases. For example,
ARRDC1 and ARRDC3 (as well as ARRDC2) were shown to be
capable of interacting with WWP1, WWP2, AIP4 and NEDD4 (Nabhan
et al., 2010; Rauch et al., 2011). Similarly, the NEDD4 family-
interacting proteins (NDFIP1 and NDFIP2) contain PPxY motifs and
interact with multiple NEDD4 family members (Harvey et al., 2002;
Shearwin-Whyatt et al., 2004), which in this case promotes the
NEDD4 ligase catalytic activity (Mund et al., 2009). As mentioned in
section 4.1, the Smad proteins bind SMURF1 and SMURF2, and they
have also been shown to bind WWP1 and WWP2 (Komuro et al.,
2004; Soond et al., 2011). Collectively, these observations indirectly
support the hypothesis that ARRDC2 may be involved in
physiologically relevant interactions with several NEDD4 family
members, underlining the importance of the approach used here to
scan for coimmunoprecipitation with all nine family members.
Additional experiments would be required to directly test this
hypothesis. Most importantly, it would be necessary to determine
whether endogenous ARRDC2 and NEDD4 ligases interact, for
example by coimmunoprecipitation with specific antibodies targeted
against endogenous proteins. Subsequent experiments could then
probe the impact of such interactions upon molecular physiological
events.
205
Biochemical experiments revealed that ARRDC2 may be subject to
ubiquitination; immunoblotting suggested that ARRDC2 may exist
predominantly in monoubiquitinated form, although further
experiments would be required to convincingly demonstrate this
(section 4.3.2), and coimmunoprecipitation confirmed that ARRDC2
can be mono- and multi-/poly-ubiquitinated. The ligase(s)
responsible for ARRDC2 ubiquitination is unknown. There are hints
that overexpression of some NEDD4 ligases (NEDL1, WWP2) may
enhance ARRDC2 ubiquitination. However, abolishing ARRDC2
interaction with NEDD4 ligases through PPxY motif mutation did not
affect the detection of ARRDC2 ubiquitination, suggesting that other
unidentified ligase(s) may be responsible. There are more powerful
methods available for assessing the potential role of NEDD4 ligases
in ARRDC2 ubiquitination  for example, analysing the effect of
overexpression of catalytically inactive mutant ligases  that would
be required to exclude their role. Although the approach used does
not reveal the proportion of ARRDC2 that is ubiquitinated, it is
notable that constitutive, signal-independent ubiquitination of
ARRDC2 was detected. Another Į-arrestin that appears to exist
predominantly in monoubiquitinated form is the yeast protein ART1.
ART1 is also constitutively ubiquitinated, and this may be required
for ART1 subcellular targeting (in this case to the Golgi) and function
(Lin et al., 2008). In contrast, ubiquitination of ART4 appears to be
largely absent in basal conditions but is stimulated by glucose
signalling (Becuwe et al., 2012), and a fungal Į-arrestin, PalF, is
reported to be ubiquitinated only in response to alkaline pH (Herranz
et al., 2005). Ubiquitination of ǃ-arrestin is also signal-dependent,
thought to occur largely upon agonist stimulation of GPCRs (Mosser
et al., 2008; Shenoy et al., 2003; Shenoy et al., 2001; Shenoy et
al., 2009). Shenoy and colleagues showed that in response to ǃ2AR
stimulation, ǃ-arrestin2 ubiquitination is performed by the RING E3
ligase Mdm2, since the use of Mdm2-null cells or expression of a
dominant-negative Mdm2 abolished ǃ-arrestin2 ubiquitination
(Shenoy et al., 2001). Whether other E3 ligases (for example,
NEDD4 family ligases) are also capable of ubiquitinating ǃ-arrestins,
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such as upon stimulation of alternative GPCRs, has not been
investigated. It would be interesting to test whether ARRDC2
ubiquitination is similarly enhanced upon stimulation of GPCRs and
whether this may be dependent upon Mdm2 and/or NEDD4 family
ligases.
Despite lacking PPxY motifs, ǃ-arrestins have also been reported
to interact with NEDD4 family ligases: ǃ-arrestins recruited NEDD4
or AIP4 for the ubiquitination and downregulation of ǃ2AR or CXCR4,
respectively (Bhandari et al., 2007; Shenoy et al., 2008). The
mechanism of potential ǃ-arrestin-NEDD4 ligase interaction is
unclear; direct binding has only been demonstrated for the
interaction of ǃ-arrestin1 with AIP4 (using GST pull-down of purified
proteins). It remains possible that ǃ-arrestin1/2 interaction with
NEDD4 may be mediated by an intermediate protein. It would be
tempting to suggest that Į-arrestin(s) could represent the direct
NEDD4 interactor(s), and hetero-oligomerisation between Į- and ǃ-
arrestins may explain the ǃ-arrestin-NEDD4 interaction detected.
This suggestion is supported by the ability of ARRDC2 to hetero-
oligomerise with ǃ-arrestin1/2, as reported here, and could be
tested, for example by examining the ability of ARRDC protein
overexpression or knockdown to affect ǃ-arrestin-NEDD4 ligase
interaction. Conversely, if ǃ-arrestins are indeed able to directly
recruit NEDD4 ligases, given the potential for Į-/ǃ-arrestin hetero-
oligomerisation described above, this may actually explain the lack
of effect of ARRDC2 PPxY motif mutation upon its ubiquitination,
since the ǃ-arrestin may still recruit the ligase(s) to the complex.
Although some degree of constitutive association between ǃ-
arrestins and NEDD4/AIP4 has been detected in
coimmunoprecipitations, the interactions have been shown to be
enhanced by GPCR agonist stimulation (Bhandari et al., 2007;
Shenoy et al., 2008). This suggests that binding to GPCRs may
induce a ǃ-arrestin conformation that is preferable to binding
NEDD4 ligases. The same has not been tested for Į-arrestin
interactions with NEDD4 ligases in the majority of cases. In both
lower eukaryotes and humans, constitutive interaction of Į-arrestins
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and NEDD4 ligases has been demonstrated by the
coimmunoprecipitation of overexpressed proteins. In one report, the
constitutive interaction of an Į-arrestin (ART3) and NEDD4 family
ligase (Rsp5) appeared to be enhanced by the presence of aspartic
acid, presumably upon recruitment of ART3 to the aspartic acid
transporter Dip5 (Hatakeyama et al., 2010), suggesting that ART3
interaction with Rsp5 may also be suboptimal in the absence of a
particular signal. However, this has generally not been tested for Į-
arrestin-NEDD4 ligase interactions. As has been mentioned,
coimmunoprecipitation of overexpressed proteins has the potential
for amplification of genuine interactions. It may be that the relevant
interaction is in fact a signal-dependent one. As commented above,
it would be informative to test whether endogenous Į-arrestins and
NEDD4 ligases interact, and whether this is dependent on a signal
such as recruitment of the Į-arrestin to an activated GPCR.
6.5 ARRDCs and ǃ-arrestins: partners in GPCR
regulation?
Data presented here reveal a potential role for ARRDC2 in the
regulation of GPCRs. ARRDC2 is specifically recruited to GPCRs
(ǃ2AR, įOR), possibly involving a direct association, and influences
their intracellular trafficking. As has been recognised, a functional
consequence of such regulation remains to be demonstrated. The
possibility of overexpressing PPxY motif mutants of ARRDC2 and
assessing their effect receptor trafficking has been mentioned. It is
worth recognising the likely power of this approach to determine
whether ARRDC2 regulates GPCR trafficking via a ubiquitin ligase
adaptor mechanism. Preliminary experiments suggesting in fact that
mutant ARRDC2ƩƩ PD\ QRW DOWHU ǃ2AR trafficking have been
included (Figure 6.1), although quantification of any effect and
supporting evidence, for example in the form of immunoblotting
measurement of receptor downregulation, would need to be
performed to clarify this result. Despite the obvious need for these
further experiments, the data here, along with the complementary
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evidence of ARRDC2 as a ubiquitin ligase adaptor strongly support
the hypothesis that ARRDC2 regulates GPCR function, likely in a
similar manner to that seen for ARRDC3 (Nabhan et al., 2010).
Also presented here is the first evidence for the ability of Į- and
ǃ-arrestins to interact, which could provide insight into the
mechanism by which ARRDCs may regulate GPCRs. Although the
function of arrestin dimerisation remains unclear, interactions have
been reported to impact the subcellular targeting of partners: the
coexpression of ǃ-arrestin1/2 has been shown to prevent ǃ-
arrestin1 targeting to the nucleus (Storez et al., 2005). Similarly
here, ARRDC2 overexpression impacted ǃ-arrestin targeting,
through the induction of intracellular ǃ-arrestin1 puncta, and the
generation of a punctate BiFC signal with ǃ-arrestin2. Furthermore,
the potential for GPCR dimerisation  and the possible interaction of
arrestin dimers with such receptor complexes  has been mentioned
(section 5.1). The ability of ARRDC2 to oligomerise with arrestin
family members supports the proposal that Į- and ǃ-arrestin
heterodimers might interact with GPCR dimers, perhaps leading to a
much more dynamic system involving competition and/or exchange
between Į- and ǃ-arrestins as GPCR binding partners. In this
context, it is possible that Į-arrestins  through their presentation of
PPxY motifs  are the predominant recruiters of NEDD4 family
ligases to GPCR complexes; the apparent ability of ǃ-arrestins to
mediate ligase recruitment and receptor ubiquitination may in fact
reflect their recruitment of Į-arrestins through dimerisation. This
may even be true for the recruitment of AIP4 to CXCR4, which has
been reported to require ǃ-arrestin1 (Bhandari et al., 2007).
Although ǃ-arrestin1 has been reported to interact directly with AIP4
using purified proteins, it remains possible that in the native system
the essential interaction is between an ARRDC and AIP4. The
constitutive and ligand-regulated formation of CXCR4 homo- and
heterodimers has been well established through various biochemical
and microscopic techniques (Isik et al., 2008; Luker et al., 2009;
Percherancier et al., 2005; Vila-Coro et al., 1999), and has been
corroborated by recently published crystal structures (Wu et al.,
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2010). Hypothetically, activated CXCR4 dimers could bind
heterodimers of ARRDCs and ǃ-arrestin1, in which ARRDC binding
requires dimerisation with ǃ-arrestin1 (i.e. since, as has been
mentioned, ARRDCs do not contain the known GPCR-binding
modules present in ǃ-arrestins, binding of an ARRDC to CXCR4 may
require concurrent association with ǃ-arrestin). Recruitment of AIP4
would then be dependent upon interaction with PPxY motifs in the
ARRDC protein; disrupting ǃ-arrestin1 would result in ARRDC-AIP4
not being recruited to the receptor complex. This mechanism would
still be consistent with the observation that ǃ-arrestin1 is required
for CXCR4 ubiquitination and lysosomal degradation (Bhandari et al.,
2007). It could be tested, for example, by depleting ARRDC(s) and
measuring any effect on CXCR4 ubiquitination and degradation, as
well as on the interaction of ǃ-arrestin1 and AIP4 in living cells.
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Figure 6.1 Initial attempt to assess the effect of ARRDC2 PPxY
motif mutants on ǃ2AR trafficking
Confocal microscopic images of U2OS cells transiently transfected with
plasmids expressing ssǃ2AR plus ARRDC2ǻǻ-GFP. Cells were treated with
isoprenaline (ISO, 10 µM, 1h or 8h, as indicated) or without (Control), as
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indicated. In addition, cells were co-stained with 250 ng/µl AF-633-
conjugated Transferrin for the final 15 min of the control/ISO incubation.
ssǃ2AR was visualised by labelling with 0.1 µM SNAPsurface BG-AF546 prior
to the experiment. In merged images, ARRDC2ǻǻ is shown in green,
ssǃ2AR is in blue and transferrin is in red. Scale bar = 10 µm.
Although many GPCR functions adhere to the paradigms provided
by model receptors such as ǃ2AR, there are a number of exceptions
where receptors function non-canonically, including with respect to
ǃ-arrestin mechanisms (see Chapter 1). As such, there remain
significant gaps in our knowledge that ǃ-arrestins appear not to fill.
There are a number of possible explanations, including that the
related Į-arrestins may fill some of these gaps. An example is GPCR
internalisation, which in most cases is thought to require ǃ-arrestins
as endocytic adaptors. There are GPCRs whose internalisation is ǃ-
arrestin-independent. For example, microscopy showed that
urotensin receptor appears to internalise normally in ǃ-arrestin1/2
knockout MEFs (Giebing et al., 2005), and the same was shown for
N-formyl peptide receptor using flow cytometry, in contrast to the
non-internalising ǃ2AR (in the absence of ǃ-arrestins), which was
included as a control (Vines et al., 2003). It may be that these
receptors interact directly with the endocytic machinery, as has
been demonstrated for dileucine or tyrosine-based motifs in the C-
tail of several other GPCRs (Diviani et al., 2003; Fraile-Ramos et al.,
2003; Paing et al., 2006). Furthermore, Į-arrestins lack known
clathrin- or AP2-interacting motifs found in ǃ-arrestins, although
interactions between yeast Į-arrestins and clathrin/clathrin adaptor
proteins have been reported (O'Donnell et al., 2010). Nevertheless,
it may be that Į-arrestins are able to mediate internalisation of
some GPCRs in a non-canonical fashion. This could be investigated
by assessing the impact, for example, of Į-arrestin siRNA, upon the
internalisation of GPCRs (such as those mentioned above) in ǃ-
arrestin1/2 knockout MEFs. Perhaps a more likely role for Į-
arrestins is in governing the multiple sorting decisions for GPCRs
once internalised, given that Į-arrestins appear largely to target to
211
the endocytic/vesicular system. The number of proteins involved in
intracellular GPCR sorting, and hence the number of distinct
mechanisms, is ever expanding. This variety reflects the fine
regulation that is required, which is increasingly being recognised as
specific to both receptor type and context (cell type, nature of
stimulus etc). The involvement of Į-arrestins would provide yet
another possible mode of receptor regulation which, if early
investigations are an indication, may well be of great physiological
importance (Draheim et al., 2010; Patwari et al., 2009; Patwari et
al., 2011).
6.6 Are GPCRs the only ARRDC2 cargo?
Finally, it is worth considering whether ARRDC2 might associate with
and regulate non-GPCR cargoes and, given this possibility, whether
the methodology used here to investigate ARRDC2 function was the
best approach. Recent years have seen the knowledge of the ǃ-
arrestins expand from GPCR regulators to flexible adaptors capable
of interacting with multiple different proteins (Gurevich et al.,
2008b). Not only do ǃ-arrestins scaffold many different effector
proteins upon binding to GPCRs, but they can also regulate several
structurally divergent non-GPCR cell surface receptors (section 1.3).
A precedent for Į-arrestin regulation of non-GPCR cell surface cargo
also exists, with reports in yeast of Į-arrestins (or ARTs) acting as
ubiquitin ligase adaptors for several nutrient transporters
(Hatakeyama et al., 2010; Lin et al., 2008; Nikko et al., 2009;
Nikko et al., 2008). As commented in section 1.4.2, these are
thought to be 12 TM-spanning transporters with no apparent
structural similarity to GPCRs, suggesting that Į-arrestins may also
associate with diverse cargo. Similar to ǃ-arrestin interactions with
GPCRs, however, Į-arrestin interaction with the transporters may be
dependent upon transporter phosphorylation. This has been
indicated for the association of ART2 with Smf1, which was directly
shown to be strongly enhanced by constitutive Smf1
phosphorylation (Nikko et al., 2008), and ART3 with Dip5, which
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was indirectly indicated due to the inhibitory effect of non-
phosphorylated Dip5 mutants upon Dip5 endocytosis, a process
dependent upon ART3 association (Hatakeyama et al., 2010).
The mechanisms behind potential ǃ-arrestin interaction with non-
GPCRs, although not studied in detail, may also involve
phosphorylation. ǃ-arrestin2 binding to TGFǃRIII was triggered by
receptor phosphorylation (Chen et al., 2003), and the NHE5 binding
domain on ǃ-arrestin2 was mapped to a positively charged cluster
(residues 318-332) (Szabo et al., 2005). Thus, ǃ-arrestin interaction
with alternative cargo may be enabled by contacts with negatively
charged phosphate moieties, in a similar way to their interaction
with GRK-phosphorylated GPCR C-tails. Similarly, although human
Į-arrestins lack a recognised phosphate sensor, an interaction
between ARRDC3 and ITGǃ4 has been reported to be promoted by
ITG phosphorylation (Draheim et al., 2010). Based on these
observations it is reasonable to propose that ARRDC proteins may
associate with non-GPCR cargo.
The approach used here to investigate ARRDC2 function 
choosing to focus on specific ubiquitin ligases and GPCR cargo  was
hypothesis-driven, based on the molecular function of the known Į-
arrestins and related ǃ-arrestins, and carried the advantage of
defining a molecular mechanism for ARRDC2 with respect to these
factors. However, a disadvantage is the need to choose a small
number of cargo (in this case two GPCRs) out of a huge number of
potential partners, both GPCR and, as described above, non-GPCR.
In this case these decisions were based, as mentioned, on the small
amount of data available on other Į-arrestins and on the roles of the
related ǃ-arrestins. One way to better inform these decisions would
be to investigate the tissue and cell type specific expression of
endogenous ARRDC2; cell-specific cargo could then be chosen based
on knowing where ARRDC2 is expressed in native tissues.
An alternative approach that would not presume a certain cargo is
exemplified in the report by Nabhan and colleagues investigating
ARRDC3 (Nabhan et al., 2010). The principle of this approach is to
determine a physiological impact of the protein in question without
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necessarily immediately knowing the underlying mechanism. This
approach thus begins at the genetic level; the authors performed a
screen (using RNA interference; RNAi) to identify any genes with a
role in ǃ2AR downregulation, of which ARRDC3 was identified. From
this information the authors then went on to attempt to define the
mechanism behind the observed effect. This approach has the
benefit of being a broad survey that does not presume a particular
cargo or mechanism, and it likely identifies proteins that have a
relevant physiological role within the system in question (in the
current example, ǃ2AR regulation). However, it comes with the
caveat that if there are redundant interactions that govern the
function in question  for example, if several ARRDC proteins have
overlapping roles  then single genetic knockouts will not
necessarily reveal a phenotype, meaning that functions will be
masked.
In summary, this thesis has described the identification of ARRDC2
as a human Į-arrestin that is dynamically targeted to the endocytic
system. Within this system, ARRDC2 is able to associate with and
regulate the intracellular sorting of NEDD4 family ubiquitin ligases
and GPCRs. Future studies will investigate the likely overlap of these
functions in the definition of ARRDC2 as a cargo-specific (GPCR)
ubiquitin ligase adaptor, and will determine the mechanisms
involved  namely whether ARRDC2, and other Į-arrestins, regulate
GPCRs via collaboration or competition with ǃ-arrestins.
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